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Part I
INtroDUCtIoN

Chapter 1
General introduction
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INtroDUCtIoN
risk factors 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the 
third most common cause of cancer mortality [1-4]. HCC is one of the few cancers with 
well-defined major risk factors [1,5]. Worldwide, in 80% of the cases HCC develops in 
cirrhotic livers, and cirrhosis is the strongest predisposing factor [1,6,7]. The incidence 
is high in Asia and parts of Africa [5-13]. Geographical differences in incidence reflect 
variations of the main causal factors such as hepatitis B virus infection (HBV) which is 
common in Asia and Africa [14]. HBV infection leads to the development of HCC through 
direct and indirect pathways. Being an oncogenic virus, it can cause HCC in the absence 
of cirrhosis, as it has the ability to integrate into the host genome affecting cellular 
signalling and growth control [15]. 
Another unique feature of HCC is that it is a vaccine preventable disease. Imple-
mentation of a nationwide HBV vaccination programme for newborns in Taiwan has 
convincingly demonstrated a drop in the incidence of HCC in the years thereafter [16]. In 
Japan, Europe, and the United States about 60% of the patients with HCC are attributed 
to chronic hepatitis C virus (HCV) infection, 20% are attributed to chronic HBV infection 
and about 20% are equally divided between cryptogenic and alcoholic liver disease [17]. 
Hepatitis C as an infection transmitted by blood or plasma products before 1990 and 
is an important factor in the development of HCC in western countries [18]. HCV causes 
HCC mainly through indirect pathways: chronic inflammation, cell deaths, and regenera-
tion. In the pathogenesis the concurrent presence of the use of alcohol, the presence 
of diabetes and overweight play also an important role as a co-factor in HCV infection 
[15,17]. 
Alcohol use is increasing in many countries, suggesting that alcohol induced liver 
disease will continue to be a common cause of HCC throughout the World [19]. Moreover, 
obesity constitutes a significant risk of cancer mortality in general and an increasingly 
recognized risk factor for hepatocellular cancer in particular [20]. Longitudinal case stud-
ies indicate that obesity-associated steatosis and secondary non-alcoholic fatty liver 
disease more in particular non-alcoholic steatohepatitis (NASH) derives this association. 
A condition that can lead to cirrhosis and HCC alone, or may act synergistically with 
other disorders such as hepatitis C [20]. 
screening
To decrease cancer-related mortality, entrance in a surveillance program of patients 
with established cirrhosis is recommended, to detect early HCC [21]. Surveillance is 
recommended for patients with cirrhosis in whom potentially effective treatment for 
HCC can be offered if tumours can be detected early [22]. The available data on tumour 
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growth suggest that the interval from undetectable lesions to a 2 cm diameter lesion 
is approximately 4-12 months [23]. Until 2012 screening for HCC was applied with the 
combination of the serum alfa-fetoprotein (AFP) level and ultrasonography at 6 months 
intervals [24]. 
Clinical features
Patients with HCC present with one or more of several clinical features including right 
upper quadrant pain, weight loss and early satiety [25]. However, more and more he-
patocellular cancers are now detected at an asymptomatic stage because of growing 
awareness of these tumours in patients with chronic liver disease and cirrhosis [21]. 
Physical findings in patients with HCC generally reflect the severity of the underlying 
chronic liver disease and cirrhosis [25]. 
Diagnosis
The diagnosis of HCC is based on the combination of clinical, laboratory, imaging and 
pathology examinations [1]. Imaging characteristics of HCC are dependent on size with 
nodules >2 cm showing a characteristic pattern which is determined by the dominant 
arterial supply of the tumour. HCC in the cirrhotic liver is characterized by hyperdense 
enhancing nodules, caused by an increase in arterial supply during the early phase of 
contrast enhancement when compared with background of liver parenchyma. During 
the later phase the density becomes lower than the surrounding hepatic parenchyma 
because of the lack of portal venous supply, the so called wash-out phase. 
HCC in a non-cirrhotic liver is characterized by a large dominant, hyperdense enhanc-
ing mass. It is usually larger than HCC found in cirrhotic liver [11,26]. It can be difficult to 
differentiate HCC from a large hepatic adenoma or fibrolamellar HCC based on imaging 
findings alone [27].
A decision to biopsy a focal liver lesion suspected for HCC should be discussed by a 
multidisciplinary team, including a hepatobiliary and transplant surgeon because there 
is a risk of needle tract seeding that is estimated at 2,7% [28]. There is no indication for bi-
opsy of a focal lesion in a cirrhotic liver when the patient is: not a candidate for any form 
of therapy because of serious co-morbidity; in case of decompensated cirrhosis and the 
patient is on the waiting list for liver transplantation, when the patient is a candidate for 
resection that can be performed with an acceptable morbidity and mortality risk. 
staging systems 
A staging system should separate HCC patients into groups with homogeneous progno-
sis, and serve to select appropriate treatment. Because prognostic modelling in HCC is 
more complex, tumour node metastasis staging has been modified repeatedly. Cancer 
of the Liver Italian Program (CLIP) and the Barcelona-Clinic Liver Cancer staging (BCLC) 
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include aspects of performance status, tumour extent, liver function and treatment and 
provides the best prognostic stratification of patients with HCC [1,29-31]. However, none 
has received universal acceptance.
treatment
Curative
Liver transplantation is the only definitive treatment for both HCC and the underlying 
liver disease. Dependent on the aetiology of the liver disease the initial liver disease may 
recur in the transplanted liver. Antiviral therapy at present can e.g. completely prevent 
HBV recurrence but in patients with HCV 30% will develop cirrhosis in their graft after 
5-years of follow-up [32]. The selection policy for transplantation for HCC patients follows 
the Milan criteria: one nodule less than 5 cm or two-three nodules up to 3 cm each. These 
criteria have been extensively validated with regard to their prognostic value [33]. 
Resection is reserved to a single HCC with preserved liver function [32]. 
Percutaneous ablation includes several techniques used to destroy malignant tissue. This 
technique is relatively inexpensive, requires a very short hospitalization time and sel-
domly presents complications. RFA is the best option for early, (un)resectable HCC [32].
Palliative 
Palliative treatment can be proposed to selected patients with HCCs not amenable to 
curative treatment, after careful evaluation of residual liver function and co-morbidities. 
They include transarterial chemoembolization (TACE) or transarterial embolization (TAE) 
alone [32]. Sorafenib has demonstrated a median increase survival of 3 months in Child-
Pugh class A patients with advanced HCC [34]. 
Due to patient diversity, HCC patients continue to create challenging clinical prob-
lems. An interdisciplinary approach with surgeons, gastroenterologists, radiologists, 
oncologists, and pathologists if therefore required.
This thesis includes studies that address various aspects of HCC: epidemiology, 
screening, staging and outcome. The thesis is, in addition to the introduction (Chapter 1) 
and the discussion and conclusions (Chapter 11), divided into four parts: part II – trends 
in hepatobiliary cancer, part III- screening for hepatocellular carcinoma, part IV - optimi-
zation of staging and part IV – outcome. 
treNDs IN HePatoBIlIarY CaNCer 
HCC is the most common primary liver cancer, and it is estimated that worldwide, each 
year 500 000 new patients are being diagnosed with this cancer [1]. Other low-endemic 
countries reported increasing incidence rates for liver cancer and HCC due to improved 
detection, by improvement of imaging modalities [7,32]. Because of these changes in 
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detection, changes in the incidence and survival of HCC and other primary liver tumours 
are also expected to have occurred in the Netherlands. Therefore, a population-based 
study was performed to determine whether the reported changes in incidence were also 
observed in the Netherlands, including all patients with a primary liver tumour. Trends in 
incidence, treatment and survival were observed in all patients with HCC between 1989 
and 2009 (Chapter 2). 
Improved imaging techniques have facilitated the diagnosis of liver malignancies, 
changes in intrahepatic cholangiocarcinoma (ICC) incidence and survival can occur [32]. 
Therefore, trends in incidence, and survival were studied in patients with ICC between 
1989 and 2008 (Chapter 3).
sCreeNING For HePatoCellUlar CarCINoMa
Until 2012 screening for HCC was widely applied with alpha-fetoprotein (AFP) and 
ultrasonography in patients at risk e.g. patients with cirrhosis and patients chronically 
infected with hepatitis B virus [32]. However, AFP has a low sensitivity when used as a 
screening test [32]. Due to lack of an efficacious test, new markers have been investi-
gated. To define the present state of the art for HCC screening, Chapter 4 offers a review 
of the literature discussing biomarkers most likely to be introduced as new instrument 
for HCC screening. 
As chronic hepatitis and cirrhosis are known risk factors for HCC development, these 
patients are defined as an acceptable population to screen on regular basis [1,32]. The 
natural history of HCC development suggests that chronic hepatitis and cirrhosis induce 
premalignant steps [15]. However, HCC occasionally appears in the absence of chronic 
liver disease or cirrhosis [11]. It is suggested that HCC in non-hepatitis and non-cirrhotic 
livers are the result of a malignant transformation of hepatocellular adenoma [35,36]. 
This hypothesis could include the co-existence of both hepatocellular adenoma and 
HCC within the same tumour. The possible relationship between the presence of HCC in 
the non-cirrhotic liver and a hepatocellular adenoma as precursor lesion was explored 
(Chapter 5). 
oPtIMIZatIoN oF staGING
The tests used for diagnosing HCC include different imaging modalities (ultrasonogra-
phy, computed tomography (CT) or magnetic resonance imaging (MRI)), biopsy and AFP 
serum levels [32]. Dynamic contrast-enhanced MRI has a higher sensitivity in detecting 
HCC than CT [32]. After detection and treatment HCC can recurrence. Various factors 
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associated with fatal recurrence after orthotopic liver transplantation and resection for 
HCC have been well documented [37-39]. The most important ones are vascular inva-
sion, differentiation grade, tumour size, and multifocal tumours as long-term survival 
is strongly correlated with these findings. However, identification of especially vascular 
invasion and differentiation grade are by means of histological examination often done 
within the resected specimen [32]. If the presence of vascular invasion and the type of 
differentiation grade can be evaluated with a preoperative imaging, without a biopsy, 
long term-survival might be predicted more accurately preoperatively and subsequently 
the treatment strategy for some patients might be adapted. Therefore we explored 
whether contrast-enhanced MRI has the potential to predict outcome for patients with 
HCC (Chapter 6). 
Accurate staging is important to determine the prognosis and to guide therapy [32]. 
According to the AASLD guidelines nodules larger than 1 cm found on ultrasound screen-
ing of a cirrhotic liver should be investigated further with either 4-phase multidetector 
CT scan or dynamic contrast enhanced MRI [32]. In absence of consensus on international 
guidelines as to which patients require preoperative staging by bone scintigraphy and 
thorax CT, many clinicians continue to routinely perform these staging investigations 
in all patients, especially in those at risk for postoperative complications. However, the 
rising costs of healthcare and (in particular) of cancer care challenge the appropriate-
ness of current practices and emphasise the need for more cost-effectiveness analyses. 
The positive yield of a routine bone scintigraphy in patients with early-stage hepatoma 
evaluated for liver transplantation was reported to be very low [39]. To assess the role 
of baseline scintigraphy and its benefit for eligible patients to receive treatment with 
curative intent, a review of our clinical practice was performed (Chapter 7).
oUtCoMe
HCC typically develops in the presence of underlying cirrhosis, particularly in high-
endemic areas. In low-endemic, like the Netherlands, HCC as well appears in absence 
of underlying liver cirrhosis [8-10]. Many investigators tried to report on prognostic 
factors for HCC in a non-cirrhotic liver. However, they still included patients positive for 
serological markers of hepatitis B or C virus infection, alcohol abuse or hematochro-
matosis. These are known risk factors for the development of cirrhosis and eventually 
HCC [14,15,19]. In HCC patients with no underlying cirrhosis, the ‘normal’ quality of the 
non-tumoral liver parenchyma might make this type of HCC a different entity, with a 
different aetiology, clinical presentation, management and prognosis [40]. In Chapter 
8 we aimed to identify the factor(s) predictive for survival and recurrence of HCC in the 
non-cirrhotic liver for patients able to receive treatment with curative intent. 
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The liver represents one of the three most common sites of metastasis, and primary 
hepatic cholangiocarcinoma and HCC often share overlapping morphological appear-
ances [6]. The diagnosis of HCC might be difficult in the absence of risk factors e.g. cirrhosis 
or hepatitis B/C virus infection. One of the challenges in histopathological diagnosis of 
hepatocellular mass lesions is to distinguish HCC (particularly well-differentiated) from 
hepatocellular adenoma [35]. Complicating the diagnostic process is that pathologists 
are frequently asked to handle and diagnose liver needle core biopsies with various 
biopsy artefacts. As an overview of the immunoprofile of HCC in non-cirrhotic livers has 
not been presented before, we established the role of the immunohistochemical stain-
ing pattern in HCC in the non-cirrhotic liver as a diagnostic or prognostic test (Chapter 9). 
If HCC appears in a cirrhotic liver, in many patients HCC occurs against the background 
of a chronic viral infection. Worldwide approximately 400 million people are chronically 
infected with HBV [41,42]. In Rotterdam, the Netherlands, the prevalence of hepatitis B 
virus infection (hepatitis B core antibodies) was 20% [43]. In the last 15 years, reliable 
quantification of HBV DNA over a large dynamic range has become feasible. Several 
hospital-based and community-based studies have subsequently found significant as-
sociations between the level of serum HBV DNA and the risk to develop liver cirrhosis or 
HCC [42]. The impact of viral load on survival of HCC patients after surgery with curative 
intent may be overshadowed by tumour-related factors or stage of the liver disease at 
detection of HCC. It has been hypothesized that anti-viral therapy for HCC patients with 
active HBV replication, along with HCC treatment might reduce the recurrence rates for 
HBV-associated HCC in high endemic areas. Unfortunately the effect of anti-viral therapy 
on HCC outcome in low-endemic areas was not discussed [44]. Chapter 10 attempt to 
determine whether HBV DNA levels at time of HCC appearance is associated with overall 
survival in a low-endemic area.
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aBstraCt
objective To examine recent trends in incidence and outcome among patients with 
hepatocellular carcinoma (HCC) in an unselected population in Western Europe. 
Methods Data from the nationwide Netherlands Cancer Registry were used to estimate 
trends in incidence for all 6514 patients newly diagnosed with primary liver cancer 
between 1989 and 2009. Trends in incidence, treatment, and relative survival accord-
ing to sex and age were estimated in 5143 patients with HCC, also using the European 
Standardized Rates (ESR). 
results The ESR for all primary liver cancers combined increased significantly between 
1989 and 2009 as did the ESR for HCC among men (estimated annual percentage change: 
2.2%, 95% confidence interval: 1.6–2.7) and for women aged below 60 years, suggesting 
etiological influences in these groups. Especially, the nonhistologically confirmed HCC 
incidence increased. More patients underwent surgery for HCC, from 9% in 1989–1994 to 
23% in 2005–2009, as well as chemotherapy and/or irradiation, from 6 to 11% in the same 
period. At the end of the study period, only 66% of patients received noncancer-related HCC 
therapy, that is, best supportive care, compared with 85% in 1989–1994. The 1 and 5-year 
relative survival for patients with HCC increased significantly (P < 0.001 and P <0.001).
Conclusion In as much as the modest increase in the incidence of HCC was a matter of 
better detection, due to improved imaging techniques, which may have affected the 
overall relative survival for HCC patients, the increasing trend in survival is likely to be, 
in the absence of other explanations, due to better treatment of the underlying liver 
cirrhosis. 
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INtroDUCtIoN 
Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the 
third most common cause of cancer mortality. It is estimated that worldwide, each year, 
500 000 new patients are being diagnosed with HCC [1]. In industrialized countries, HCC 
is an uncommon type of cancer [2,3]. However, the incidence rates for liver cancer and 
HCC have been increasing in low-endemic areas [4]. 
The increase in the incidence in other countries is partly due to improved detec-
tion, causing previously diagnosed cancers to be detected. Improvement of imaging 
modalities during the last decades was responsible for better characterization of liver 
lesions. Together with the screening program that has been developed for patients with 
liver cirrhosis, HCC can be detected with a smaller size [5]. The screening program in the 
Netherlands might influence not only the incidence but also the treatment and survival 
of patients with HCC. 
Because of these changes in detection, changes in the incidence and survival of liver 
cancer are also expected to have occurred in the Netherlands. Therefore, as a follow-up 
to our previous analysis [3], we conducted a population-based study in the Netherlands 
of all patients diagnosed with liver cancer between 1989 and 2009. For HCC only, trends 
in incidence, treatment, and survival, according to sex and age, were studied. 
PatIeNts aND MetHoDs
Data collection
Incidence and treatment data on liver tumors from 1989 to 2009 were provided by the 
population-based Netherlands Cancer Registry (NCR), a nationwide registry that was 
started in 1989 and is maintained by regional comprehensive cancer centers [6]. The NCR 
is based on notification of all newly diagnosed malignancies in the Netherlands by the 
automated pathological archive. Additional sources are the national registry of hospital 
discharges, haematology departments, and radiotherapy institutions. Information on 
patient characteristics, such as sex and date of birth, and tumor characteristics, such 
as date of diagnosis, localization (International Classification of Diseases for Oncology), 
histology, and primary treatment, is obtained routinely from the medical records [7]. 
The quality of the data is high, due to thorough training of the data managers, good 
access to care, and computerized consistency checks. The infrastructure of the Nether-
lands healthcare system and the notification procedure used have made it possible to 
establish a cancer registry, in which completeness is estimated to be at least 95% [8,9]. 
In the case of multiple tumors, the same rules were applied as those recommended by 
the International Association of Cancer Registries [10]. The information on vital status 
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was initially obtained from municipal registries and from 1995 onwards from the nation-
wide population registries network. These registries provide complete coverage of all 
deceased Dutch residents.
For the present study, all patients with a primary liver tumor (C22.0 and C22.1) diag-
nosed during 1989–2009 in the Netherlands were included (n=6514). Primary liver cancer 
was classified as HCC, cholangiocarcinoma, neuroendocrine tumors, blastoma, sarcoma, 
or tumors not otherwise specified. The latter category includes HCC and cholangiocarci-
noma without pathological confirmation. 
Age was divided into three groups, that is 60 years or younger, 60–74, and 75 years 
or older. The study period was divided into four unequal categories, namely 1989–1994, 
1995–1999, 2000–2004, and 2005–2009. Treatment was scored as follows: surgery includ-
ing partial liver resection, radiofrequent ablation (RFA) or liver transplantation, chemo-
therapy (systemic or regional), and irradiation therapy or other/no therapy. 
Patients younger than 15 years and older than 95 years were excluded from the sur-
vival analysis, as well as cases diagnosed at autopsy.
statistical analyses 
Annual incidence and mortality rates for the period 1989–2009 were calculated per 100 
000 person-years, using the annual mid-year population size as obtained from Statistics 
Netherlands. Rates were age standardized to the European standard population [Eu-
ropean Standardized Rates (ESR)]. Changes were evaluated by calculating the estimated 
annual percentage change (EAPC) and the corresponding 95% confidence interval (95% CI). 
Because of changes in coding during the study period, it was impossible to examine 
the mortality trends. Proportions of patients receiving different types of treatment (sur-
gery, chemotherapy, radiotherapy) were calculated according to age group and period. 
Follow-up of the vital status of all patients was calculated as the time from diagnosis to 
death, censoring due to loss to follow-up, or until 1 February 2010. Traditional cohort-
based relative survival analysis was used for the period 1989–2009, which represents the 
actual survival of patients diagnosed during this period. As follow-up was complete until 
February 2010, the 3-year and 5-year relative survival of patients diagnosed in the period 
2005–2009 could not be calculated using the cohort-based method. Therefore, we used 
period-based relative survival analysis. Survival trends within 1989–2009 were evaluated 
by a Poisson regression model [11]. SAS software (SAS system 9.2, SAS Institute, Cary, 
North Carolina, USA) was used to perform the statistical analyses.
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resUlts
Incidence
Between 1989 and 2009, a total of 6514 patients were diagnosed with primary liver can-
cer in the Netherlands. The incidence of liver cancer was approximately three times as 
high in men compared with women (Fig. 1). For both sexes, a significant increase in the 
incidence of primary liver cancer was observed: ESRs for men increased from 2.2 per 100 
000 in 1989 to 3.0 in 2009 (EAPC: 2.1%, 95% CI: 1.5–2.7) and that for women from 0.8 per 
100 000 in 1989 to 1.1 in 2009 (EAPC: 1.0%, 95% CI: 0.2–1.8; Fig. 1). 
HCC was the predominant histology (n=5143), comprising 79% of all liver cancers, 
followed by intrahepatic cholangiocarcinoma (17%, n=1110). The remaining 4% (n=261) 
were neuroendocrine tumors, blastomas, or sarcomas (Fig. 2). The distribution of primary 
liver cancers remained stable, besides an increase in blastomas, cholangiocarcinoma, 
and nonhistologically confirmed HCC.
Gender EAPC (95%CI)
Males
Females
2.1 (1.5, 2.7)*
1.0  (0.2, 1.8)* 
YearGender
200920082007200620052004200320022001200019991998199719961995199419931992199119901989
Numbers new diagnosed per year
132
330
130
323
111103108109981011288297841059593979198837975Females
300239237227256240216197178197178180153185170159164139147Males
Figure 1 Age-standardised incidence rates (ESR) for all primary liver cancers according to gender in the 
Netherlands (1989-2009) 
* Significant trend
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Morphology EAPC(95%CI)
Hepatocellular carcinoma (HCC)
Cholangiocarcinoma 
Neuro-endocrine
Blastoma
Sarcoma
Non specified – HCC
Non specified – Cholangiocarcinoma
0.6 (-0.1, 1.3)
1.6 (0.1, 3.1)*
2.7 (-1.4, 6.7)
5.8 (2.3, 9.2)*
1.6 (-2.0, 5.3)
5.6 (4.6, 6.6)*
0.2 (-2.0, 2.4)
Numbers new diagnosed per yearMorphology
Numbers new diagnosed per yearMorphology
5892667869Sarcoma
2009200820072006200520042003200220012000
364363326276279263275266264219HCC
84726959525663596545Cholangiocarcinoma
33575834862Sarcoma
3220245131Neuro-endocrine
19991998199719961995199419931992199119901989
232228231218192226214197178161171HCC
3342434242434050554946Cholangiocarcinoma
02012121112Neuro-endocrine
6855574765Blastoma
76475425511Blastoma
Figure 2: Age-standardised incidence rates (ESR) of morphologies of all primary liver cancers, both sexes, 
the Netherlands (1989-2009)
* Significant trend
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Between 1989 and 2009, 5143 new patients were diagnosed with HCC in the Neth-
erlands, with an increasing incidence rate among men and a slightly but insignificantly 
increasing incidence rate among women (Fig. 3a). In 2009, the incidence (ESR) of HCC in 
men was 1.8 and that in women was 0.5 per 100 000. Figure 3b shows the age-specific 
trends of HCC for men and women. The age-specific trends for women aged 60 years and 
over remained unchanged. A significantly increasing trend was observed among men in 
all age groups. The annual number of new male HCC cases ranged from 28 to 83 cases for 
the age group 0–60 years, 54 to 143 cases for 60–74 years, and 18 to 69 cases for age 75 
years and older, ranging in women from six to 27, 14 to 38, and 16 to 36 cases, respectively. 
treatment
Between 1989 and 2009, 16% (n=804) of the total HCC population underwent a partial 
liver resection, RFA or orthotopic liver transplantation. The local treatment rate with 
curative intent increased from 19 to 23% in 2005–2009. An increasing number of patients 
with HCC received palliative therapy, that is, chemotherapy and/or irradiation from 6% 
in 1989–1994 to 11% in 2005–2009. Over time, fewer patients received noncancer-related 
therapy; best supportive care decreased from 85 to 66% (Table 1).
Gender EAPC (95%CI)
Males
Females
2.2 (1.6, 2.7)*
1.0 (-.01, 2.2) 
YearGender
200920082007200620052004200320022001200019991998199719961995199419931992199119901989
Numbers new diagnosed per year
87
277
89
274
75737574596581467559726463667065475149Females
251203204189216201183173157169159154129160144132131110122Males
Figure 3a: Age-standardised incidence rates (ESR) for hepatocellular carcinoma according to gender in 
the Netherlands per 100,000
* Significant trend
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table 1: Time trends of treatment patterns for patients with hepatocellular carcinoma in the Netherlands 
during the period 1989-2009
therapy Period of diagnosis ^
1998-1994
n(%)
1995-1999
n(%)
2000-2004
n(%)
2005-2009
n(%)
Surgery 102(9) 136(12) 194(15) 372(23)
Chemotherapy/ irradiation 65(6) 47(4) 66(5) 172(11)
Other/ no therapy 980(85) 918(83) 1027(80) 1064(66)
Total 1147 1101 1287 1608
^ unequal period clustered 
Source: Netherlands Cancer registry
Age EAPC(95%CI)
Males <60 
Males 60-74
Males 75
Females <60
Females 60-74
Females 75
2.9 (1.8, 3.9)*
1.7 (0.8, 2.5)*
2.6 (1.3, 3.8)*
2.6 (0.3, 5.0)*
0.2 (-1.6, 2.1)
0.9 (-0.4, 2.3)
Figure 3B: Age-standardised incidence rates (ESR) for hepatocellular carcinoma according to gender and 
age groups in the Netherlands, both sexes (1989-2009)
* Significant trend
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survival
The relative survival rates for patients with HCC between 1989 and 2009 improved (Table 
2): the 1-year survival rate increased from 20 to 37% and the 5-year survival rate increased 
from 5 to 14% (both P<0.001). The survival rate increased significantly for men and 
women aged younger than 60 years and for men and women aged 60 years and older.
The relative survival rates for patients with HCC according to clinical characteristics 
and treatments are shown in Tables 3 and 4. The 1-year, 3-year, and 5-year survival rates 
for HCC patients treated surgically increased from 59, 41, and 36% in the period of 
1989–1994 to 84, 63, and 49%, respectively, during 2005–2009 (all P<0.001). The 1-year 
survival rates for HCC patients receiving chemotherapy and/or irradiation showed an 
increase from 32% in the period of 1989–1994 to 51% in the period of 2005–2009 (P=0.03). 
The 1-year and 3-year survival rates for HCC patients receiving another or no therapy 
increased from 15 and 4% in the period of 1989–1994 to 19 and 6%, respectively, during 
2005–2009 (P=0.004 and 0.001). 
table 2: Relative survival of patients with hepatocellular carcinoma in the Netherlands, according to 
period of diagnosis
Period of 
diagnosis^
N survival
%(se)
6-months 1-year 3-years 5-years
1989-1994 1068 32(1.5) 20(1.3) 8(0.9) 5(0.8)
1995-1999 1053 38(1.5) 26(1.4) 12(1.1) 9(0.9)
2000-2004 1242 41(1.4) 30(1.3) 15(1.1) 11(0.9)
2005-2009 1567 49(1.3) 37(1.3) 20(1.1) 14(1.1)
p-value <0.001 <0.001 <0.001 <0.001
^ unequal period clustered 
Source: Netherlands Cancer registry
table 3: Relative survival of patients with hepatocellular carcinoma according to age <60 or ≥60 years 
and therapy in the Netherlands in the period 1989-2009
therapy 
1989-2009
survival %(se) age < 60 years survival %(se) age > 60 years
N 6-months 1-year 3-years 5-years N 6-months 1-year 3-years 5-years
Surgery 358 88(1.8) 81(2.2) 61(2.8) 51(3.1) 429 84(1.9) 75(2.3) 52(3.0) 37(3.4)
Chemotherapy/ 
irradiation
151 64(4.0) 43(4.1) 10(3.0) ** 194 69(3.6) 48(3.9) 14(3.3) **
Other/ no therapy 854 29(1.6) 17(1.3) 7(0.9) 5(0.8) 2944 30(0.9) 18(0.7) 5(0.5) 3(0.4)
** n<10
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DIsCUssIoN
The incidence of primary liver cancer has increased for both sexes in the Netherlands 
between 1989 and 2009. Because the terms HCC and primary liver cancer are often used 
interchangeably, it is possible that the studies conducted in low-endemic areas used a 
different definition of liver cancer and therefore included several morphologies to study 
the incidence [2]. Because HCC is low endemic in the Netherlands, it is more accurate to 
describe primary liver cancers separately. In this way, populations based on Western-
world standards can be compared with high-endemic areas reliably.
Incidence
The incidence of HCC increased for men and remained unchanged among women (Fig. 
3a). Another study in a low-endemic area found an increasing incidence of HCC over 
time as well [12]. The apparent changes in HCC incidence as described worldwide are 
very pronounced. Computed tomography and high-resolution MRI of the liver have 
facilitated the diagnosis of liver malignancies, especially the imaging of HCC. In 2005, 
guidelines were published in the Netherlands recommending biopsy, only if the vascu-
table 4: Time trends of relative survival of patients with hepatocellular carcinoma and therapy in the 
Netherlands during 1989-2009
therapy Period of diagnosis^ N survival % (se)
      6-months 1-year 3-years 5-years
Surgery 1989-1994 100 74 (4.5) 59 (5.0) 41 (5.1) 36 (5.1)
  1995-1999 130 82 (3.5) 75 (4.0) 50 (4.6) 38 (4.6)
  2000-2004 190 83 (2.8) 79 (3.1) 60 (3.8) 49 (4.0)
  2005-2009 367 91 (1.6) 84 (2.1) 63 (3.1) 49 (3.4)
p-value     <0.001 <0.001 <0.001 <0.001
Chemotherapy/ irradiation 1989-1994 64 54 (6.4) 32 (6.0) ** **
  1995-1999 46 75 (6.5) 49 (7.5) 12 (4.9) **
  2000-2004 63 69 (5.9) 45 (6.4) 17 (4.9) **
  2005-2009 172 68 (3.8) 51 (4.2) 17 (3.9) **
p-value     0.15 0.03 0.01 n.a.
Other/ no therapy 1989-1994 904 26 (1.5) 15 (1.2) 4 (0.7) 2 (0.5)
  1995-1999 877 30 (1.6) 17 (1.3) 6 (0.9) 4 (0.8)
  2000-2004 989 31 (1.5) 19 (1.3) 6 (0.8) 3 (0.6)
  2005-2009 1028 31 (1.5) 19 (1.3) 6 (0.8) 3 (0.6)
p-value     0.01 0.004 0.001 0.001
** n<10 
^ unequal period clustered
HCC in a low-endemic area 35
lar profile on the image is not characteristic or the nodule is detected in a noncirrhotic 
liver [5]. Because of the improved imaging techniques, HCC can be diagnosed without a 
biopsy, which possibly explains an increasing incidence of nonhistologically confirmed 
HCC.
The age-specific trends of HCC for men can be the result of an increase in the past 
in the incidence of HCV infections, which require two or three decades to develop into 
liver cirrhosis and typically precede HCC [12]. The prevalence of HCV in the general Dutch 
population was estimated at 0.1% in 1995/1996, but within low-endemic countries, pock-
ets with higher endemicity for viral hepatitis do exist [13]. Other causes of the observed 
overall increases in HCC, mainly affecting low-incidence areas, might be the higher 
prevalence of nonalcohol fatty liver disease, which can be considered a precursor lesion 
of nonalcoholic steatohepatitis. Nonalcoholic steatohepatitis progresses to cirrhosis in 
20% of cases [14].
treatment and survival
The overall 5-year survival rates of patients with HCC increased as well as the percent-
age of patients who underwent surgery. This phenomenon could be explained by the 
promising RFA methods [15]. The increase in the application of chemotherapy and/or 
irradiation in our study could be explained by the introduction of transarterial emboliza-
tion combined with injection of chemotherapeutic agents into the hepatic artery. In 
1995, chemoembolization was the preferred palliative treatment for unresectable HCC 
[16]. Sorafenib for HCC was only introduced in 2009 in the Netherlands.
The survival rates for HCC patients who were able to undergo surgery or who re-
ceived no specific treatment increased, as well as the 1-year, 3-year, and 5-year survival 
rates for HCC patients who received chemotherapy and/ or irradiation. Survival rates 
might improve after changes in tumor-related therapy. For HCC, however, both survival 
after resection or orthotopic liver transplantation and the treatment outcome of che-
motherapy and/or irradiation are influenced markedly by the underlying liver disease 
[17]. The increasing trend in the survival of patients who did not receive a specific treat-
ment is likely to be, in the absence of other explanations, due to better treatment of the 
underlying liver cirrhosis.
In contrast, surveillance programs have become more common, also in the Nether-
lands, which enables the detection of HCC at a smaller size [5]. Surveillance is recom-
mended in patients at high risk for developing HCC, for example, with chronic hepatitis B 
carriers, hepatitis C cirrhosis, or other cirrhosis (level I evidence) [5]. Such patients might 
live longer after the diagnosis of HCC without an effect of treatment on date of death 
[17]. Because of early diagnosis of HCC, treatment may affect the outcome of disease and 
bring prolonged survival. As over 60% of the patients with HCC in the Netherlands had 
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underlying cirrhosis [18], the improved survival is likely to be affected by this lead time 
bias.
In conclusion, we found an increased age-standardized incidence of HCC among all 
male age groups and among women younger than 60 years in the Netherlands between 
1989 and 2009. Overall and treatment-specific survival improved for HCC patients. The 
modest increase in the incidence of HCC is apparently a matter of better detection and 
affected the overall relative survival for HCC patients.
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aBstraCt 
Background: To explore trends in incidence and survival of patients with intrahepatic 
cholangiocarcinoma (ICC) an unselected population in Western Europe was studied. 
Methods: All patients newly diagnosed with ICC between 1989 and 2009 were selected 
from the Netherlands Cancer Registry (n=809). Trends in incidence, treatment and rela-
tive survival were calculated according to gender and age. Follow-up for vital status was 
complete until January 1st 2010. 
results: The incidence rates of ICC increased significantly between 1999 and 2009, 
especially in the age group 45-59 years (estimated annual percentage change +3.0%, 
95% confidence interval 0.2-5.8). In the other age groups ICC incidence remained stable. 
Patients diagnosed with TNM stage I mainly underwent surgery (68%), the majority 
of the patients with stage II, III and IV received best supportive care (73%). One-year 
relative survival for patients with ICC increased significantly from 24% in 1989-1994 to 
28% in 2005-2009 (p=0.03), corresponding 3-year relative survival improved from 4% to 
8% (p=0.02). Three-month and one-year relative survival for patients with ICC receiving 
surgery was 91% and 71%.
Discussion: The incidence of ICC rose between 1999 and 2009, especially in the age 
group 45-59 years, suggesting etiological influences. Survival rates have improved dur-
ing the study period.
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INtroDUCtIoN
Intrahepatic cholangiocarcinoma (ICC) the malignancy arising form the ductal epithe-
lium of the biliary tree has a poor prognosis.1,2 Perhaps because ICC is rare diagnosis, few 
reports on the epidemiology of ICC are available, and information on survival trends 
of ICC patients are only available from single institution case series, mostly describing 
patients who underwent a surgical resection.3-5 Such studies do not reflect the outcome 
of an unselected group of patients. Because improved computed tomography (CT) and 
high-resolution magnetic resonance imaging (MRI) of the liver have facilitated the diag-
nosis of liver malignancies, changes in ICC detection and survival are expected to occur 
as is reported by two studies from the United States.6,7 Therefore, a population-based 
study in the Netherlands of all patients diagnosed with ICC between 1989 and 2009 was 
performed and trends in incidence and survival according to gender, age and treatment 
were studied. 
MetHoDs
Data collection
Incidence and treatment data on ICC (ICD-10 code C22.1) from the period 1989-2009 were 
provided by the population-based Netherlands Cancer Registry (NCR) which is managed 
by the Comprehensive Cancer Centres the Netherlands and South.8 The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the automated 
pathological archive (PALGA). Additional sources are the national registry of hospital 
discharges and radiotherapy institutions. Information on patient characteristics, such 
as gender, and date of birth, and tumour characteristics, such as date of diagnosis, 
localisation (International Classification of Diseases for Oncology (ICD-O-3), histology, 
stage (Tumour Lymph Node Metastasis (TNM) classification), and primary treatment, are 
obtained routinely from the medical records.9 The quality of the data is high, due to thor-
ough training of the data managers, good access to care and computerized consistency 
checks. The infrastructure of the Netherlands health care system and the notification 
procedure used have made it possible to establish a cancer registry in which complete-
ness is estimated to be at least 95% of the country.10,11 In the case of multiple tumours, 
the same rules were applied as those recommended by the International Association of 
Cancer Registries.12  The information on vital status was initially obtained from municipal 
registries and from 1995 onwards from the nationwide population registries network, 
providing complete coverage of all deceased Dutch residents.
ICC arises from the intrahepatic bile duct epithelium while extra-hepatic cholangio-
carcinomas and Klatskin tumours involve the biliary tree within the hepatoduodenal 
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ligament.13 To limit potential misclassification bias patients with a non-classified tumour 
(histological or clinical), an extra-hepatic cholangiocarcinoma or a Klatskin tumour were 
excluded (n=301). 
Age was divided into five groups, i.e. <30, 30-44, 45-59, 60-74, and ≥75 years. The study 
period was divided into four categories, namely 1989-1994, 1995-1999, 2000-2004, and 
2005-2009.  TNM stage was determined postoperatively, clinical stage was used in case 
pathological TNM was missing. Treatment was scored as follows: surgery with curative 
intent including partial liver resection, chemotherapy (systemic or regional)/ irradiation 
therapy or no specific anti-cancer therapy i.e. best supportive care. 
Patients younger than 15 years and older than 95 years were excluded from the sur-
vival analysis, as well as patients who had the diagnosis made at autopsy. 
statistical analyses
Annual incidence rates for the period 1989-2009 were calculated per 100,000 person-
years, using the annual mid-year population size as obtained from Statistics Nether-
lands. Rates were age-standardised to the European standard population (European 
Standardised Rates (ESR)). Changes were evaluated by calculating the estimated an-
nual percentage change (EAPC) and the corresponding 95% confidence interval (95% 
CI). Data regarding mortality trends were not available. Follow-up of vital status of all 
patients was calculated as the time from diagnosis to death, lost to follow-up or until 
the 1st of January 2010. The cohort-based method for relative survival analysis was used. 
Survival trends within 1989-2009 were evaluated by a poisson regression model.14 SAS 
software (SAS system 9.2, SAS Institute, Cary, NC) was used to perform the statistical 
analyses.
resUlts 
Incidence
During the period 1989-2009 809 patients were diagnosed with ICC of whom 785 (97%) 
were pathologically confirmed. Median age was 68 years (range 23-95) and did not 
change over time. The age-standardized incidence rate (ESR per 100,000) was similar for 
males and females. The overall incidence of ICC decreased from 0.22 per 100,000 in 1989 
to 0.12 in 1999 (EAPC -5.0%, 95%CI -9.2, -0.7) and thereafter increased to 0.35 per 100,000 
in 2009 (EAPC +9.4%, 95% CI 4.6, 14.3). Figure 1 shows the incidence rates by gender. 
Figure 2 displays in five age groups the trends of ICC for both genders combined. A 
significantly increasing trend was observed in the age group 45-59 years (EAPC +3.0%, 
95% confidence interval 0.2-5.8). The average annual number of new patients diagnosed 
with ICC (both sexes) was 0.3 (range 0-1) patients for age group 0-29 years, 2.9 (range 
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Figure 1: Trends (three year moving averages) in age-standardised incidence rates (ESR) for intrahepatic 
cholangiocarcinoma according to gender, in the Netherlands (1989-2009)
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Figure 2: Trends (three year moving averages) in age-specific incidence rates (ESR) for intrahepatic 
cholangiocarcinoma in the Netherlands, 1989-2009
* Significant trend; Age group < 30 yrs: n<10
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0-8) patients  for 30-44 years, 9.2 (range 3-16) patients for 45-59 years, 16.8 (range 4-31) 
patients for 60-74 years and 11.4 (range 6-22) patients for age 75 years and over.
treatment
Data regarding treatment and TNM stage between 1989 and 2009 were available in 511 
patients and are summarized in table 1. 
survival
Data regarding survival between 1989 and 2009 were available in 760 patients and miss-
ing in 49 patients. The relative survival rates for patients with ICC between 1989 and 2009 
improved (Table 2). The short term (3-months, 6-months and 1-year) survival proportions 
for ICC patients who underwent surgery were 91%, 81% and 71%, respectively. The long 
term (3-year and 5-year) survival proportions for ICC patients who underwent surgery 
were 40% and 34%, respectively. For ICC patients receiving chemotherapy and/or irra-
diation corresponding short term numbers were 93%, 74% and 51%, respectively. For ICC 
patients receiving no anti-cancer therapy the short term rates were 39%, 23% and 12%, 
respectively. There were no long term survivors. 
table 1: Treatment according to TNM stage in patients with intrahepatic cholangiocarcinoma in the 
Netherlands between 1989 and 2009. 
tNM stage N treatment n(%)
surgery Chemotherapy and/or irradiation* No specific anti-cancer therapy
I 31 21(68) 0(0) 10(32)
II 47 15(32) 4(8) 28(60)
III 121 35(29) 19(16) 67(55)
IV 312 7(2) 49(16) 256(82)
*patients were treated according to hospital protocols, no exact chemotherapy and/or irradiation 
treatment regimes were available from the registry over time
table 2: Relative survival of patients with intrahepatic cholangiocarcinoma in the Netherlands, since 1989 
according to period of diagnosis 
Period of diagnosis  N survival % (se)
    3-months 6-months 1-year   3-year
1989-1994 174 50 (3.9) 33 (3.7) 24 (3.3) 4 (1.6)  
1995-1999 137 45 (4.3) 30 (4.0) 17 (3.2) 7 (2.3)  
2000-2004 181 55 (3.7) 37 (3.6) 24 (3.2) 11 (2.4)  
2005-2009 268 56 (3.1) 41 (3.1) 28 (2.9) 8 (2.6)  
p-value for trend   0.04 0.02 0.03 0.02  
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DIsCUssIoN
Incidence
This population-based study demonstrates an increase of ICC incidence in the Nether-
lands between 1999-2009 and improvements in survival. The increasing ICC incidence 
confirms and expands the previous findings on hepatocellular carcinoma reported in 
low endemic areas.6,15 The question is whether the rising incidence rate of ICC is a true 
increase or a reflection of improved diagnostic tests resulting in more detected tumours 
(e.g. MRI, multiphase CT, positron emission tomography (PET) scan and endoscopic ret-
rograde cholangiopancreatography) which became only available at larger scale since 
2002 in the Netherlands. In absence of generally used serum markers better imaging 
techniques might cause an increased detection or reclassification of hepatobiliary tu-
mours. ICC arises from the intrahepatic bile duct epithelium while extra-hepatic cholan-
giocarcinomas and Klatskin tumours involve the biliary tree within the hepatoduodenal 
ligament.13 To limit potential misclassification bias, patients with a non-classified tumour 
(histologically or clinically), an extra-hepatic cholangiocarcinoma or a Klatskin tumour 
were not included. The number of patients (97%) with ICC histologically confirmed is 
therefore rather high. 
Tumours previously described as unclassified might be classified as ICC today.16 
In case of misdiagnosis one would expect the incidence of at least one hepatobiliary 
tumour to decrease upon the rise of ICC. This has not happened, as the incidence of 
hepatocellular carcinoma also increased, and therefore the increasing incidence of ICC 
seems to be real.15 Increased detection of cancer is usually associated with an increase in 
the proportion of patients with early-stage cancers in all age-groups. Therefore, it would 
have been interesting to study trends according to disease-stage. Unfortunately due to 
changes in TNM-staging classification during the study period, it was not possible to 
draw any conclusion from trends by disease-stage.  
If the increase of ICC is a true reflection of an increased frequency, as can be sug-
gested, the reason for this increase is unknown.6,17 Several medical conditions are 
potentially related to ICC, including biliary cirrhosis, cholecystitis, alcoholic liver disease, 
liver cirrhosis, type II diabetes mellitus, chronic pancreatitis, hepatitis C viral infection 
(HCV), hepatitis B viral infection (HBV), obesity, non-alcohol fatty liver disease (NAFLD), 
non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), primary bili-
ary cirrhosis (PBC) and inflammatory bowel diseases including ulcerative colitis.18 One 
possible explanation, for the observed increases, supported by recent studies, might 
be an increase of HCV and/or HBV related ICC.19  However, details on presence of HCV 
and/or HBV in this population were not available, preventing us from further investi-
gating these hypotheses. Chronic inflammation, cholestasis, and chronic liver damage 
are associated with malignant transformation of the biliary epithelium.18 Perhaps ICC 
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increasing incidence might be influenced by an increasing prevalence of PSC.6,16,17 PSC-
related cancers are reported to peak after the 4th or 5th decade of life.18,20 In this study 
rising incidence occurred predominantly in patients aged from 45 to 59 years which is 
possibly explained by an increasing prevalence of PSC.7 Though data regarding changes 
in prevalence of risk factors for ICC were not analyzed, the increasing incidence of ICC 
is likely to be a true phenomenon rather than a reflection of improved diagnosis or a 
detection bias.11 Other explanations of the observed trends may be misclassification and 
changes in registration and/or diagnostic practices over time, therefore these data need 
to be interpreted with caution. The distinction between intrahepatic and extrahepatic 
cholangiocarcinoma is somewhat arbitrary, especially if it concerns a hilar cholangiocar-
cinoma. But, as extrahepatic cholangiocarcinoma in the Netherlands is five to six times 
more common than ICC, misclassification of only a small proportion of the extrahepatic 
tumours as intrahepatic has a relatively large influence on the incidence of ICC.
treatment and survival
Tumour resection is the only potential cure for ICC, mostly patients in TNM stage I are 
able to receive this therapy. Preoperative evaluation includes an assessment of patients’ 
fitness for surgery, evaluation of presence of metastatic disease and analysing the pos-
sibility to create a resection margin free from cancer.21 If any of these conditions are not 
fulfilled, surgical therapy is not indicated and palliative modalities are recommended.
Aljiffry et al. reviewed the literature according to outcome after surgical resection 
for ICC and found 5-year survival rates ranging from 15-40%, comparable with the 5-year 
survival rate of this study of 34%.13 Because only a few patients received surgery, trends 
in survival over time could not be calculated for surgery.  
Following complete surgical resection, a strategy aimed at optimizing local control 
with postoperative radiation alone or in combination with chemotherapy may theoreti-
cally provide benefit.22 However, the available literature consists mainly of uncontrolled 
small series, and many reports consist of a mix of bile duct cancers, gallbladder cancer, 
ampullary cancer, and either pancreatic or hepatocellular cancers; as a result, the ben-
efit of any type of adjuvant therapy remains uncertain.5,23 In general, no single drug or 
combination has consistently led to objective tumour shrinkage or an increased median 
survival beyond the expected 8 to 15 months.5,23 It is interesting to see that patients who 
received chemotherapy/irradiation had a similar short term survival rate, especially 
3-months and 6-months (93% and 74%) compared with patients who underwent surgery 
(91% and 81%). Studies on palliative chemotherapy on patients with ICC have reported a 
median survival time between 6 and 15 months.13 The survival benefit for patients able to 
receive surgery was increased with duration of follow-up, as the long term survival in pa-
tients receiving surgery is much better compared to patients receiving chemotherapy/
irradiation. 
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As the benefit of any type of adjuvant therapy remains doubtful, the improved 
survival can be attributed to improved palliative treatments (stenting and drainage), 
improved overall supportive medical care, or both. 
The improved survival could indicate lead-time bias related to early detection as 
patients with associated factors are controlled more often. For instance patients with 
PSC who have a lifetime risk of ICC which ranges from 8 to 20% and therefore these data 
need to be interpreted with caution.16
In conclusion, this population-based analysis appears to demonstrate an increasing 
incidence of ICC since 1999. Overall survival of patients with ICC appears to be improved, 
suggesting possible influences of improved imaging techniques, a better patient selec-
tion for surgery, or improved surgical techniques. Due to limitations both these state-
ments should be interpreted with caution.  This study demonstrates that even though 
improvements in ICC survival were achieved over time, patients with these tumours 
continue to have a very poor prognosis. Despite several advances over the last decades, 
ample opportunity for improvement still remains.  
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aBstraCt
Purpose Early detection of hepatocellular carcinoma (HCC) is essential for improved 
prognosis and long-term survival. To date, screening for HCC depends on serological 
testing (alpha-fetoprotein, AFP) and imaging (ultrasonography), both of which are not 
highly sensitive. A meta-analysis was performed to discuss recent developments in 
biomarkers that may be effective in screening for HCC. 
Methods A systematic search of PubMed, Embase, and Web of Science was performed 
for articles published between January 2005 and October 2010, and focusing on bio-
markers for HCC in urine, serum, or saliva. Data on sensitivity and specificity of tests 
were extracted from each included article and displayed with a summary ROC. A meta-
analysis was carried out in which the area under the curve for each biomarker was used 
to compare the accuracy of different tests. 
results In seven well-defined studies, three biomarkers were identified for potential 
use, namely, Golgi protein 73 (GP73), interleukin-6 (IL-6), and squamous cell carcinoma
antigen (SCCA). Comparison with AFP showed that GP73 was superior (p = 0.006; 95 % 
CL -0.23, -0.12), IL-6 was similar (p = 0.66; 95 % CL -0.31, 0.25), and SCCA was inferior to AFP 
(p = 0.001; 95 % CL 0.12, 0.23). 
Conclusion GP73 is a valuable serum marker that seems to be superior to AFP and can 
be useful in the diagnosis and screening of HCC. Although GP73 may improve the detec-
tion and treatment of one of the most common malignancies worldwide, additional 
research is required. 
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INtroDUCtIoN
The incidence of hepatocellular carcinoma (HCC) is rising in many countries [1]. Alpha-
fetoprotein (AFP) levels and ultrasonography are widely applied for HCC screening. 
However, AFP alone has a sensitivity of 60 % at a cut-off value of 20 ng/mL, and ultraso-
nography has a sensitivity of 65–80 % with a specificity ≥90 % when used as a screening 
test [1]. 
The lack of efficacious tests necessitates investigation for new HCC markers. Recent 
studies have focused on tests that can detect HCC, including tests for DCP, also known as 
prothrombin induced by vitamin K absence II (PIVKA II), the ratio of glycosylated AFP (L3 
fraction) to total AFP, alpha fucosidase, glypican 3, and HSP-70. However, as sensitivity 
and specificity values of these serological markers were low, they proved to be inad-
equate for HCC screening purposes, even when combined [1]. 
General criteria for effective disease screening have been proposed by the World 
Health Organization (WHO). These criteria are as follows: the disease screened for should 
represent a major cause of death, the natural history of the disease should be well 
characterized, screening for the disease should be cost-effective, and the screening test 
should be acceptable to the population. In addition, facilities for diagnosis and treat-
ment should be available, and there should be a treatment for the disease that improves 
the outcome if the disease is detected at an early stage [2]. These WHO criteria are met 
for HCC [1, 3].
To define the present state-of-the-art technology for HCC screening, we initiated a 
systematic review and metaanalysis, and discuss biomarkers most likely to be introduced 
as new instruments for HCC screening.
MaterIals aND MetHoDs
literature search strategy
A systematic search of PubMed, Embase, and Web of Science was performed for articles 
published between January 2005 and October 2010 (cut-off date 1 October 2010) and 
relevant to HCC biomarkers in urine, serum, or saliva. In 2005, Bruix et al. [1, 4] published 
the AASLD guidelines, which they updated in 2011. However, with respect to screening 
tests, their paper did not report on new findings [1]. Therefore, in the present study a 
new literature search was initiated based on the search terms listed in Table 1.
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literature screening
Studies were evaluated for their relevance to our present topic. Study selection was ac-
complished through four levels of study screening (C.D.M.W. in consensus with S.M.A) 
(Fig. 1). At level 1, studies were excluded for the following reasons: review, letters, case 
reports, editorials, and comments. At level 2, abstracts of all the studies accepted at level 
1 were reviewed for relevance. The full text was obtained for relevant papers, as well as 
any citations for which a decision could not be made from the abstract. At level 3, inclu-
sion required a control group with ≥10 cirrhotic patients (hepatitis B and/or hepatitis C 
and/or alcohol abusers), ≥10 patients with a HCC, and ≥10 confirmed healthy persons. 
Finally, at level 4, those studies that tested the biomarker in a second independent 
population were included together with the studies that were a continuation of studies 
included at level 3. All studies without repeated measurements, as validation of their 
method, were excluded.
table 1: Terms used in the systematic search for the present review
Database search terms
Pubmed (hepatocellular carcinoma[mesh] OR hepatoma*[tw] OR liver cell neoplasm*[tw] OR 
hepatocellular neoplasm*[tw] OR liver cell cancer*[tw] 
OR hepatocellular cancer*[tw] OR liver cell tumo*[tw] OR hepatocellular tumo*[tw] OR liver 
cell carcinom*[tw] OR hepatocellular carcinom*[tw]) AND
(biological markers[mesh] OR Biomarker*[tw] OR Biological Marker*[tw] OR Biologic 
Marker*[tw] OR Biochemical Marker*[tw] OR Immunologic Marker*[tw]
OR Immune Marker*[tw] OR Laboratory Marker*[tw] OR Serum Marker*[tw] OR Clinical 
Marker*[tw]) AND (blood[mesh] OR blood[sh] OR blood[tw] OR
serum*[tw] OR plasm[tw] OR plasma[tw] OR urine[mesh] OR urine[sh] OR urine*[tw] OR 
saliva[tw]) NOT (animals[mesh] NOT humans[mesh]) AND
limits Publication date: 2005-3000 OR entrance date: 2005-3000 AND
Language: English OR Dutch
Embase (((‘liver cell’ OR hepatocell*) NEAR/3 (neoplasm* OR cancer* OR tumo* OR carcinom*)):ti,ab,de) 
AND (marker/exp OR (biological NEAR/3 marker*):ti,ab,de
OR biomarker*:ti,ab,de) AND (blood/exp OR blood:ti,ab,de OR serum*:ti,ab,de OR 
plasm:ti,ab,de OR plasma:ti,ab,de OR urine*:ti,ab,de OR saliva:ti,ab,de)
limits Publication date: 2005-present AND
Human
Language: English OR Dutch
Web of Science (hepatoma* OR liver cell neoplasm* OR hepatocellular neoplasm* OR liver cell cancer* OR 
hepatocellular cancer* OR liver cell tumo* OR hepatocellular
tumo* OR liver cell carcinom* OR hepatocellular carcinom*) AND (Biomarker* OR Biological 
Marker* OR Biologic Marker* OR Biochemical Marker* OR
Immunologic Marker* OR Immune Marker* OR Laboratory Marker* OR Serum Marker* OR 
Clinical Marker*) AND (blood OR serum* OR plasm OR plasma
OR urine* OR saliva) NOT (animal* NOT human*)
limits Publication date: 2005-present AND
Language: English
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Data extraction and critical appraisal 
From each included article, we extracted data on study design, study population, and 
test results. The level of evidence of each article was scored using the Oxford Centre for 
Evidence-based Medicine Level of Evidence scale [5].
Data on sensitivity and specificity were extracted from each included article. If per-
centages were not reported, the sensitivity and specificity at several cut-off points were 
taken from the ROC curve in the included manuscripts.
statistics
Sensitivities and specificities of the included studies were logistically transformed, 
and a linear regression line was fitted through the resulting points. This line was then 
backtransformed to obtain the summary ROC (sROC) curve, according to the method 
described by Littenberg and Moses in 1993 [6]. A conventional ROC curve describes the 
impact of threshold in a single patient population. The sROC curve, a compact descrip-
tion of the accuracy of the diagnostic test, describes the test in many populations. Note 
that we did not extrapolate the curve past the range of empiric data.
The area under the curve (AUC) for the biomarkers of the included studies was 
taken from the reports. For each biomarker, the pooled AUC was calculated using the 
inverse standard errors as weights. This pooled AUC, together with their similarly pooled 
 
 
Studies excluded n = 779 
Level 1  
Paper identified after initial search 
n = 2822 
Level 2 
Abstract initially screened for relevance 
n = 2043 
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Full-text review for final inclusion 
n = 19 
Studies excluded n =2024 
Studies excluded n =12 
Level 4 
Studies included in the analysis 
n = 7 
Figure 1: Flow diagram showing selection of the seven articles
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standard error, was used to compare the accuracy of the diagnostic tests. AFP was con-
sidered as a reference for comparison to the other markers and was compared with the 
pooled AUC of each new biomarker using Student’s t test. SAS software (SAS system 9.2, 
SAS Institute, Cary, NC, USA) was used to perform the statistical analyses. A result was 
considered statistically significant at a p value of <0.05.
resUlts
Among 2,822 articles identified by the initial search, seven were within the scope of the 
study (Fig. 1) [7–13]. Two articles described Golgi protein 73 (GP73) as a HCC biomarker 
[7, 8], two described interleukin-6 (IL-6) [9, 10], and three described squamous cell car-
cinoma antigen (SCCA) [11–13]. All identified studies provided level 2b evidence on the 
Oxford Level of Evidence scale and included a control group with ≥10 cirrhotic patients 
(hepatitis B and/or hepatitis C and/or alcohol abusers), ≥10 patients with a HCC, and ≥10 
confirmed healthy persons [5].
GP73
GP73, also named Golgi phosphoprotein 2 (GOLPH2), is a 400-amino acid, 73 kDa trans-
membrane glycoprotein that normally resides within the cis-Golgi complex [7]. Marrero 
et al. tested GP73 in the sera of 352 patients, of whom 144 had HCC, 152 had cirrhosis, and 
56 did not have any disease [7]. At the optimal cut-off point of 10 relative units (RU), the 
sensitivity of GP73 was 62%, with a specificity of 88%.
A recent study by Mao et al. tested GP73 in the sera of 4,217 subjects: 789 with HCC, 
427 who were HBV or HCV carriers, 614 with cirrhosis, and 1,690 healthy controls [8]. GP73 
sensitivity was 74.6% and specificity was 97.4% at an optimal cut-off value of 8.5 RU. The 
sROC of GP73 in these studies is shown as the gray dotted line in Fig. 2.
Il-6
IL-6 is a pleiotropic cytokine playing a central role in hematopoiesis, and in the differ-
entiation and growth of a number of cells with different histological origins [9, 10]. The 
expression of IL-6 on hepatocytes, its upregulation by hepatitis B virus X protein, and its 
increased hepatic expression in liver cirrhosis have made IL-6 an intriguing cytokine to 
study in HCC [9].
Porta et al. [9] studied IL-6 in the sera of 90 patients: 30 with HCC, 30 with cirrhosis, 
and 30 healthy subjects. At the cut-off of 12 pg/mL, they found a sensitivity of 73% with 
a specificity of 87%. 
Hsia et al. [10] also studied IL-6 in the sera of 128 patients, of whom 26 patients had 
HCC, 50 had chronic HBV or HCV infection, and 29 were without any disease (healthy 
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controls). The authors found a sensitivity of 46% with a specificity of 95% for IL-6 at a 
cut-off of 3 pg/mL. The sROC of IL-6 of these studies is shown as the black straight line 
in Fig. 2.
sCCa
SCCA, a component of the high molecular weight serine protease inhibitors named 
serpins, is physiologically expressed in the squamous epithelia [11–13]. Increased levels 
have been detected in several epithelial cancers such as those of the head, neck, cervix, 
and lung [11–13]. 
Giannelli et al. [11] tested SCCA in the sera of 251 patients: 120 with HCC, 90 with cir-
rhosis, and 41 healthy subjects. At an SCCA cut-off of 0.368 ng/mL, the sensitivity was 
84% with a specificity of 48%. 
In 2007, Giannelli et al. [12] reported on serum SCCA testing in 961 patients at a cut-off 
of 3.8 ng/mL; a sensitivity of 42% with a specificity of 83% was found.
In 2008, Hussein et al. [13] evaluated SCCA in the sera of 94 patients, including 49 
patients with HCC, 30 with chronic liver disease without HCC, and 15 healthy persons. 
They used several cut-off points for SCCA: 100% sensitivity and 7% specificity were found 
at cut-off 0.3 ng/mL; 78% sensitivity and 84% specificity, at cut-off 1.5 ng/mL; and 39% 
sensitivity and 100% specificity were found at cut-off 3.5 ng/mL. The sROC of SCCA in 
these three studies is shown as the black dotted line in Fig. 2.
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GP73      
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Figure 2: The sROC with the sensitivity and 1-specificity of GP73, AFP, IL-6, and SCCA
GP73=Golgi protein 73; AFP=Alpha-fetoprotein; IL-6=Interleukin-6 ; SCCA= Squamous cell carcinoma 
antigen
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aFP
Under physiological conditions, AFP is a fetal-specific glycoprotein with a molecular 
weight of around 70 kDa. It is synthesized primarily by cells of the embryonic liver, of the 
vitelline sac, and of the fetal intestinal tract in the first trimester of pregnancy [14]. The 
serum concentration of AFP declines rapidly after birth, and its expression is repressed in 
adults [14]. In the pathological state of chronic liver disease, particularly, that associated 
with a high degree of hepatocyte regeneration, AFP can be expressed in the absence of 
cancer [14]. All studies compared the performance characteristics of their biomarker to 
those of AFP in differentiating HCC from non-malignant chronic liver disease [14]. The 
seven articles defined within the scope of this study all tested serum AFP in their popula-
tion. The sensitivity and specificity for AFP are summarized in Table 2. The sROC of AFP of 
the seven studies is shown as the gray straight line in Fig. 2. 
sroC 
The sROC is a method for summarizing discrepant data on the accuracy of diagnostic 
technologies; it summarizes the central tendency of a set of accuracy reports. 
Comparing the ‘gold standard’ with the three new biomarkers displayed that GP73 
was superior to AFP (p = 0.006; 95 % CL -0.23, -0.12), IL-6 was similar to AFP (p = 0.66; 95 
% CL -0.31, 0.25), and SCCA was inferior to AFP (p = 0.001; 95 % CL 0.12, 0.23). 
DIsCUssIoN
This systematic review has attempted to correlate recently discovered biomarkers for 
HCC screening with AFP. Our findings suggest an advantage of GP73 over AFP as a serum 
marker for HCC screening. In our review process, many papers were excluded because of 
table 2: Characteristics and outcome measures of the included studies describing serum AFP levels in the 
patients tested.
authors Year published No. of patients Cut-off value aFP 
(ng/ml)
sensitivity (%) specificity 
(%)
Marrero et al.6 2005 352 112 25 97
Mao et al.7 2010 4,217 35 58 85
Porta et al.8 2008 90 12.8 63 88
Hsia et al.9 2007 128 20 62 88
Giannelli et al.10 2005 251 12.6 45 87
Giannelli et al.11 2007 961 18.8 41 94
Hussein et al.12 2008 94 7.7 90 93
AFP = alpha-fetoprotein
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limitations in study design: mostly because of a poor definition of the underlying etiol-
ogy and the absence of a healthy control group. Due to our rigorous selection criteria, 
the review was
limited to seven studies with level 2b evidence, all testing their biomarker in serum 
[5]. Preferably, HCC screening should be performed using a non-invasive diagnostic test. 
Although the field of tumor markers in HCC is rapidly evolving, no ideal marker tested 
with a proper study design currently exists. 
Since HCC is among the cancers with the worst prognosis, early diagnosis and treat-
ment are essential for effective treatment [1]. The use of serological markers in patients 
at highest risk for developing HCC may decrease HCC mortality. However, for many 
years AFP has been the only standard serum marker for the detection of HCC, despite 
its unsatisfactory sensitivity [1]. Therefore, several new biomarkers (such as GP73, IL-6, 
and SCCA) have been investigated for their diagnostic accuracy and potential clinical 
application.
Giannelli et al. reported SCCA to be a good biomarker for discriminating early HCC 
from liver cirrhosis. Combining the three studies reporting on SCCA in a metaanalysis, 
we found SCCA to be inferior to AFP (p = 0.001).
In this systematic review, our meta-analysis of publications reporting on IL-6 showed 
that the accuracy of IL-6 was similar to that of AFP (p = 0.66).
Recent studies have identified serum GP73 as a potential biomarker for HCC. The 
study of Marrero et al. showed GP73 to be promising but had a small sample size [7]. A 
second study performed in medical centers in China and the USA showed GP73 to be a 
valuable tumor marker for HCC [8]. Combining both studies in our meta-analysis showed 
GP73 to be superior to AFP (p = 0.006). Although GP73 appears to be a better marker 
than AFP for diagnosing HCC, additional research is required that focuses on GP73.
Mao et al. found the elevation of serum GP73 to be modest in virus carriers, moderate 
in patients with cirrhosis, and dramatic in patients with HCC [8]. This indicates that the 
performance of GP73 might depend on the etiology of the underlying disease. This is 
important if one wants to differentiate between non-malignant disease and early HCC 
in; for instance, patients with chronic viral hepatitis. The authors also claimed tumor 
recurrence to be correlated with an elevated GP73 level in the blood [8]. Thus, besides 
being an interesting screening test, GP73 might also be useful as a surveillance test. The 
role of intrahepatic metastasis of the original tumor versus the development of de novo 
tumors could not be tested by Mao et al. The authors found no effect based on tumor 
size and tumor differentiation on the serum levels of GP73 [8].
The small amount of data available per paper on differences in etiology, tumor recur-
rence, and tumor development (numbers of tumors) precluded us from establishing the 
performance of GP73 in relation to these three parameters.
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It would be interesting to examine whether combined measurements of GP73 and 
AFP further increase the sensitivity for detection of HCC. Although GP73 is a promis-
ing marker, more studies are warranted, especially because this protein is detected by 
Western blot analysis which hampers its reliability and availability in clinical use. Further 
studies are needed to analyze and validate early-stage HCC markers. Recently, Shang 
et al. [15] evaluated osteopontin as a marker of early-stage HCC. Although this study 
has some limitations, it is an important first step in the evaluation of new markers of 
early-stage
HCC [15]. The next step should be large-scale validation to determine whether os-
teopontin is superior to GP73 and to analyze whether osteopontin in combination with 
GP73 complements screening tests.
In conclusion, GP73 is a valuable serum marker that is superior to AFP and can be 
useful in the diagnosis and screening of HCC. GP73 may improve the detection and treat-
ment of one of the most common malignancies worldwide. More studies are needed to 
further elucidate the influence of the etiology of disease on the signal strength of GP73.
Recently introduced biomarkers 63
reFereNCes
 1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 
1020–1022
 2. Wilson JMG, Junger G. Principles and practice of screening for disease. Geneva: World Health 
Organization; 1968
 3. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success 
against cancer? JAMA 2000; 283: 2975–2978
 4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–1236 
 5. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidencebased Medicine, Levels of Evidence 
(March 2009). http: //www. cebm.net/index.aspx?o=1025.
 6. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new 
meta-analytic method. Med Decis Mak 1993; 13: 1313–1321
 7. Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum 
marker for hepatocellular carcinoma. J Hepatol 2005; 43: 1007–1012
 8. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular 
carcinoma. Gut 2010; 59: 1687–1693
 9. Porta C, De Amici M, Quaglini S, et al. Circulating interleukin-6 as a tumor marker for hepatocel-
lular carcinoma. Ann Oncol 2008; 19: 353–358
 10. Hsia CY, Huo TI, Chiang SY, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte 
growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007; 33: 208–212
 11. Giannelli G, Marinosci F, Trerotoli P, et al. SCCA antigen combined with alpha-fetoprotein as 
serologic markers of HCC. Int J Cancer 2005; 117: 506–509
 12. Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for 
improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim 2007; 383: 147–152
 13. Hussein MM, Ibrahim AA, Abdella HM, et al. Evaluation of serum squamous cell carcinoma anti-
gen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian J 
Cancer 2008; 45: 167–172  
 14. Gomaa AI, Khan SA, Leen ELS, et al. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 
2009; 15: 1301–1314 
 15. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepato-
cellular carcinoma. Hepatology 2012; 55: 483–490

Chapter 5
the likelihood of hepatocellular adenoma 
as a risk factor for hepatocellular 
carcinoma in a non-cirrhotic liver
Adapted to: Hepatocellular adenoma as a risk factor for hepatocellular carcinoma in a non-
cirrhotic liver: a plea against’. Accepted Gut
Caroline D.M. Witjes
Fiebo J.W. ten Kate 
Susanna M. van Aalten 
Roy S. Dwarkasing 
François E.J.A. Willemssen 
Cornelis Verhoef 
Robert A. de Man 
Jan N.M. IJzermans
66 Chapter 5
aBstraCt 
objective: Hepatocellular adenoma (HCA) is a rare benign tumour, with a small risk 
of malignant transformation into hepatocellular carcinoma (HCC). This study explores 
whether an HCA component or a transition zone can be demonstrated in HCC in a non-
cirrhotic liver, to confirm the concept of adenoma-carcinoma transition. 
Design: Paraffin-fixed liver tissue slides of patients diagnosed with HCC in a non-cirrhotic 
liver were retrieved from the archives of pathology department. Pre-operative images 
were analyzed, and recurrence and survival rates calculated. 
results: Between January 2000 and May 2011, 48 patients with 52 HCCs in a non-cirrhotic 
liver were operated. Median age at diagnosis was 65 (range 21-82) years, 24 patients 
(50%) were male. The median tumour size was 10 cm (range 2-24 cm), median body 
mass index was 23 (range 18-34). All lesions were without any HCA component or signs 
of a transition zone. In 9 patients HCA immunohistochemical staining and revision of 
the pre-operative imaging was performed because of doubt between HCA and well-
differentiated HCC. No HCA component or transition zone was found on routine stains 
or by immunohistochemical staining. 
Conclusion: Using extensive immunohistochemical staining no HCA components or 
transition zones from benign to malignant could be demonstrated in a large cohort 
of patients who developed HCC in a non-cirrhotic liver. We conclude that it is highly 
unlikely that HCC in a non-cirrhotic liver originates from a liver adenoma. 
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INtroDUCtIoN
Hepatocellular adenoma (HCA) is a rare benign liver tumour that most frequently occurs 
in young women and carries a small risk of malignant transformation into hepatocel-
lular carcinoma (HCC) [1-4]. HCC is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality [5,6]. Natural history of HCC de-
velopment suggests that chronic hepatitis and cirrhosis induce common premalignant 
steps whatever the origin of the disease [5]. HCC occasionally develops in the absence 
of chronic liver disease or cirrhosis [7]. It is questioned whether these tumours have a 
specific aetiology and a common pathway of carcinogenesis. It is suggested that HCC in 
non-hepatitis and non-cirrhotic livers may be the result of a malignant transformation 
of HCA [3,8]. This hypothesis assumes the co-existence of both HCA and HCC within the 
same tumour at a certain moment. The exact point at which the switch to malignant 
transformation occurs remains unknown [4]. Progression from a precursor lesion might 
be a multistep process, accompanied by a transition zone from benign hepatocytes 
towards dysplastic and malignant hepatocytes. Hypothesizing that HCC may arise from 
HCA is based on the assumption that at a certain moment residual HCA or a transition 
zone with dysplastic changes (as found in colorectal cancers) is present within the ma-
lignant liver lesion [9]. 
As to date, no reports can be found in literature supporting this concept and we 
doubt whether this mechanism is indeed of any relevance for the pathogenesis of HCC 
in non-cirrhotic livers. This study explores whether an HCA component or a transition 
zone can be demonstrated within HCC lesion in non-cirrhotic livers. 
MaterIal aND MetHoDs
Patients
The Erasmus University Medical Centre Rotterdam is a tertiary referral centre for focal 
liver lesions. From January 2000 to May 2011, 48 patients who were radiologically diag-
nosed with HCC in a non-cirrhotic liver were treated by surgical resection, i.e. segment 
or wedge resection and hemihepatectomy. A total of 52 lesions were surgically excised. 
Clinical data for age, gender, body mass index (BMI), aetiology, biochemical parameters 
and serum tumour markers alpha-fetoprotein (AFP) were retrospectively collected. 
Only patients with complete data at the time of resection and who were negative for 
HCC risk factors (i.e. hepatitis C viral infection, hepatitis B viral infection, alcohol abuse, 
haemochromatosis, metabolic syndrome or cirrhosis of any other cause) were included. 
Patients with a fibrolamellar HCC were excluded. 
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After treatment, patients had a follow-up using contrast-enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) combined with determination 
of serum AFP at 3 and 6 month intervals for up to 2 years post-treatment. After 2 years, 
follow-up was continued annually up to 5 years. HCC recurrence was defined as the 
occurrence of a focal liver lesion with HCC characteristics with or without increase of 
AFP, enlargement of lymph nodes in the liver hilum, or suspected extrahepatic lesions, 
showing growth at follow-up.  
Histopathological and immunohistochemical analysis
Paraffin-fixed liver tissue slides were retrieved from the archives of the pathology depart-
ment. From each tumour at least one sample per 1 cm tumour diameter was included. For 
each lesion, macroscopic characteristics (size, number of tumours and surgical resection 
margin) and microscopic features were evaluated (F.J.W.K.). Non-tumoral liver tissue was 
evaluated for fibrosis and cirrhosis according to the classification of the METAVIR group 
as follows: F0 (no fibrosis); F1 (portal fibrosis), F2 (few porto-central bridges), F3 (many 
porto-central bridges) and F4 (cirrhosis) [10]. Steatosis was graded according to Kleiner 
et al.: Grade 1 (5-33% of the hepatocytes), grade 2 (33-66% of the hepatocytes), grade 
3 (more than 66% of the hepatocytes). Steatosis, if not observed or <5% was graded 
as grade 0 [11]. Lesions were evaluated for the presence of a fibrous tumour capsule 
and presence of necrosis and steatosis. The tumours were defined as HCC if nuclear 
polymorphia, a lack of reticulin pattern and presence of a capsula was demonstrated. 
Tumour differentiation grade was determined according to the Lauwers classification, 
and was based on the areas of tumour showing the highest grade [12]. Vascular invasion 
was defined as microscopic tumour invasion identified in the branches of the hepatic 
portal vein which was contiguous to the tumour [13]. Patients who had prior treatment 
with radiofrequency ablation or transarterial (chemo) embolization were only included 
for analysis if vital tumour tissue was found to characterize the lesion. A transition zone 
was defined as an area within the tumour lesion where benign hepatocytes were found 
in close relationship with dysplastic or malignant hepatocytes.  
Immunohistochemistry was performed on selected paraffin sections of the tumour. 
Immunostaining included L-FABP (polyclonal antibody, 1:100 dilution, Bio-Connect), SAA 
(monoclonal mouse antibody, 1:200 dilution, Dako), CRP (mouse monoclonal antibody, 
1:1600 dilution, Bio-Connect), GS (monoclonal mouse antibody, 6/glutamine syn., B&D, 
CC1-standard) and β-catenin (monoclonal mouse antibody, clone 14, Autostainer, PT 
high, Dako). A nuclear staining for β-catenin, focal or diffuse, was considered positive. 
L-FABP was considered positive when the tumour tissue was negative compared to the 
non-tumoral liver tissue. For each immunohistochemical staining a positive and nega-
tive control was used for control.
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Imaging 
The available pre-operative liver imaging was analysed independently by two expe-
rienced radiologists (F.E.J.A.W. and R.S.D.). They reviewed the images (CT or MRI) per-
formed prior to the operation independently while blinded to the clinical history and 
pathologic diagnosis. Each radiologist was asked to make a diagnosis for every lesion 
detected; they had to report their certainty of diagnosis (uncertain, doubt, definite).   
statistical analysis
Continuous variables were summarised as median with ranges, and categorical variables 
were summarised as frequency and percentages. The Mann-Whitney U test, t-test or the 
χ2-test were used whenever appropriate. Statistical significance was considered at a p-
value < 0.05. The Kaplan-Meier method was used to calculate the survival rate. 
resUlts   
Clinical features
Of 241 patients with HCC in a non-cirrhotic liver 48 patients (24 male; 50%) with 52 
lesions were shown to be free of any known risk factor for the development of HCC. 
Lesions had a median size of 10 cm (range 2-24 cm). Median age at diagnosis was 65 
(range 21-82) years, median BMI was 23 (range 18-34) and median AFP at diagnosis was 
6 ng/ml (range 2-2,745,000). Of the 48 patients treated with surgical resection, 15 (31%) 
had prior treatment with radiofrequency ablation or transarterial (chemo) embolization 
as downstaging therapy. 
During follow-up 17 patients (35%) had recurrence of HCC after a median period of 6 
(range 2-42) months. The 1, 3 and 5-year survival rate was 86%, 64% and 37%, respectively. 
Pathological features
Non-tumoral liver characteristics
Non-tumoral liver tissue was available in all cases. Pathological analysis per patient of 
the non-tumoral liver tissue showed steatosis grade 0 in 28 (58%) patients, steatosis 
grade 1 in 11 (23%) patients or grade 2 in 8 (17%) patients, and steatosis grade 3 in 1 (2%) 
patient. No fibrosis (F0) was present in 36 (75%) patients, whereas all others had F1 (n=11; 
23%) or F2 (n=1; 2%). 
On preoperative imaging, 42 HCC patients were found to have a single HCC node in 
the liver. Multiple HCCs (2-3 nodules) were found in 10 patients. Non-tumoral liver tissue 
didn’t show dysplastic hepatocellular lesions.  
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tumour characteristics
All lesions radiologically diagnosed as HCC were histologically confirmed. In 45 patients 
(94%) the surgical resection margins were free of tumour. Differentiation according to 
the Lauwers classification resulted in 12 well-differentiated (23%), 33 moderately-differ-
entiated (64%) and 7 poorly-differentiated (14%) tumours. A total of 33 lesions (63%) had 
presence of vascular invasion. Capsule was present in 24 lesions (46%), 27 lesions (52%) 
revealed tumour necrosis, and in 22 lesions (43%) steatosis was present in the tumour. 
In none of the tumours was a HCA component detected, and no transition zone from 
HCA into HCC was found in any of the patients. 
Immunohistochemical staining and radiological diagnosis
In 9 patients with 9 nodules there was some doubt between the diagnosis HCA and well-
differentiated HCC when analyzing the hematoxilin & eosin (HE) stained slides. In these 
cases an acinar growth pattern, a tumour capsule and a high mitotic activity were less 
often seen. In these patients, immunohistochemical stainings were used to differentiate 
between HCA and HCC. Table 1 summarises the results of the immunohistochemical 
staining tests of these ‘doubtful’ HCCs. The immunohistochemical staining profile of HCA 
is also presented in Table 1 [14]. After extended immunohistochemical staining there 
were no signs of a HCA component in the HCC lesion or a transition zone. Table 1 also 
presents the diagnosis made by the two radiologists after revising the pre-operative 
imaging. In these 9 patients there was no HCA component found on radiological exami-
nation.
table 1: Histological immunostaining and radiological characteristics of patients with ‘doubtful’ HCC and 
the immunostaining profile of HCA lesions.14
staining Hepatocellular carcinoma (n=9) Hepatocellular adenoma (n=57) 14
Glutamine synthetase 
positive
4 (44) 5 (9)
β-catenin positive 2 (22) 7 (12)
CRP positive 8 (89) 36 (63)
SAA positive 3 (33) 36 (63)
L-FABP positive* 4 (44) 11 (19)
Radiologist 1 Certain HCC (n=9) -
Radiologist 2 Certain HCC (n=8)
Doubt HCC (n=1)**
-
Data are numbers (%)
* the tumour being negative compared to the non-tumoral liver tissue; ** another imaging modality was 
required for decision-making
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DIsCUssIoN
This study explored whether a HCA component or a transition zone is present in HCC 
which develops in a non-cirrhotic liver. Although HCA is suggested to have a small risk of 
malignant transformation into HCC, so far a HCA component or a transition zone in HCC 
which would strengthen this hypothesis was not demonstrated. Therefore, we conclude 
that it is highly unlikely that HCC in a non-cirrhotic liver arises from HCA. 
In a recent review by Stoot et al. malignant transformation was reported in 4.2% of 
the HCA cases and in 4.5% of the resected HCA cases [15]. Most case series reporting 
on malignant transformation of HCA have a limited sample size and report only on re-
sected adenomas. This may have led to an overestimation of the true risk. Furthermore 
a selection bias of reported studies cannot be excluded. In the present study, because 
it is possible that HCA lesions were resected before transformation into HCC was initi-
ated, we included patients at the end of the transformation process, i.e. lesions of highly 
differentiated HCC in non-cirrhotic livers [4]. If indeed HCA has the ability to transform 
into a malignant lesion a stepwise progression would be expected, comparable to the 
adenoma-carcinoma progression sequence in colorectal cancer [2,9,16]. Cases of HCA 
transformed into HCC are described with a pattern of a nodule within a nodule or 
two tumours lying next two each other without a transition zone [2,8,15-17]. However, 
a randomly scattered HCC throughout the HCA or absence of a thin fibrous capsule 
was not mentioned [18]. Without an explicit description of these features, we cannot 
assume that the two nodules are related to each other. We had the unique opportunity 
to study a large cohort of patients resected for HCC in a non-cirrhotic liver. In the 48 
patients with 52 lesions, there were no signs of HCA or a transition zone from HCA into 
HCC. No premalignant lesions could be demonstrated. There are some cases in which it 
might be difficult to distinguish HCA from well-differentiated HCC. HCC or borderline 
tumours in which the differential diagnosis between adenoma and HCC is debatable, 
are hypothesized to have a higher risk of malignant transformation [18]. It is reported 
that β-catenin activated HCA is associated with an enhanced risk of malignant trans-
formation and progression into HCC [19]. Several studies have identified mutations of 
β-catenin gene in HCAs and reported that activated β-catenin mutations deregulate the 
β-catenin pathway [15].
In the present study, in 9 of the 52 cases the differential diagnosis included HCA as 
well as a highly-differentiated HCC. The specimens of these patients were studied using 
additional immunohistochemical staining. Ruling out the potential diagnosis of HCA on 
the absence of validated markers for HCA is daring, as different types of adenoma are 
likely to vary in the potential rate of malignant progression. However, this staining did 
not provide any argument for a history of HCA and was not similar to the pattern found 
in HCA lesions (Table 1). A median of 10 (range 2-23) paraffin-fixed slides per tumour 
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seems representative. However, as this is a retrospective study, there is no guarantee 
that the entire tumour tissue is included in the paraffin-fixed slides which are evaluated 
by one observer. In all 9 lesions the definite diagnosis was established as HCC, and not 
HCA. In addition, reviewing the radiological images all lesions were diagnosed as HCC; 
only in one case did one of the radiologists request a second imaging modality. None of 
the lesions was diagnosed as a non-malignant lesion, which might have led to a different 
management. 
In conclusion, this study explored the hypothesis that HCC in non-cirrhotic livers may 
result from malignant transformation of HCA. Using extensive immunohistochemical 
staining we found no HCA components or transition zones to confirm this hypothesis. 
Therefore, we conclude that it is highly unlikely that a HCA in a non-cirrhotic liver will 
degenerate into a malignancy, and that data that aim to legitimise resection are biased 
and may lead to overtreatment.  
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aBstaCt 
Purpose: To explore the potential use of magnetic resonance imaging (MRI) in predicting 
the outcome for patients with hepatocellular carcinoma (HCC), imaging characteristics 
were correlated with pathological findings and clinical outcome.
Materials and Methods: With permission from the Ethical Board, clinical data and tis-
sues of resected HCC patients were collected, including the preoperative MRI. The role 
of MRI characteristics on recurrence and survival were evaluated with univariate and 
multivariate analyses.
results: Between January 2000 and December 2008, 87 patients with 104 HCCs were 
operated on. Microvascular invasion was present in 55 lesions (53%). HCC was character-
ized as well differentiated in 15 lesions (14%), as moderate in 50 lesions (48%), and as 
poorly differentiated in 34 lesions (33%). Due to preoperative treatment in five lesions 
(5%) no vital tumor was left. In 85 lesions (88%) washout of contrast was noted. Of the 
87 patients, 28 (32%) with 37 lesions developed HCC recurrence; these patients had 
microvascular invasion significantly more often and a moderate or poorly differentiated 
tumor (P < 0.001 and P = 0.025, respectively). MRI more often showed washout when 
HCC was moderately or poorly differentiated (P < 0.001) or microvascular invasion was 
present (P = 0.032).
Conclusion: Differentiation grade and microvascular invasion are significantly associ-
ated with the presence of washout demonstrated on dynamic contrast-enhanced MRI.
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INtroDUCtIoN 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality (1). The tests used to diagnose 
HCC include different imaging modalities, biopsy, and alpha-fetoprotein (AFP) levels (2). 
Dynamic contrast-enhanced magnetic resonance imaging (MRI) has a higher sensitivity 
in detecting HCC (81%) compared with computed tomography (CT) (68%) and is widely 
used as preoperative imaging (3). Typical imaging characteristics of HCC on MRI are a 
large (>2 cm) hyperintense lesion on T2-weighted images, arterial enhancement and 
washout in the venous phase, and a pattern of ‘‘rapid rising and rapid descending’’ (4,5). 
An enhancing capsule is also often noticed. 
Various risk factors for fatal recurrence after orthotopic liver transplantation (OLT) or 
resection for HCC have been well documented. The most important ones are microvas-
cular invasion, differentiation grade, tumor size, and multifocal tumors (6–14). Identifica-
tion of microvascular invasion and differentiation grade by histological examination of 
resected specimens is important because long-term survival is strongly correlated with 
these findings (9). 
If microvascular invasion and differentiation grade can be evaluated by imaging and 
without biopsy, long-term survival might be predicted more accurately preoperatively 
and the treatment strategy for some patients might be adapted. 
To explore the potential use of MRI in predicting the outcome for patients with HCC, 
in this study we correlated imaging characteristics with pathological findings and clini-
cal outcome.
MaterIals aND MetHoDs
The local Institutional Ethical Review Board granted permission for analysis of the pre-
operative MRI and all the histological specimens. All patients with HCC operated on in 
our center from January 2000 to December 2008 with at least one preoperative MRI 
were included in this study. The most recent MRI prior to the operation or preoperative 
downstaging treatment was analyzed. The preoperative diagnosis of HCC was based on 
imaging and clinical and laboratory findings. Diagnosis was histologically confirmed 
after surgery. After diagnostic MRI and before surgery, tumor progression was followed 
by ultrasound or contrastenhanced CT every 3 months (2). During preoperative follow-
up no changes in tumor size were noted. Treatment with curative intent was defined as a 
complete surgical resection, including wedge resection, segment resection, hemihepa-
tectomy, and OLT. 
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Not included in the study were patients who received lobectomy for palliative treat-
ment (n = 1) and patients whose preoperative radiologic evaluation did not include an 
MRI (n = 49). 
The medical charts of the included patients were analyzed. Data on age, gender, 
etiology, biochemical parameters, and serum tumor markers were reported. All patients 
were classified according to the Child-Pugh and BCLC scoring system. Slices of the 
resected specimens from these patients were blindly scored by one pathologist. The 
MRI scans were blindly scored by two radiologists (6 years abdominal interest, and 1 
year abdominal fellow) with special interest in liver imaging. In case of different find-
ings, consensus was defined afterwards. After treatment, patients had a follow-up using 
contrast-enhanced CT or MRI combined with determination of serum AFP at 3 and 6 
month intervals for up to 2 years posttreatment. After 2 years, follow-up was continued 
annually up to 5 years. In the presence of liver cirrhosis, lifetime follow-up was pursued. 
HCC recurrence was defined as the appearance or reappearance of a lesion with 
vascular enhancement in the treated area or elsewhere on imaging, ie, local recurrence, 
a new lesion in the liver, enlargement of lymph nodes in the liver hilum, or suspected 
extrahepatic lesions and an increase of serum AFP. 
MrI
All patients had a protocolized contrast-enhanced MR scan using a 1.5T unit (Philips 
Medical Systems, Best, the Netherlands; or General Electric, Signa, Milwaukee, WI). A 
four-channel phased-array body coil was used. The scan sequence started with a single-
shot fast spin echo (SSFSE) (repetition time [TR] msec, echo time [TE] msec 832/80–120; 
flip angle 90⁰) with varying TE values (short TE = 80 and long TE = 120) fat-suppressed 
T2-weighted FSE (TR/TE 3000/80, flip angle 90⁰), and T1-weighted in-phase and opposed-
phase spoiled gradient recalled (SPGR) sequences (shortest/TE 4.6 msec and 2.3 msec, re-
spectively; flip angle 90⁰). After administration of an intravenous gadolinium-chelate (28 
ml [double dose]; Magnevist [gadopentetate dimeglumine], Schering, Berlin, Germany), 
at 3 ml/s using a power injector, dynamic imaging with 3D T1-weighted fat-suppressed 
SPGR (General Electric) or 2D T1-weighted SPGR (Philips) images were performed in at 
least three phases (arterial, portal, and delayed). Imaging parameters: TR 5.8 msec, TE 
1.94 msec, flip angle 15.0⁰, NSA 0.5, matrix 256 x 192, field of view (FOV) 38.0 cm, slice 
thickness 4.0 mm, acquisition time each phase 20–23 seconds, scanned in breath-hold. 
Arterial phase was timed using a test bolus technique. The portal and delayed phases 
were performed at 45 and at 120 seconds, respectively, after the acquisition of the arte-
rial phase. In addition, a delayed-phase 3D T1-weighted SPGR sequence was performed 
at least 4 minutes after contrast injection. Slice thickness of 4–7 mm was used in all 
sequences.
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No adverse reactions were reported during the entire study. A total of 13 patients 
were scanned elsewhere using an identical protocol, and images were reviewed at our 
institution by the same radiologists. 
MrI analysis
All preoperative MRI examinations were transferred to a picture archiving and communi-
cation system (PACS) and workstation (AquariusNET; Terarecon, San Mateo, CA). Exami-
nations with major respiratory artifacts were excluded (n = 8). The liver was evaluated 
according to the presence and type of cirrhosis, and presence of portal hypertension 
and ascites. All visible lesions were categorized as benign, malignant, or possibly malig-
nant. Benign lesions were not further analyzed. Characteristics of the malignant lesions 
were assessed. Tumor size (longest diameter), number, shape, capsule, and margin were 
evaluated in the arterial, portal, and venous phase. The shape of the tumor was scored 
as round, lobular, or irregular. Washout was reported as present when the tumor had the 
typical features (eg, arterial enhancement wash-in and portal venous or delayed loss of 
enhancement) compared to the surrounding liver parenchyma washout (5).
Intensities were compared with the liver parenchyma and defined as hypointense, 
isointense, or hyperintense. The presence of fat was noted at the T1 opposed-phase 
images.
The dynamic MRI data were analyzed on a Workstation (AquariusNET). Tumor signal 
intensity of the individual lesions were measured using a region of interest (ROI) manu-
ally placed by the same investigator. The size of the ROI was as large as possible, thereby 
avoiding necrotic areas. A circle of at least 2 cm2 was drawn in the tumor. The ROI was 
manually placed in the lesion at the position of interest. This position was automatically 
copied to all sequences. After copying, the position of the ROI was checked and in case 
of a wrong position the position of the ROI was corrected manually. 
The signal intensity values derived from the ROI were plotted against time in a tumor-
intensity curve (TIC). Per individual lesion, 4–12 images were used to create the TIC. The 
increase in signal intensity during contrast enhancement was assessed by percentage. 
No clinical, laboratory, or pathological information other than the presence of HCC was 
provided during image analysis.
Patients with a recent MRI, ie, a maximum interval of 6 months (26 weeks) between 
the MRI and treatment, were included in the analysis in which radiological findings were 
compared with histological characteristics.
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surgical Pathology Parameters
All slices of the resected specimens from patients were analyzed by a pathologist with 
expertise in liver pathology. Features including the presence or absence of fibrosis or cir-
rhosis and dysplasia in the surrounding liver tissue, type of tumor, differentiation grade, 
microvascular invasion, and the surgical resection margin were recorded. The outcome 
of the histological examination was defined as the gold standard. The histological grade 
was determined according to the Lauwers classification (11), and was based on the areas 
of tumor showing the highest grade. Microvascular invasion was defined as microscopic 
tumor invasion identified in the hepatic portal vein which was contiguous to the tumor 
(8).
statistical analysis
The Kaplan–Meier method was used to calculate recurrence rate; the difference was 
tested using the logrank test. Cox regression univariate analysis was used to assess the 
importance of prognostic factors (age, gender, etiology, AFP, tumor size, presence of 
cirrhosis, presence of dysplasia, tumor differentiation grade, and presence of microvas-
cular invasion) on recurrence. Multivariate Cox regression analysis was performed to 
assess the independent prognostic factors. Strong colinearity between differentiation 
grade and microvascular invasion made interpretation of the results of one multivariate 
Cox regression analysis impossible. Therefore, two models are presented: Model 1: dif-
ferentiated grade and Model 2: presence of microvascular invasion. Both models were 
adjusting for age, gender, level of AFP, and tumor size.
Differences in radiological variables between histological differentiation grade and 
histological microvascular invasion were compared using the Mann–Whitney U-test, 
t-test, or the x2-test whenever appropriate. Statistical significance was considered at P 
< 0.05. 
The tumor intensity was visualized in a TIC. The shape of the patient specific intensity 
curve was fitted with a nonlinear regression model: a first-order opencompartment 
model [15]. Differences between the TIC were assessed comparing the patient-specific 
estimated parameters of the nonlinear regression model.
resUlts
Clinical Characteristics
From January 2000 through December 2008, 597 patients visited our hospital for treat-
ment of HCC. Of these, 100 patients were able to receive surgical curative treatment 
having received at least one preoperative MRI. No vital tumor was left in five patients 
(tumor differentiation could not be assessed on histological analysis because of exten-
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sive tumor necrosis), and in eight patients MRI was not included for analysis because of 
artifacts; these 13 patients were excluded from the analysis.
A total of 87 patients were included with a total of 104 HCCs. Their median number 
of tumors was 1 (range 1–6). The median time between the preoperative MRI and the 
operation was 10 (range 1–126) weeks. Of the 87 patients with HCC, 62 (71%) received 
resection and 25 (29%) underwent OLT. Of the 62 patients treated with resection, 6 
(10%) had prior treatment with radiofrequency ablation (RFA) or transarterial(chemo)
embolization (TACE). Of the 25 patients receiving OLT, 13 (52%) underwent RFA or TACE 
as bridging to transplantation. 
radiological Characteristics
Of the 104 HCCs, 97 (93%) were depicted on MRI. Seven HCCs were too small to detect 
with MRI. They were found in explanted livers and were detected by histological ex-
amination only; these seven HCCs were recorded as missing data. Morphology of the 
HCCs was predominantly round-shaped in 74 lesions (76%), versus lobular in 20 lesions 
(21%); three lesions (3%) had an irregular contour. In 85 lesions (88%) there was washout 
of contrast present during the portal or late venous phase. A total of 82 lesions (85%) 
showed capsular enhancement. 
Pathological Characteristics
In 101 lesions (94%) the diagnosis of HCC was confirmed. In three lesions (3%) focal areas 
of cholangiocellular differentiation in HCC were noted. In three tumors (3%) the surgical 
resection margin was not free of tumor. Differentiation according to the Lauwers clas-
sification resulted in 15 well-differentiated lesions (14%), 50 moderately differentiated 
(48%), and 34 poorly differentiated (33%) tumors. Five nodules (5%) did not display 
enough vital tumor due to preoperative treatment with RFA or TACE. A total of 55 lesions 
(53%) had microvascular invasion. 
recurrence
During follow-up 28 patients had recurrence of HCC after a median period of 10 (range 
1–24) months. Patients with recurrence of HCC were characterized by higher preopera-
tive AFP serum levels and larger tumor size. In addition, they more often had a moder-
ate or poorly differentiated tumor and presence of histological microvascular invasion 
(Table 1). 
Strong colinearity between differentiation grade and microvascular invasion made 
interpretation of the results of one multivariate Cox regression analysis impossible. 
Therefore, two models are presented. Model 1: adjusting for age, gender, level of AFP, 
and tumor size, a moderately and/or poorly differentiation grade was shown to be 
significantly associated with recurrence of HCC (Fig. 1A). The recurrence rate of well, 
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moderate, and poorly differentiated HCC was 15%, 40%, and 61%, respectively, 2 years 
after treatment with curative intent. Model 2: adjusting for age, gender, level of AFP, and 
tumor size, the presence of microvascular invasion was shown to be significantly associ-
ated with recurrence of HCC (Fig. 1B). The recurrence rate of HCC without, suspected, and 
with microvascular invasion was 4%, 66%, and 69%, respectively, 2 years after treatment 
with curative intent.
table 1: Summary of patient characteristics of the hepatocellular carcinoma patients with and without 
recurrence after treatment with curative intent. 
patient characteristic no recurrence (n=59)* recurrence (n=28)* p-value**
age (years)
gender (♂)
etiology
hepatitis B viral infection
hepatitis C viral infection
alcohol
none
AFP (ng/ml)
57 (21-82)
48 (81)
9 (15)
17 (29)
12 (20)
21 (36)
8 (1-17700)
55 (1-78)
19 (68)
 
4 (14)
3 (11)
9 (32)
12 (43)
34 (2-121000)
0.766
0.199
0.363
<0.001
histological characteristic
     
tumor size (mm)
presence of cirrhosis
43 (3-170)
36 (61)
90 (20-190)
12 (43)
0.003
0.140
radical resection (R0)
dysplasia
none
small and/or large cell
unclassified
differentation
well
moderately
poorly
unclassified
presence of microvascular invasion 
56 (97)
33 (57)
24 (41)
1 (2)
11 (19)
29 (50)
13 (22)
5 (9)
5 (10)
27 (96)
16 (57)
12 (43)
-
2 (7)
14 (50)
12 (43)
-
6 (21)
0.848
0.549
0.025
<0.001
* numbers (%) or median (range)
** score test univariate Cox regression 
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Figure 1a: Recurrence of HCC after treatment with curative intent comparing patients with a well, 
moderate and poorly-differentiated HCC
Figure 1B: Recurrence of HCC after treatment with curative intent comparing patients in the absence 
of microvascular invasion, suspected for presence of microvascular invasion and in the presence of 
microvascular invasion
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survival
The 1- and 3-year survival rate of patients without, suspected, or with microvascular 
invasion was 92%, 88%, and 82%, respectively, and 57%, 68%, and 40%, respectively (P 
< 0.001).
Patients with well-differentiated HCCs had a better overall survival compared with 
those with moderate and poorly differentiated HCCs. The 1- and 3-year survival rates for 
patients with well-differentiated HCC was 100% and 92%, respectively, 72% and 52% for 
patients with moderately differentiated HCC, and 76% and 56% for patients with poorly 
differentiated HCC (P = 0.021).
MrI Characteristics for Pathological Differentiation and Vascular Invasion 
Radiological findings were compared with histological characteristics. Only patients 
with a recent MRI (n = 76) were included in this analysis. Histological characteristics 
associated with recurrence of HCC, HCC differentiation grade, and microvascular inva-
sion were analyzed to determine which radiological characteristics correspond to these 
pathological characteristics, which were considered the gold standard. Patients with a 
well-differentiated HCC had a radiological capsular enhancement significantly less often 
and less often washout compared with patients with a moderate or poorly differentiated 
HCC (P = 0.003 and P < 0.001) (Table 2). 
Patients with HCC without microvascular invasion on microscopic evaluation had 
a radiological capsular enhancement significantly less often and less often washout 
compared with patients with microvascular invasion suspected or present (P = 0.040 
and P = 0.032) (Table 3). 
tumor - Intensity Curve
The increase in tumor signal intensity during the contrast enhancement sequences was 
assessed in a curve. The shape of the patient-specific tumor–intensity curve was fitted 
with a nonlinear regression model (15). Comparing the shape of the TIC of HCCs with 
microvascular invasion with the shape of the TIC of HCCs without microvascular inva-
sion, by comparing the patient-specific estimated parameters of the nonlinear regres-
sion model, showed no significant difference (P = 0.405). The TIC shape did not differ 
between the different histological grades (P = 0.120). The shape of the TIC of the HCC 
with and without recurrence showed no significant difference (P = 0.880).
DIsCUssIoN
In this study we attempted to correlate morphologic presence of microvascular invasion 
and differentiation grade with enhancement features of HCC on MRI. Even though treat-
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table 2: Summary of the radiological characteristics of the well, moderately and poorly-differentiated 
hepatocellular carcinoma (HCC).
  HCC differentiation grade  
radiological characteristic well (n=13)* moderate (n=34)* poor (n=29)* p-value
morphology
round
irregular
lobular
presence of fat
    
presence of a capsule
T1
low signal 
inhomogeneous aspect
T2
high signal
inhomogeneous aspect
dynamic phase
presence of wash-out
12 (91)
1 (9)
-
2 (15)
6 (46)
7 (54)
6 (46)
11 (85)
6 (46)
5 (38)
22 (65)
-
12 (35)
15 (44)
32 (94)
27 (79)
23 (68)
32 (94)
25 (74)
30 (88)
21 (72)
2 (7)
6 (21)
9 (31)
25 (86)
24 (83)
21 (72)
27 (93)
20 (69)
27 (93)
0.138
0.211
0.003
0.179
0.543
0.565
0.410
<0.001
* numbers (%)
table 3: Summary of the radiological characteristics of the hepatocellular carcinoma (HCC) with and 
without microvascular invasion.
  histological microvascular invasive HCC  
radiological 
characteristic
present (n=45) suspected (n=12) absent (n=19) p-value
morphology
round
irregular 
lobular
presence of fat
    
presence of a capsule
T1
low signal 
inhomogeneous aspect
T2
high signal
inhomogeneous aspect
dynamic phase
presence of wash-out
31 (69)
2 (4)
12 (27)
12 (27)
40 (89)
39 (87)
28 (62)
42 (93)
29 (64)
40 (89)
9 (75)
-
3 (25)
4 (33)
11 (92)
7 (58)
10 (83)
10 (83)
10 (83)
10 (83)
15 (79)
1 (5)
3 (16)
9 (47)
11 (58)
12 (63)
11 (58)
17 (89)
11 (58)
11 (58)
0.903
0.167
0.040
0.246
0.210
0.491
0.243
0.032
* numbers (%)
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ment options with curative intent are emerging and are currently providing a better 
perspective, HCC continues to have a dismal prognosis based on recurrence of disease 
after curative treatment. Histological presence of microvascular invasion and a moderate 
or poor differentiation grade are accepted as independent predictors of poor survival 
(7,8,11,12,14). In the present study, after adjusting for age, gender, level of AFP, and tumor 
size, the histological differentiation grade and presence of microvascular invasion were 
significantly associated with recurrence of HCC (Fig. 1a,b).
Based on our observations, the presence of washout is important because it might 
be an indication of microvascular invasion and/or a moderate or poorly differentiated 
tumor. Okamoto et al (16) also found a relationship between washout and histological 
grade. Unfortunately, they did not analyze microvascular invasion, which is strongly cor-
related with HCC longterm survival. This is in contrast to a recent study showing tumor 
multifocality on imaging to be the only variable that was significantly correlated with 
the presence of microvascular invasion (17); these authors found that no other imaging 
features were useful. However, they only selected patients with small tumors, able to 
receive liver transplantation. 
Our findings might have important clinical implications for the imaging work-up of 
these patients, as recurrence of HCC after treatment is common. Two years after treat-
ment with curative intent, 69% of our patients with histological microvascular invasion 
had recurrence of HCC (Fig. 1a); for patients with a poorly differentiated HCC this figure 
was 61% (Fig. 1b).
Differences in enhancement pattern between benign and malignant lesions in the 
liver have been reported (5). The enhancement characteristics of the tumor can be 
visualized by a TIC (18–21). However, the shape of the TIC does not seem to differentiate 
between recurrence and no recurrence, the various histological differentiation grades, 
or the presence or absence of microvascular invasion.
Nevertheless, our data show that the presence of washout is an important indicator 
of microvascular invasion and moderate or poorly differentiated HCC. Moreover, HCC 
can be visualized with a TIC. Recently, Kitao et al (22) found organic transporting poly-
peptide 8 (OATP8) to be helpful in HCC diagnosis, but not in predicting HCC outcome. 
Because current dynamic imaging is not yet able to predict the outcome for patients 
with HCC, we have to depend on histology. Obtaining tissue for histological analysis may 
not be ideal, even when discounting the risk of bleeding and needle track seeding when 
taking a fine-needle liver biopsy (2). It has to be stressed that biopsies of small lesions 
(<2 cm) may not be reliable (2). Needle placement can be difficult, and on a small biopsy, 
it may be difficult to distinguish well-differentiated HCC from dysplasia, although new 
immunohistochemical markers may be useful for this (2,23). A positive biopsy is helpful, 
but a negative biopsy can never be accepted as conclusive.
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There are a number of limitations. First, in this retrospective study we included 
patients with and without cirrhosis, with only one HCC lesion in many patients. In case 
of absence of cirrhosis tumors were often large. Based on imaging findings, eg, tumor 
size, multifocality, and relation to main vessels, patients are scheduled for surgery. There 
might be a possibility that the parameters analyzed in this study are partly influenced by 
the imaging findings on which treatment management was planned. Second, because 
we had a limited number of patients for each differentiation grade the ability to show 
differences in tumor intensity for several small groups is low.
Future studies should focus on the feasibility of predicting microvascular invasion 
and the various differentiation grades by improving imaging techniques, eg, diffusion-
weighted imaging and hepatobiliary contrast agents to distinguish between the various 
differentiation grades and microvascular invasion of HCC, while focusing on the pres-
ence of washout and capsular enhancement.
In conclusion, moderate to poorly differentiated HCC and microvascular invasion are 
significantly associated with the presence of a capsule and washout demonstrated on 
dynamic contrast-enhanced MRI. It is possible to visualize HCC by a TIC. However, at 
present, the shape of the TIC cannot be used to predict prognosis or to differentiate be-
tween the various grades of malignancy, as demonstrated by histological examination.
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aBstraCt 
Background: Patients with hepatocellular carcinoma (HCC) undergo extensive staging 
investigations when being assessed for surgical resection. The aim of this study was to 
assess the use and yield of baseline bone scintigraphy in patients with HCC necessitat-
ing high-risk surgical resection.  
Material and Methods: All patients diagnosed with HCC between 2000 and 2010 within 
a tertiary referral centre were reviewed. Recurrence and survival rates were compared 
between patients with and without bone scintigraphy in their preoperative work-up.
results: A total of 366 patients were diagnosed with resectable HCC. In the work-up for 
resection 137 (41%) HCC patients underwent bone scintigraphy, showing bone metasta-
ses in 3 (2%). There was no significant difference in long-term survival between patients 
with and without bone scintigraphy. None of the patients with a positive bone scintigra-
phy died due to skeletal bone metastases. Only one patient had an indication for bone 
scintigraphy based on clinical suspicion. Two patients were found to have asymptomatic 
skeletal metastases prior to surgery. Symptomatic skeletal metastases were identified at 
an estimated cost of €27,008 per case. 
Conclusion: Clinically unsuspicious bone lesions turned out to be metastases in two 
patients with an estimated cost of €27,008 per case. Recurrence rate, disease-free and 
overall survival showed no significant difference between patients with and without 
preoperative baseline bone scintigraphy. There is no justification for routine preop-
erative bone scintigraphy to detect asymptomatic skeletal metastases in patients with 
resectable HCC. 
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INtroDUCtIoN 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality [1].
For patients with solitary HCC in combination with the setting of decompensated cir-
rhosis and for those with early multifocal disease (up to 3 lesions, none larger than 3 cm), 
a liver transplantation offers the best change for long-term survival [1,2]. In the absence 
of cirrhosis or with compensated Child A cirrhosis, surgical resection has been reported 
as a successful alternative [3]. Liver transplantation and surgical resection may both 
be considered as treatments with curative intent [4]. However, in successfully resected 
patients, underlying liver cirrhosis may cause high morbidity and even result in mortal-
ity due to liver failure. Therefore, in patients with HCC accurate staging is important to 
define the risks and benefits of resection [4].
In the absence of consensus as to which patients require preoperative staging by 
bone scintigraphy and computed tomography (CT) of the chest clinicians continue to 
routinely perform these investigations in all patients, especially in those at risk for post-
operative complications. The rising costs of healthcare and (in particular) of cancer care, 
challenge the appropriateness of current practices and emphasise the need for more 
cost-effectiveness. The positive yield of a routine bone scintigraphy in liver transplant 
candidates with early-stage hepatoma was reported to be very low [5]. Based on these 
results a bone scintigraphy is no longer considered as a prerequisite for liver transplant 
listing in patients with HCC according to the UNOS guidelines. Only symptomatic 
patients listed for liver transplantation, clinically suspected of having bone metastases 
should undergo bone scintigraphy.   
To assess the use of baseline bone scintigraphy and its benefit for potentially curable 
patients, a review of our clinical practice was performed. The influence on disease man-
agement, and cost of bone scintigraphy for patients with resectable HCC was evaluated. 
MetHoDs
Clinical characteristics
All patients with HCC diagnosed in our centre from January 2000 to December 2010 
were analyzed (n=799). The diagnosis of HCC was based on imaging, clinical and labora-
tory findings including serum alpha-fetoprotein (AFP). The diagnosis was histologically 
confirmed if necessary. Treatment with curative intent was defined as a complete surgi-
cal resection, also including orthotopic liver transplantation (OLT) and radiofrequency 
ablation (RFA). HCC treatment was performed according to the Milan criteria [2].
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The medical charts of the included patients (n=336) were analyzed. Data on age, gen-
der, etiology, biochemical parameters and serum tumor marker (AFP) were collected. 
High-risk surgery was defined as a large surgical resection up to an extended hemihepa-
tectomy in a non-cirrhotic liver or surgery close to the hilar main portal branches or 
hepatic vein trunks. Based on clinical judgment these patients presented with a higher 
morbidity and/ or mortality risk and therefore, in the work-up for resection, 137 HCC 
patients (41%) were identified as high-risk surgical procedures and underwent bone 
scintigraphy.  Patients who underwent RFA underwent a bone scintigraphy prior to 
referral to our tertiary center. During follow-up patients underwent contrast-enhanced 
CT or magnetic resonance imaging (MRI) combined with determination of serum AFP 
at 3 and 6-month intervals for up to 2 years post-treatment. A bone scintigraphy was 
performed during follow-up on indication, i.e. in the presence of possible metastases 
related complaints; bone pain, motor or sensory nerve disturbance, weight loss, and 
jaundice. After 2 years, follow-up was continued annually up to 5 years. In the presence 
of liver cirrhosis, lifetime follow-up was pursued. Recurrence or disease was defined as 
the occurrence of a focal liver lesion with HCC characteristics, enlargement of lymph 
nodes in the liver hilum, or suspicious extrahepatic lesions and an increase of serum AFP. 
Bone scintigraphy
The patients had a bone scintigraphy at baseline, pre-treatment for metastases screen-
ing. Total-body images were acquired 2-4 h after injection of 550 MBq or 825 MBq (if 
the bodyweight exceeded 100kg) 99mTc-hydroxymethylene diphosponate (Mallinckrodt 
Medical, Petten, the Netherlands). Bone scintigrams were acquired using a double-head 
gamma camera (DST SMV; DST Sopha Medical Vision, Brie, France) in the whole-body 
mode, in 20 minutes. Bone lesions, which showed as hotspots on scintigraphy, were 
further analyzed by conventional plain radiography, CT or MRI. 
statistical analysis
Variables were compared using the Mann-Whitney U test, t-test or with the χ2-test when-
ever appropriate. Statistical significance was set at p < 0.05. Survival curves were drawn 
using the Kaplan-Meier method, the log-rank test was used for determining statistical 
significance. All analyses were performed using the Statistical Package for Social Sci-
ences 17.0 (SPSS inc., Chicago, IL, USA).
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resUlts 
Clinical characteristics
From January 2000 through December 2010, 336 patients were treated for resectable 
HCC at our tertiary referral center. Of these patients 98 (29%) were women and 238 (71%) 
were men, with a median age of 60 years (range 1-82). 
Bone scintigraphy before curative treatment 
At diagnosis 137/336 (41%) patients who were planned to undergo high-risk surgery 
(a large surgical resection up to extended hemihepatectomy in a non-cirrhotic liver 
or surgery close to the hilar main portal branches or hepatic vein trunks) underwent 
bone scintigraphy, showing skeletal metastases in 3 patients (2%) (Figure 1). Two out of 
these three patients were asymptomatic. One out of these three patients underwent 
diagnostic work-up for metastatic disease because of suspected positive lymph nodes 
on the abdominal CT scan. These 3 patients did not require palliative treatment for their 
skeletal metastases. All died due to tumor progression with liver failure. 
In the entire cohort, 2 patients out of 137 patients underwent a bone scintigraphy 
because of high-risk surgery had an incidental finding of metastatic bone disease. Ex-
cluding 1 asymptomatic patient in whom a bone scintigraphy was clinically indicated, 
136 bone scintigraphies were routinely performed. The total cost of performing these 
bone scintigraphies was estimated at €54,015. This translates to an estimated cost of 
€27,008 per case of unsuspected skeletal metastases detected. 
 
 
 
 
 
‘Resectable’ HCC 
n = 336  no bone scintigraphy at baseline (n = 199) 
treatment 
bone scintigraphy at baseline (n = 137) 
resection (n=102) 
OLT (n=31) 
RFA (n=66) 
resection (n=62) 
OLT (n=39) 
RFA (n=33) 
treatment 
positive for metastases (n=3) 
negative for metastases (n=134) 
Figure 1: Flowchart for bone scintigraphy in patients with resectable hepatocellular carcinoma and 
applied treatment.
HCC =  hepatocellular carcinoma, OLT = orthotopic liver transplantation, RFA =  radiofrequency ablation 
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treatment
A total of 333 HCC patients received treatment with curative intent: resection (n=164), 
OLT (n=70), and RFA (n=99). The baseline clinical characteristics of these patients are 
summarized in Table 1. Of all 333 patients receiving treatment with curative intent, 134 
(40%) had a negative bone scintigraphy, of whom 62 underwent a resection, 39 OLT, and 
33 RFA (Figure 1).
survival and recurrence
The 1- and 5-year survival rates of patients with a bone scintigraphy were 86% and 30% 
respectively, and without a bone scintigraphy 86% and 34%, respectively (p= 0.369) 
(Figure 2). Median overall survival of patients with a bone scintigraphy and without a 
bone scintigraphy was 37 months and 43 months, respectively.
Out of 110 patients with recurrent of HCC 46 patients (42%) had a bone scintigraphy. 
Median time to recurrence was 9 months (range 2-102 months). The time to recurrence 
did not differ between patients with and without bone scintigraphy (p= 0.990) (Figure 
3). At 3 years after treatment with curative intent, the recurrence rate of patients with 
a bone scintigraphy and without a bone scintigraphy was 43% and 40%, respectively. 
Table 2 summarizes the pattern of disease recurrence (local or distant). Patients with 
bone metastases had metastases related complains like bone pain, motor or sensory 
nerve disturbance, weight loss, and jaundice. Of the 14 patients with bone metastases, 
all died due to tumour progression with liver failure, none of these patient had spinal 
paralysis induced by bone metastases. Out of these 14 patients, 8 patients (57%) received 
palliative radiotherapy for their bone metastases.   
table 1: Summary of the baseline characteristics of the hepatocellular carcinoma patients treated with 
curative intent.
Patient 
characteristics
study population
n=333*
Bone scintigraphy 
present
n=134*
Bone scintigraphy 
absent
n=199*
Presence vs. 
absence bone 
scintigraphy
p-value
Age (years) 60 (1-82) 58 (1-78) 60 (10-82) 0.007
Gender (♂) 236 (71%) 96 (72%) 140 (70%) 0.947
Aetiology
HBV
HCV
Alcohol
None
82 (25%)
75 (22%)
49 (15%)
128 (38%)
40 (30%)
39 (29%)
36 (27%)
39 (29%)
42 (21%)
46 (23%)
43 (22%)
89 (45%)
0.061
0.336
0.092
0.003
AFP (ng/ml)
Presence of cirrhosis
15 (1-834350)
225 (68%)
24 (2-424100)
99 (74%)
9 (1-834350)
126 (63%)
0.017
0.087
Tumour size (mm) 33 (3-193) 33 (10-193) 33 (3-170) 0.278
*number (%) or median(range)   
HBV = hepatitis B viral infection; HCV = hepatitis C viral infection; AFP = alfa-fetoprotein 
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p=0.369 
30 54 86 present 
34 61 86 absent 
5-year 3-year 1-year  
survival (%) bone scintigraphy 
33 47  71  101 130  199 absent 
17 24  37  65 96  134 present 
number at risk bone scintigraphy 
absent 
Bone scintigraphy 
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Figure 2: Survival of hepatocellular carcinoma after treatment with curative intent comparing patients 
with and without bone scintigraphy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 10  18  34 70  199 absent 
3 5  13  23 49  134 present 
number at risk bone scintigraphy 
p=0.990 
45 43 24 present 
43 40 26 absent 
5-year 3-year 1-year  
recurrence rate (%) bone scintigraphy 
absent 
Bone scintigraphy 
present 
Figure 3: Recurrence of hepatocellular carcinoma after treatment with curative intent comparing patients 
with and without bone scintigraphy
table 2: Localization of hepatocellular carcinoma recurrence after treatment with curative intent 
localization No. of patients
Local recurrences 30
New lesion in the liver 48
Lung 9
Abdomen 7
Bones 14
Lymph nodes 2
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DIsCUssIoN
In this study the value of bone scintigraphy for asymptomatic HCC patients selected for 
surgical resection was investigated. The effectiveness of bone scintigraphy was found 
to be very low, confirming data reported in literature on liver transplant candidates [5]. 
The skeletal system is a common metastatic site in breast cancer, prostate cancer and 
lung cancer. Bone scintigraphy is advocated for the detection of metastases as it is con-
sidered an optimal examination for preoperative staging [6,7]. Although the incidence 
of HCC bone metastases has increased, the skeletal system remains an uncommon 
metastatic sites for HCC [4,8-11]. Symptoms attributable to the corresponding lesions are 
present in 77% of the HCC patients with bone metastases, manifesting as pain, motor or 
sensory nerve disturbance, or local bone swelling [12].
Bone scintigraphy may be of clinical importance, as the presence of metastases might 
change the prognosis or treatment. Patient characteristics at baseline differ regarding 
age, aetiology and AFP. Young patients are more suitable for high risk surgery, there 
patients receiving a bone scintigraphy were younger. Due to an aetiology of cirrhosis 
or chronic hepatitis liver capacity decreases and surgical resection becomes riskier and 
therefore the screened patients had less often absence of an aetiology [3].  Previous 
reports displayed that serum AFP level might be higher in patients with cirrhosis com-
pare to patients without cirrhosis, however the presence or absence of cirrhosis did not 
influenced [10]. In our population baseline characteristics between patients with and 
without bone scintigraphies did not differ regarding survival. The conclusion that there 
was no difference in overall survival between the screened group and non-screened 
group might be biased as the screened patients who were positive for bone metastases 
were not operated. However, it does speak of lack of worse outcome in the non-screened 
group who could have had undetected metastases. Moreover, median survival of HCC 
patients with untreated bone metastases seems similar to survival of HCC patients with 
treated bone metastases [7,13,14]. The cause of death in HCC patients with bone metas-
tases is seldom related to these metastases [7]. 
The current staging classification assumes that preoperative evaluation of HCC 
patients will identify a substantial number with subclinical extra-abdominal disease, 
thereby avoiding unnecessary treatment of these patients. The data from the current 
study do not support this assumption. Bone scintigraphy has a well-established role in 
identifying skeletal metastases. The role of bone scintigraphy in staging patients with 
HCC able to undergo surgical resection, OLT or RFA is less clear. Of all newly diagnosed 
patients with ‘resectable’ HCC, 41% underwent a staging bone scintigraphy. This low 
rate is the result of a biased indication for bone scintigraphy in our center, as a strict 
staging protocol was not defined until recently. Most of the patients undergoing a bone 
scintigraphy had to undergo a high-risk operation, e.g. resection of a large volume of the 
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cirrhotic liver. It is difficult to determine the justifiable cost to avoid unnecessary treat-
ment using these data. This study shows that costs of €53,221 were generated for bone 
scintigraphies (n=134) without detection of even 1 patient with subclinical metastases. 
Therefore, the policy of bone scintigraphy in patients with HCC undergoing treatment 
with curative intent is not effective. This is in line with the National Comprehensive Can-
cer Network guidelines who recommend bone scanning on indication and not routinely-
only [14]. Because the economic cost of staging investigations in the Dutch healthcare 
system is difficult to quantify, we approximated the cost of staging scans in our own 
hospital. We acknowledge the limitation of such an estimation especially because this is 
a single centre based study without a cost-effective analysis. However, we believe this is 
reasonable as the cost of a bone scintigraphy in our study (€397.17) compares favourably 
with that in an American study ($711) [5,16]. Therefore the economic cost of detecting 
each one of these cases of incidental skeletal metastases is approximately €27,008. This 
figure would be much higher if the cost of performing a bone scintigraphy was taken 
from the American model. 
The present study has some limitations, related to the single centre and retrospec-
tive design which were already mentioned above. Although all patients were recruited 
prospectively into the database, the clinical indication for bone scintigraphy was based 
on subjective decisions. This implies a patient selection bias, hence it would have been 
better if all patients were randomized into a screened group and non-screened group. 
From a scientific point of view a randomized controlled trial would be interesting to 
perform, but the clinical relevance to conduct such as study may be discussed.  
Despite these limitations, we conclude that baseline bone scintigraphy in patients 
with HCC is not indicated unless specific bone-related complaints or clinical suspicion of 
extrahepatic disease is present in patients able to receive treatment with curative intent. 
We suggest that, in the absence of concluding data in favour of staging investigations, 
clinical judgement should remain to have an important role. 
In case of a resectable HCC a thorough history and clinical examination focusing on 
skeletal pain, tenderness and/or other signs of systemic disease must indicate the need 
for a selective bone scintigraphy. 
In conclusion, the routine use of a bone scintigraphy to detect metastases in asymptom-
atic patients included for surgical treatment for resectable HCC is not indicated. 
In a large cohort of 336 patients with resectable HCC, unsuspected bone metastases 
were discovered in only 2 patients. Post-operative HCC recurrence rate, disease-free and 
overall survival showed no significant difference between patients with a bone scintig-
raphy and without a bone scintigraphy. 
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aBstraCt 
Background: Hepatocellular carcinoma (HCC) may be diagnosed in the absence of cir-
rhosis. However, most patients have risk factors for cirrhosis, such as hepatitis B/C virus 
infection, alcohol abuse or haemochromatosis. Little is known about prognostic factors 
for survival of HCC with a non-cirrhotic liver and in the absence of any of these well 
established risk factors. 
Methods: Survival rates and risk factors for survival and recurrence were analysed in 
all patients diagnosed between 2000-2010 with HCC in a non-cirrhotic liver and in the 
absence of well established risk factors. 
results: Ninety-four patients were analysed. Treatment with curative intent consisted 
of surgical resection in 43 patients (46%) and RFA in 4 patients (4%). Palliation was of-
fered to 3 patients (3%) by TACE 14 patients (15%) by radio- or chemotherapy, and 30 
patients (32%) by best supportive care. In patients treated by curative intent and alive 
30 days after treatment (n=40) 1 and 5-year overall survival rates were 95% and 51%. 
Patients with a high preoperative alfa-fetoprotein (AFP) serum level, the presence of 
microvascular invasion in the resected specimen, a complicated postoperative course, 
and a major resection, due to a greater amount of tumour volume, had a significantly 
worse outcome and a higher recurrence rate. In multivariate analysis high AFP serum 
level at presentation was significantly associated with recurrence and a worse survival. 
Conclusion: HCC presenting in a non-cirrhotic liver in the absence of well established 
risk factors has a poor prognosis. Increased AFP serum levels are significantly associated 
with clinical outcome. 
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INtroDUCtIoN
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality [1]. The incidence of HCC is high 
in Asia and parts of Africa, whereas it is low but increasing in the Western world even in 
the Netherlands [1-5].
HCC is the most common primary tumour of the liver and typically develops in the 
presence of underlying cirrhosis, particularly in high-endemic areas [1]. In low-endemic 
areas in 5-40% of HCC patients no cirrhosis is diagnosed [6-10]. Although many inves-
tigators have reported on prognostic factors for HCC in a non-cirrhotic liver, they still 
included patients positive for serological markers of hepatitis B or C virus infection, 
alcohol abuse or hemochromatosis. These are known well established risk factors for the 
development of cirrhosis and eventually HCC [11]. 
In HCC patients with no underlying cirrhosis, the ‘normal’ quality of the non-tumoral 
liver parenchyma might make this type of HCC a different entity, with a different aetiol-
ogy, clinical presentation, management and prognosis [12]. 
The aim of this retrospective study was to asses clinical presentation, surgical out-
come, and prognostic factors of our serie of patients who had HCC without presence of 
underlying cirrhosis or well established risk factors for cirrhosis and HCC. 
MetHoDs
Clinical characteristics 
All patients with HCC diagnosed in a tertiary reference centre between January 2000 
and December 2010 were analyzed. Patients included (n=94) had no underlying cirrhosis 
and none of the well established risk factors for cirrhosis or HCC as determined by nega-
tive hepatitis B and C serological markers (anti-HCV negative, HBsAg negative, anti-HBc 
negative), a negative history of alcohol abuse (ones a week over 6 glasses of alcohol 
[13]), absence of haemochromatosis or a metabolic liver disease. Preoperatively, HCC 
was diagnosed by means of imaging criteria in two imaging techniques. In case HCC 
was diagnosed, treatment was discussed in a multidisciplinary meeting according to the 
AASLD guidelines [1]. In all patients alpha-fetoprotein (AFP) serum levels were assessed. 
The AFP cut-off point for our hospital is 9 ng/ml. Data on age, gender, size and number 
of lesions, and presence and extent of extrahepatic disease were collected.  
Patients were primarily assessed for surgical resection, those not amenable for this 
option were considered for radiofrequency ablation (RFA). Treatment with curative 
intent was defined as a complete surgical resection, including wedge resection, seg-
ment resection, hemihepatectomy and RFA. Presence of a conventional HCC in a non-
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cirrhotic liver was postoperatively histological confirmed in all patients. Patient with a 
fibrolamellar hepatocellular carcinoma were excluded. Tumour differentiation grade 
was determined according to the Lauwers classification [14].
Postoperative complications were reported up to 30 days post-surgery and were 
grouped as complicated (pharmacological treatment or intervention needed) or un-
complicated. Patients not amenable for curative therapy were offered palliative options, 
consisting of either transarterial chemo-embolization (TACE), radiotherapy, palliative 
systemic therapy or best supportive care. 
Follow-up 
After surgical resection, patients had a follow-up using contrast-enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) combined with determination 
of serum AFP at 3 and 6-month intervals for up to 2 years post-treatment. After 2 years, 
follow-up was continued annually for up to 5 years. HCC recurrence was defined as the 
appearance of a new focal liver lesion with HCC characteristics, enlargement of lymph 
nodes in the liver hilum, or suspected extrahepatic lesions. The diagnosis was histologi-
cally confirmed if necessary. Data regarding survival of patients that were lost to follow-
up was obtained from the general practitioner or the civil registration systems.
statistical analysis
Variables were compared using the Mann-Whitney U test, t-test or with the χ2-test, as 
appropriate. Statistical significance was considered at a p-value < 0.05. Receiver operat-
ing characteristic (ROC) plots were used to define the optimum cut-off point for serum 
AFP. Multivariate Cox regression analysis was performed to assess the independent 
prognostic factors. According to the literature the patient characteristic ‘recurrence of 
disease’ has a high negative impact on survival, therefore the analysis was performed 
within a model adjusting for recurrence. Within this model, preoperative biochemical 
and postoperative tumour characteristics with a p-value <0.05 in univariate analysis 
together with the baseline characteristics age and gender were included to determine 
the independent contribution of each variable. Survival curves were drawn using the 
Kaplan-Meier method. Differences between Kaplan-Meier curves were tested using the 
log-rank test. All analyses were performed using the Statistical Package for Social Sci-
ences 17.0 (SPSS, Chicago, IL, USA). 
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resUlts 
Patient characteristics
Ninety-four patients with HCC without underlying cirrhosis and with no established 
risk factors for HCC were identified. Of these, 46 patients (49%) were female and the 
median age was 62 (range 10-87) years. Table 1 summarises biochemical and radiological 
characteristics. 
outcome 
Forty-three patients (46%) underwent a surgical resection and 4 (4%) underwent RFA. 
Out of 43 patients who underwent a surgical resection, 3 patients died within 30 days 
after surgery; 2 patients died due to a myocardial infarct and 1 patient died because of 
an eventful postoperative course secondary to a bleeding. Median time to death was 44 
months (range <1-128).
After complete surgical resection (n=40) of a histologically confirmed conventional 
HCC in a non-cirrhotic liver the 1, 3 and 5-year survival rate was 95%, 60% and 51%, 
respectively. Of the 17 patients with an increased serum AFP (>9 ng/ml), 13 (76%) had 
a normalized serum AFP after surgical resection. The 4 patients without a normalized 
serum AFP had HCC metastasis within 5 months after surgery. Fifteen (38%) out of 40 
patients treated by surgical resection had recurrence of HCC during follow-up. Median 
table 1: Biochemical and radiological characteristics of hepatocellular carcinoma (HCC) patients without 
well established risk factors.
Characteristics*
Albumin (g/l) 41 (27-52)
ASAT (U/l) 50 (16-897)
ALAT (U/l) 40 (6-461)
AP (U/l) 159 (55-2024)
Bilirubin (umol/l) 10 (4-199)
AFP (ug/l) 12 (1-834350)
Number of tumours 1 (1-7)
Radiological tumour size (mm) 98 (5-250)
TNM
Stage I
Stage II
Stage IIIA
Stage IIIB
Stage IV
28 (30)
16 (17)
12 (13)
6 (6)
32 (34)
ASAT: aspartate aminotransferasis; ALAT: alanine aminotransferasis; AP: alkaline phosphatise; AFP: alfa-
fetoprotein
*median (range) or numbers (%)
112 Chapter 8
time to recurrence was 8 (range 1-20) months. Of the patients treated with a minor resec-
tion (n=12) 3 patients had recurrence of HCC. In case of wedge resections HCC recurrence 
was found in the ipsilateral hemi-liver. 
Table 2 presents the operative characteristics and postoperative histological charac-
teristics of the patients treated with surgical resection.
In 47 patients (50%) not amenable for curative treatment, palliative treatment was 
considered. They received either TACE/TAE (3 patients; 3%), radiotherapy or systemic 
chemotherapy (14 patients; 15%), or best supportive care (30 patients; 32%). 
Factors associated with survival and recurrence of HCC after surgical resection
The optimal AFP cut-off point selected by ROC-plot in 40 patients treated with a surgical 
resection was between 8.0 ng/ml and 9.5 ng/ml. Patients with a poor survival after surgi-
cal resection more often underwent a major resection, had presence of microvascular 
table 2: Surgical and pathological parameters in HCC patients undergoing surgical resection
Parameters*  (n = 40)
Type of resection
Minor resection
Segment
Major resection
Left hemihepatectomy
Right hemihepatectomy
Extended left hemihepatectomy  
Extended right hemihepatectomy
11 (28)
10 (25)
16 (40)
1 (2)
2 (5)
Mortality and morbidity postoperative
Uncomplicated
Complicated 
25 (63)
15 (37)
Fibrosis 
F0
F1
F2
19 (48)
17 (42)
4 (10)
Steatosis
G0
G1
G2
G3
22 (55)
15 (38)
2 (5)
1 (2)
Microvascular invasion
Presence
Absence
Undefined
22 (55)
17 (43)
1 (2)
Differentiation grade
good
moderate
poor
undefined
8 (20)
22 (55)
8 (20)
2 (5)
*median (range) or numbers (%)
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invasion, a moderately or poorly-differentiated tumour, a complicated postoperative 
course, an increased preoperative serum AFP, and recurrence of disease (Table 3). After 
adjusting for recurrence, in the Cox regression analysis an increased preoperative AFP 
serum level was shown to be significantly associated with a worse survival (Table 4A).
table 3: Biochemical, radiological, surgical and pathological characteristics associated with overall 
survival following surgical resection (n=40) (univariate analysis).
Characteristics survivors Non-survivors p-value
AFP (ng/ml)
≤9 
> 9 
74%
47%
26%
53%
0.010
TNM
stage I/II
stage III
62%
62%
38%
38%
0.345
Number of tumours
1
>1
59%
83%
41%
17%
0.134
Radiological tumour size (mm)
≤5
5-10
>10
80%
56%
57%
20%
44%
43%
0.514
Postoperative 
Uncomplicated
Complicated
72%
50%
28%
50%
0.008
Type of resection 
minor
major
82%
55%
18%
45%
0.030
F0
F1
F2
68%
53%
75%
32%
47%
25%
0.512
G0
G1
G2
G3
55%
63%
50%
100%
45%
27%
50%
0%
0.176
Microvascular invasion (histology)
presence
Absence
55%
76%
45%
24%
0.035
Differentiation grade (histology)
good
moderate
Poor
87%
59%
40%
13%
41%
60%
0.048
Recurrence
Present 
Absent
13%
82%
87%
18%
<0.001
AFP: alfa-fetoprotein
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table 4a: prognostic factors associated with overall survival in multivariate analysis (n=40)
Characteristics Hazard ratio (95% confidence limits) p-value
Age (years) 0.98 (0.94-1.02) 0.263
Gender 0.41 (0.80-2.07) 0.280
AFP (ng/ml)* 1.21 (1.02-1.45) 0.034
Differentiation grade good vs. 
moderate vs. poor
1.98 (0.45-8.72) 0.370
Microvascular invasion absence vs. 
present
3.55 (0.69-18.33) 0.130
AFP: alfa-fetoprotein
* Continues variable
table 4B: prognostic factors associated with recurrence in multivariate analysis
Characteristics Hazard ratio (95% confidence limits) p-value
Age (years) 0.97 (0.93-1.01) 0.120
Gender 1.29 (0.39-4.65) 0.702
AFP (ng/ml)* 1.29 (1.02-1.63) 0.031
Differentiation grade good vs. 
moderate vs. poor
1.05 (0.21-5.10) 0.957
Microvascular invasion absence 
vs. present
7.03 (1.03-47.97) 0.047
AFP: alfa-fetoprotein
* Continues variable
  
 
 
 
 
 
 
 
 
Number at risk     
AFP ≤9 (ng/ml) 23 17 12 11 
AFP >9 (ng/ml) 17 6 1 1 
 
AFP ≤9 (ng/ml) 
AFP >9 (ng/ml) 
Figure 1: Overall survival of hepatocellular carcinoma patients without well established risk factors 
starting at 30 days after surgical resection comparing normal vs. increased serum levels of alfa-fetoprotein 
(AFP)
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Patients with recurrence of HCC were characterized by higher preoperative AFP 
serum levels (p=0.003) and presence of microvascular invasion (p=0.005). 
In the Cox regression analysis an increased preoperative AFP serum level and pres-
ence of microvascular invasion were shown to be significantly associated with appear-
ance of HCC recurrence (Table 4B).
The 1 and 3-year survival rate of patients with a high and a low AFP serum level was 
53% and 86%, and 21% and 75%, respectively (p=0.010) (Figure 1).
DIsCUssIoN
In this study we evaluated the outcome of HCC treatment in patients without well estab-
lished risk factors for cirrhosis or HCC. Several studies have explored clinicopathological 
characteristics in HCC patients without cirrhosis [1,11,15]. Although they studied HCC in 
the absence of cirrhosis, they often included patients with well established risk factors 
for cirrhosis or HCC or analyzed a small group of patients [11,16]. This selection bias will 
influence overall survival as it is known that, for example, chronic hepatitis B influences 
survival in HCC patients [17]. We were able to include a large group of patients, all non-
cirrhotic HCC patients without well established risk factors, and had the opportunity to 
study this unique population.
Diagnosis 
In the absence of a screening program developed for patients with liver cirrhosis, early 
detection in an asymptomatic stage is seldom seen and diagnosis of non-cirrhotic HCC is 
usually made at an advanced stage with large tumours [18]. By then many patients have 
already developed an unresectable tumour, either because of tumour size, anatomical 
localization, or the presence of multiple bilobare intrahepatic metastases [19]. In the 
present study, nearly 50% of the patients referred with HCC without liver cirrhosis and 
well established risk factors were beyond curative surgical options. The studied popula-
tion is homogenises for conventional hepatocellular carcinoma, none of the patients 
had a fibrolamellar hepatocellular carcinoma. 
survival and recurrence 
In our population of HCC patients without well established risk factors the survival rates 
were comparable with patients with a Child-Pugh A liver cirrhosis treated with surgical 
resection (5-year survival rate 50%), with similar associated factors [1,20]. As the optimal 
AFP cut-off point selected by ROC-plot was between 8.0 ng/ml and 9.5 ng/ml, the AFP 
cut-off point of for hospital (9 ng/ml) was an adequate cut-off point. Although, AFP as 
serological marker for HCC in screening and surveillance in patients with cirrhosis is 
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debated [21], AFP seems a useful marker in patients with HCC without well established 
risk factors, especially when AFP serum level is increased. It is likely that the 4 patients 
without normalization of AFP who had metastases within 5 months of surgery already 
had metastatic disease at surgery that was not identified by imaging due to small size. 
According to the literature little is known about the value of AFP serum level in 
patients with HCC without well established risk factors. Our study displays the presence 
of an increased AFP serum level preoperatively to be the most important factor associ-
ated with a worse outcome and recurrence of HCC in multivariate analysis. In case AFP 
serum level is increased in patients who have to undergo a high-risk operation, e.g. an 
extended hemihepatectomy or in patients with many comorbidities it might be worth 
reconsidering the high-risk treatment. 
therapy considerations
If a surgical resection is performed with curative intent in a non-cirrhotic liver, 38% of 
the patients suffer from recurrence of disease. Solitary recurrence might benefit from 
repeated resection, but in most patients recurrence after primary resection will be 
multifocal because of intra-hepatic dissemination from the primary tumour [1]. Out of 
15 patients with recurrence after treatment with curative intent, 3 had recurrence after a 
local surgical resection. Their disease recurrence appeared as a tumour in the ipsilateral 
hemi-liver, whereas the contralateral hemi-liver was free of tumour recurrence. Thus, in 
HCC patients with a well-preserved liver function, there might be a preference to per-
form a major resection because, after minor resections, patients tend to more often have 
recurrence in the ipsilateral hemi-liver. In the absence of well established risk factors, the 
presence of a small satellite tumour, too small to detect on imaging, might cause tumour 
recurrence in the ipsilateral liver lobe. 
Until now liver transplantation is a therapy considered for cirrhotic patients only. In 
patients with underlying cirrhosis treated with liver transplantation 5-year survival rates 
up to 70% are reported [1]. This higher survival rate makes transplantation a treatment 
option for HCC patients without well established risk factors worth considering [19]. 
The Milan criteria and the algorithms used for HCC in cirrhotic livers are probably not 
applicable to HCC in a non-cirrhotic liver without well established risk factors, because 
it is a different disease with (probably) different aetiology and pathogenesis [22,23]. 
Based on these findings we propose the following treatment strategy for patients with 
unresectable HCC in a non-cirrhotic liver without well established risk factors. Patients 
with extrahepatic spreading or gross vascular involvement should be strictly excluded 
for liver transplantation. If biopsy is performed and the presence of a moderate or 
poorly-differentiated tumour with microvascular invasion is noted, caution is needed, 
especially when the preoperative serum AFP level is high. A large tumour size per se 
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(outside the Milan criteria) should not be seen as a strict contraindication for consider-
ing liver transplantation in patients with HCC without well established risk factors.
This study evaluating a single institution’s experience of HCC patients without well 
established risk factors is influenced by confounding factors, as the data were acquired 
retrospectively and might be influenced by patient selection. However, as patients with 
HCC without underlying cirrhosis and HCC are relatively rare, no previous study was 
able to describe such a large cohort. Our study might be based on a small amount of 
patients (n=40), still we analyzed the largest cohort presented so far. Although the study 
population is unique, because some of our conclusions are based on a small number of 
patients (patients with local recurrence: n=3) experiences from other centres are needed. 
However, based on our observations, the absence of well established risk factors seems 
to have less impact on final outcome parameters in HCC patients. One can speculate 
whether the presence of cirrhosis is an independent prognostic parameter, or whether 
the overall assessment of HCC and the recurrence of HCC after treatment with curative 
intent, determine the final outcome in patients with HCC. Therefore, expansion of treat-
ment options by liver transplantation in non-cirrhotic patients is worth re-considering. 
In conclusion, this retrospective analysis of a large cohort of HCC patients without 
well established risk factors shows that they were diagnosed with an advanced stage 
of disease. If surgical resection is performed, good results can be achieved. The higher 
the preoperative AFP serum level is the worse the outcome. Patients might benefit 
from major resections as disease recurrence often appears in the ipsilateral liver lobe 
instead of the contralateral liver lobe. Although cirrhosis is absent, liver transplantation 
as a treatment option for HCC patients without well established risk factors is worth 
considering and should be further explored. 
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aBstraCt 
Background: Hepatocellular carcinoma (HCC) typically develops in cirrhotic livers. The 
diagnosis of HCC might be difficult in absence of risk factors e.g. cirrhosis or hepatitis 
B/C virus infection. We aimed to explore whether immunohistochemical staining of HCC 
in a non-cirrhotic liver contributes to diagnostic and prognostic characteristics, and 
whether these immunohistochemical characteristics differ from HCC in a cirrhotic liver. 
Methods: Paraffin embedded, formalin fixed tissue slides from live resection specimens 
of patients with HCC in a non-cirrhotic liver were analyzed. 
results: From January 2000 through April 2011, 47 patients with 50 HCCs in a non-
cirrhotic liver were operated. The tumours were stained positive for AFP in 15 cases 
(30%), for CD34 in a diffuse pattern in 44 (88%), for CK7 in 22 (44%), for CK19 in 6 (12%), 
for GPC3 in 20 (40%), for GS in 32 (62%) and for β-catenin in 16 (32%). Moderate or poorly 
differentiated HCC more often expressed β-catenin, and GPC3 and showed a higher 
percentage of MIB-1 positive hepatocytes. More patients with presence of vascular 
invasion presented with a positive expression of MIB-1 in the tumour. A positive AFP 
immunohistochemical staining was significantly related with a high pre-operative AFP 
serum level (p=0.001). The larger the tumour the more often diffuse CD34 staining was 
present (p=0.037). None of the immunohistochemical stainings was associated with a 
worse overall survival. Of the patients treated with a surgical resection 17 had recurrence 
of HCC and these patients more often had a positive CK19 staining (p=0.048).  There was 
similarity in immunohistochemical expression of several markers comparing HCC in a 
non-cirrhotic liver with HCC in a cirrhotic liver.
Conclusion: Immunohistochemical expression of several markers in HCC in a non-
cirrhotic and HCC in a cirrhotic liver are comparable. Immunohistochemical markers 
β-catenin, GPC-3 and MIB-1 are markers helpful in establishing HCC differentiation grade, 
without being a predictor for overall survival. 
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INtroDUCtIoN
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality [1]. The incidence of HCC is high 
in Asia and parts of Africa, whereas it is low but increasing in the Western world [2-4]. 
HCC constitutes a major health problem and its relevance is expected to increase in the 
near future [4]. HCC is by far the most common primary malignant tumour of the liver 
and typically develops in a cirrhotic liver, particularly in high-endemic areas [1]. In low-
endemic areas 5-40% of the HCC patients has a non cirrhotic liver [5-10]. The diagnosis 
of HCC might be difficult in absence of risk factors e.g. cirrhosis or hepatitis B/C virus 
infection. The liver represents one of the three most common sites of metastasis, and 
primary hepatic cholangiocarcinoma and HCC often share overlapping morphologic 
appearances [3]. One of the challenges in histopathological diagnosis of hepatocellular 
mass lesions is to distinguish HCC (particularly well-differentiated) from hepatocellular 
adenoma [11]. Moreover, complicating the diagnostic process is that pathologists are 
frequently asked to handle and diagnose liver needle core biopsies with various biopsy 
artefacts. 
Serum alpha-fetoprotein (AFP) level remains the best available marker for the diag-
nosis of HCC clinically, although it does not fulfill the requirements of an ideal tumour 
marker [12-14]. However, only about 25-40% of the HCCs in a cirrhotic liver are positive 
for AFP by immunohistochemistry [15]. It is not clear, however, how expression of AFP 
immunohistochemistry correlates to HCC in a non-cirrhotic liver.
As to our knowledge, an immunohistochemical profile of HCC in non-cirrhotic livers 
has not been presented before, neither from a clinical perspective, nor from a patho-
logical perspective. Only a few immunohistochemical markers are investigated for the 
distinction between benign and malignant hepatocellular lesions [15]. Being representa-
tive for a low-endemic area we initiated the present study to investigate the expression 
of immunohistochemical markers in HCC in a non-cirrhotic liver and studied an unique 
population. We analyzed in the current study the expression of AFP, CD34, cytokeratine 
7 (CK7), cytokeratine 19 (CK19), glypican-3 (GPC3), (antigen) Ki67 (MIB-1), glutamine 
synthetase (GS) and β-catenin in patients with HCC arising in a non-cirrhotic liver. We 
established the role of the immunohistochemical staining pattern as a diagnostic or 
prognostic test and compared whether this immunohistochemical profile differs from 
the immunohistochemical profile of HCC in a cirrhotic liver. 
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MaterIal aND MetHoDs
Cases
The Erasmus University Medical Centre Rotterdam in the Netherlands is a tertiary refer-
ral centre for focal liver lesions. Yearly over 200 liver resections are being performed of 
which a minority in patients with HCC in non-cirrhotic livers. In the present study all 
patients (n=47) with HCC in a non-cirrhotic liver who had a surgically resection between 
January 2000 and April 2011 were included. These patients were demonstrated to be 
negative for HCC risk factors i.e. hepatitis C viral infection, hepatitis B viral infection, 
alcohol abuse or hemochromatosis. Patients with a fibrolamellar HCC were excluded. 
Survival time was determined from the date of the histopathological diagnosis to the 
end of the study on 1 April 2011 with a median survival time of 45 months (range 1-129 
months). Confirmation regarding survival of patients that were lost to follow-up was 
obtained from the general practitioner or the civil registration systems.
HCC recurrence was defined as the occurrence of a focal liver lesion with HCC char-
acteristics, enlargement of lymph nodes in the liver hilus, or suspected extrahepatic 
lesions which were, if necessary, pathologically confirmed.
Histopathology 
Paraffin embedded formalin fixed liver tissue slides were retrieved from the archives 
of the department of pathology, Erasmus MC Rotterdam. For each lesion microscopic 
features were evaluated (F.J.W.K.). Tumour differentiation grade was determined accord-
ing to the Lauwers classification, and was based on the areas of tumour showing the 
poorest differentiation grade [17]. Non-tumoral liver tissue was evaluated for fibrosis/ 
cirrhosis according to the classification of the METAVIR group as follows: F0 (no fibrosis); 
F1 (peri-portal fibrosis), F2 (few porto-central bridges), F3 (many porto-central bridges) 
and F4 (cirrhosis) [18]. Steatosis was graded according to Kleiner et al.: Grade 1 (5-33% of 
the hepatocytes), grade 2 (33-66% of the hepatocytes), grade 3 (more than 66% of the 
hepatocytes). Steatosis, if not observed or <5% was graded as grade 0 [19].
Immunohistochemistry
Immunohistochemistry was performed on representative sections of the tumour. Im-
munostaining for AFP (rabbit polyclonal antibody, Dako), CD34 (mouse monoclonal 
antibody, clone QBEnd/10, Neomarkers, CC1-Standard), GPC-3 (mouse monoclonal 
antibody, clone Ig12, Santa Cruz, Biotechnology, CC1-Mild), CK19 (mouse monoclonal an-
tibody, clone RCK108, Dako Mo888, Benchmark Ultr. Ventana, CC1-standard), CK7 (mouse 
monoclonal antibody, OV_TL 12/30, Biogenex, CC1-standard), MIB-1 (mouse monoclonal 
antibody, clone Ki67, M7240, Dako), GS (monoclonal mouse antibody, 6/glutamine syn., 
B&D, CC1-standard) and β-catenin (monoclonal mouse antibody, clone 14, Autostainer, 
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PT high, Dako) was performed in these cases. In case CD34 staining was not diffusely 
positive it was graded as negative. CK7 and CK19 staining was graded as positive in cases 
with >5% positive cells. A nuclear staining for β-catenin, focal or diffuse, was considered 
positive. For each immunohistochemical staining a positive and negative control was 
used. To compare immunohistochemical staining of HCC in a non-cirrhotic liver to 
the immunohistochemical profile of HCC in a cirrhotic liver a control group was used, 
including 41 cases with 65 HCCs in a cirrhotic liver. In all cases we performed immunohis-
tochemical staining of AFP, CD34, GPC-3, CK19, CK7, MIB-1, GS and β-catenin. 
statistical analysis
Continuous variables were summarized as median with ranges and categorical variables 
were summarized as frequency and percentages. The Mann-Whitney U test, t-test or 
the χ2-test were used whenever appropriate. Statistical significance was considered at 
a p-value < 0.05. The Kaplan-Meier method was used to calculate the survival rate, the 
difference between Kaplan-Meier curves was tested using the log-rank test. All analyses 
were performed using the Statistical Package for Social Sciences 17.0 (SPSS, Chicago, IL, 
USA).
resUlts 
Clinical, pathological and immunohistochemical features
From January 2000 through April 2011, 47 patients with 50 lesions were treated by surgi-
cal resection of HCC in a non-cirrhotic liver. Clinical and pathological characteristics are 
summarized in Table 1. These patients were demonstrated to be negative for HCC risk 
factors i.e. hepatitis C viral infection, hepatitis B viral infection, alcohol abuse or hemo-
chromatosis. In all cases of HCC absence of cirrhosis was confirmed histologically. 
Differentiation according to the Lauwers classification resulted in 12 well-differentiat-
ed (24%), 31 moderately-differentiated (62%) and 7 poorly- differentiated (14%) tumours. 
Vascular invasion was present in 30 (60%) tumours. The immunohistological staining 
pattern of HCC in a non-cirrhotic liver and HCC in a cirrhotic liver as conducted in the 
present study l and in literature are displayed in table 2. 
Comparison with clinicopathological characteristics
The relationship between the expression of AFP, CD34, CK7, CK19, GPC3, MIB-1, GS and 
β-catenin and the differentiation grade are given in table 3A. The relationship between 
the expression of AFP, CD34, CK7, CK19, GPC3, MIB-1, GS and β-catenin and presence of 
vascular invasion are given in table 3B. Patients with a moderate or poorly differenti-
ated HCC had a significantly higher prevalence of β-catenin, GPC3 and MIB-1 expression. 
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More patients with presence of vascular invasion presented with a higher prevalence of 
MIB-1 expression in the tumour.  
A positive AFP immunohistochemical staining was significantly related with an in-
creased pre-operative AFP serum level (p=0.001). The larger tumour size the more often 
table 2: Staining pattern immunohistochemical markers in hepatocellular carcinoma in a non-cirrhotic 
liver and in hepatocellular carcinoma in a cirrhotic liver according to our hospital and the literature
staining   Hepatocellular 
carcinoma in 
a non-cirrhotic liver  
[rotterdam]
Hepatocellular carcinoma 
in 
a cirrhotic liver 
[rotterdam]
Hepatocellular 
carcinoma in 
a cirrhotic liver 
[literature]
AFP Positive 30% 35% 25-40% 15
β-Cat Positive 32% 25% 20-35% 20,21
CD34 Positive 88% 95% 88% 22
GPC-3 Positive 40% 85% 76-83% 11,13,23
GS Positive   52% 60% 24
  Positive diffuse
Positive focally
42%
20%
   
CK7 Positive 44% 59% 22-40% 25,26
CK19 Positive 12% 6% 10-17% 25,26
MIB 1-10% positive
≥10% positive
22% 17% 51% 27
33% 27 
  10-30% positive
30-50% positive
>50% positive
28%
28%
22%
26%
34%
23%
 
AFP= alpha-fetoprotein; β-Cat= β-catenin; GPC-3= glypican-3; CK7= cytokeratine 7; CK19=cytokeratine 
19; MIB-1=antigen Ki67; GS= glutamine synthetase
table 1: clinical and pathological characteristics of patients with hepatocellular carcinoma in a non-
cirrhotic liver
Characteristic n=47
Clinical  
Age (years) 65 (21-82) *
Gender (male) 23 (50) **
Level of serum AFP (ng/mL) 6 (2-217800) *
Pathological  
Number tumours 1 (1-3) *
Tumour size (mm) 110 (17-240) *
Fibrosis grade 0/I/II 35 (75)/ 11 (23)/ 1 (2) **
Steatosis grade 0/I/II/III 27 (58)/ 11 (23)/ 8 (17)/ 1 (2) **
*median (range)
**number (%) 
AFP= alpha-fetoprotein
HCC immunohistochemical 127
CD34 staining was positive in a diffuse pattern (p=0.037). None of the immunohisto-
chemical stainings was associated with a poor overall survival. After a median follow-up 
of 9 months (range 2-42 months) 17 patients had recurrence of HCC, these patients more 
often had a positive CK19 staining (p=0.048). 
DIsCUssIoN
The biological behaviour of HCC in a non-diseased liver, as defined by the absence of 
well known risk factors for cirrhosis, has been subject for debate as to define this HCC as 
an entity different from HCC in a diseased liver parenchyma [28]. HCC in a non-cirrhotic 
liver might have a different pathogenesis with a different clinical, histological and his-
table 3a: Staining pattern immunohistochemical markers in hepatocellular carcinoma in a non-cirrhotic 
liver according to the differentiation grade
      Differentiation 
grade
   
staining   Good Moderate Poor p-value*
AFP Positive 1 (8%) 10 (32%) 4 (57%) 0.074
  Negative 11 (91%) 21 (68%) 3 (43%)  
B-Cat Positive 0 (0%) 15 (48%) 1 (14%) 0.005
  Negative 12 (100%) 16 (52%) 6 (86%)  
CD34 Positive 11 (92%) 28 (90%) 5 (71%) 0.344
  Negative 1 (8%) 3 (10%) 2 (29%)  
GPC-3 Positive 0 (0%) 15 (48%) 5 (71%) 0.003
  Negative 12 (100%) 16 (52%) 2 (29%)  
GLUL Positive diffuse 2 (17%) 17 (55%) 2 (29%) 0.183
  Negative 6 (50%) 10 (32%) 3 (43%)  
  Positive weak 4 (33%) 4 (13%) 2 (29%)  
CK7 Positive 7 (58%) 13 (42%) 2 (29%) 0.421
  Negative 5 (42%) 18 (58%) 5 (71%)  
CK19 Positive 0 (0%) 4 (13%) 2 (29%) 0.175
  Negative 12 (100%) 27 (87%) 5 (71%)  
MIB 1-10 6 (50%) 5 (16%) 0 (0%) 0.034
  10-30 3 (25%) 9 (29%) 2 (28%)  
  30-50 3 (25%) 10 (32%) 1 (14%)  
  >50 0 (0%) 7 (64%) 4 (57%)  
*univariate analysis χ2-test
AFP= alpha-fetoprotein; β-Cat= β-catenin; CD34= antigen CD34; GPC-3= glypican-3; CK7= cytokeratine 7; 
CK19=cytokeratine 19; MIB-1=antigen Ki67; GS= glutamine syntetase
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tochemical presentation, which might result in a different management and prognosis 
[28]. In low-endemic areas HCC in a non-cirrhotic liver may contribute to the overall sur-
vival of HCC patients to a larger extent as compared to high-endemic areas where HCC 
in cirrhotics dominate. It may be questioned whether the prognosis of HCC in absence of 
cirrhosis is more favourable as compared to the prognosis reported in literature for HCC 
in cirrhotics. Factors that may influence prognosis of patients with HCC in non-diseased 
livers are not well described, neither from a clinical perspective, nor from a pathological 
perspective. Being representative for a low-endemic area we initiated the present study 
to investigate the expression of immunohistochemical markers in HCC in a non-cirrhotic 
liver. 
The outcome of immunohistological staining of HCC according to our clinic and the 
literature in a cirrhotic liver or in presence of risk factors e.g. hepatitis B/C viral infection 
or alcohol abuse, are summarized in Table 2 [11,13,15,20-27]. Although GPC-3 is less often 
table 3B: Staining pattern immunohistochemical markers in hepatocellular carcinoma in a non-cirrhotic 
liver according to the presence of vascular invasion
      Vascular invasion    
staining   No Yes suspect p-value*
AFP Positive 3 (16%) 12 (40%) 0 (0%) 0.158
  Negative 16 (84%) 18 (60%) 1 (100%)  
B-Cat Positive 5 (26%) 11 (37%) 0 (0%) 0.591
  Negative 14 (74%) 19 (63%) 1 (100%)  
CD34 Positive 18 (95%) 25 (83%) 1 (100%) 0.456
  Negative 1 (5%) 5 (17%) 0 (0%)  
GPC-3 Positive 4 (21%) 15 (50%) 1 (100%) 0.061
  Negative 15 (79%) 15 (50%) 0 (0%)  
GLUL Positive diffuse 8 (42%) 13 (43%) 0 (0%) 0.344
  Negative 5 (26%) 13 (43%) 1 (100%)  
  Positive weak 6 (32%) 4 (13%) 0 (0%)  
CK7 Positive 12 (63%) 10 (33%) 0 (0%) 0.082
  Negative 7 (37%) 20 (67%) 1 (100%)  
CK19 Positive 2 (11%) 4 (13%) 0 (0%) 0.893
  Negative 17 (89%) 26 (87%) 1 (100%)  
MIB 1-10 8 (42%) 3 (10%) 0 (0%) 0.009
  10-30 8 (42%) 6 (20%) 0 (0%)  
  30-50 2 (11%) 11 (37%) 1 (100%)  
  >50 1 (5%) 10 (33%) 0 (0%)  
*univariate analysis χ2-test
aFP= alpha-fetoprotein; β-Cat= β-catenin; CD34= antigen CD34; GPC-3= glypican-3; CK7= cytokeratine 
7; CK19=cytokeratine 19; MIB-1=antigen Ki67; GS= glutamine syntetase
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positive in a HCC in a non-cirrhotic liver, our immunohistochemical data demonstrate a 
similarity in immunohistochemical expression of several markers comparing HCC in a 
non-cirrhotic liver with HCC in a cirrhotic liver. These findings suggest that by defining 
immunohistological characteristics HCC in a non-cirrhotic liver cannot be discriminated 
from HCC in a cirrhotic liver. The difference in CK7 and CK19 expression between our 
patients with cirrhosis and the literature can be a result of interpretation as these mark-
ers are not always diffusely positive. In our study CK7 and CK19 were scored as positive 
in case they were focal positive or diffusely positive. The differences in MIB-1 expression 
can also be explained by interpretation variability as MIB-1 is a percentage that is ob-
server dependent. GPC-3 being less often positive in a HCC in a non-cirrhotic liver might 
be an affect of the absence of an underlying liver disease as it is reported that GPC-3 
has a strong immunoreactivity in hepatocytes in liver biopsies with chronic hepatitis C 
or cirrhosis [11,29]. Although it can not be stated from the results of this study it may be 
speculated that accordingly to the lack of differences between the immunohistological 
characteristics the oncobiological behaviour of HCC in non-cirrhotic and HCC in cirrhotic 
livers may not differ.
Clinicopathological characteristics 
AFP immunohistochemical staining was positive in 30% of the cases. Our results dem-
onstrate a strong correlation between AFP in serum and AFP in tumour specimens as 
shown by immunohistochemical staining. In addition in those cases in which absence of 
AFP in immunohistochemical staining was found serum AFP was not increased either. It 
should be noted that a negative AFP immunohistochemical staining does not exclude 
HCC, as compared to a negative serum AFP and that this marker should be interpreted 
with care in case of tumour analysis in non-cirrhotic and cirrhotic patients. Other im-
munohistochemical markers may be helpful in the differentiation of good, moderate 
and poorly differentiated tumours and presence of vascular invasion, both parameters 
known as prognostic features [30-34]. β-catenin, GPC-3 and MIB-1 are significantly more 
often positive in patients with a moderate or poorly differentiated tumour. Although 
HCC in a non-cirrhotic liver is less often GPC-3 positive, GPC-3 is a marker that is signifi-
cantly associated with a moderate or poor differentiation grade. GPC-3 is an oncofetal 
protein, a member of the glypican family of membrane-bound heparin sulphate 
proteoglycans, with roles in development and regulation of cellular proliferation and 
apoptosis in specific tissues [8]. The expression of GPC-3 is detected in the placenta and 
the fetal liver and reappears in HCC during hepatic carcinogenesis [23]. In addition MIB-1 
expression is also increased in HCCs with presence of vascular invasion. In case one has 
to distinguish well-differentiated HCC from a hepatocellular adenoma on a needle core 
biopsy β-catenin, GPC-3 and MIB-1 might be helpful. 
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It was found that CK19 more often was found to be positive in patients who showed 
recurrence of disease during their follow up. The relevance of this finding should be 
validated in larger cohort to define its use for clinical management. 
In spite of the fact that we had the opportunity to study an unique population and 
were able to report data from to the best of our knowledge the largest number of cases 
reported so far, none of the immunohistochemical markers eventually seems to be able 
to differentiate between patients with a good and a poor survival.
In summary, in the analysis of tumours in non-cirrhotic livers a positive AFP immunohis-
tochemical staining may be helpful and correlates with an increased AFP serum level. 
However, as in cirrhotic patients absence of AFP serum as well as tumour tissue does 
not exclude the presence of HCC. Immunohistochemical markers, including β-catenin, 
GPC-3 and MIB-1 may be helpful in establishing HCC differentiation grade. These markers 
can not be used as a predictor for prognosis and survival. 
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aBstraCt 
Background: Hepatitis B virus infection (HBV) is an important co-factor in the develop-
ment of hepatocellular carcinoma (HCC). We studied whether quantitative HBV DNA at 
time of HCC detection influences survival of HCC patients. 
Methods: All diagnosed HCC cases between 2000 and 2008 at our university-based 
reference centre were analysed to determine the influence of hepatitis B viral load on 
overall survival. Clinical and virological findings were evaluated in univariate and multi-
variate analyses, survival rates were assessed for HCC patients with a high viral load (HBV 
DNA ≥105 copies/ml) and low viral load (HBV DNA <105 copies/ml).
results: HCC was diagnosed in 597 patients, including 98 patients with HBV. The group 
of 37 patients (38%) who had a high viral load contained more HBeAg-positive patients, 
had lower serum albumin levels and higher serum aspartate aminotransferase (AST ) 
and alanine aminotransferase (ALT ) levels. The one- and five-year survival rates of HCC 
patients with a high viral load were 58% and 11% and for HCC patients with a low viral 
load 70% and 35%, respectively. In multivariate analysis a higher AST level and higher 
viral load were significantly associated with shorter overall survival (HR=2.30; p=0.018, 
HR=1.22; p=0.015, respectively).
Conclusion: HBeAg positivity, low albumin level or high AST or ALT levels in HCC pa-
tients are associated with a higher HBV DNA . HBV DNA level at detection is associated 
with overall survival of HCC patients. These findings support the concept that after HCC 
detection adequate suppression of HBV DNA by nucleoside analogue therapy may 
improve survival.
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INtroDUCtIoN
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the 
third most common cause of cancer-related mortality [1]. In many patients, HCC occurs 
against the background of a chronic viral infection. Chronic hepatitis B virus (HBV) infec-
tion, chronic hepatitis C viral (HCV) infection and cirrhosis are major aetiologies of HCC 
[2,3]. Worldwide  approximately 400 million people are chronically infected with HBV [4].
In the last 15 years, reliable quantification of HBV DNA over a large dynamic range 
has become feasible. Several hospital-based and community-based studies have sub-
sequently found significant associations between the level of serum HBV DNA and the 
risk to develop liver cirrhosis or HCC [5]. After an HCC has developed and surgery is per-
formed, recurrence of HCC is associated with original tumour size, number of tumours, 
grade of differentiation, level of alpha-fetoprotein (AFP), alcohol consumption and HCV 
co-infection[6-9].
The impact of viral load on survival of HCC patients after surgery with curative in-
tent may be overshadowed by tumour-related factors or stage of the liver disease at 
detection of HCC. Understanding the respective role of tumour and viral factors in HCC 
survival may provoke new treatment strategies to increase HCC survival. It has been 
hypothesised that anti-viral therapy for HCC patients with active HBV replication along 
with HCC treatment might reduce the recurrence rates for HBV-associated HCC [10].
A few recent studies have evaluated HBV replication status as a predictor of HCC 
recurrence [9,11,12]. However, to our knowledge only a few reports from high endemic 
areas published to date, often with a limited number of patients, have suggested a 
relation between viral status and prognosis in patients with HBV-associated HCC [13-
16]. In the current study in a low endemic area, univariate and multivariate analyses of 
the prognostic factors, including serum HBV DNA level, were performed to determine 
whether the HBV DNA levels at the time of HCC appearance are associated with overall 
survival.
MaterIal aND MetHoDs
study design
A hospital-wide registry, including data from patient files and virological records of all 
patients diagnosed with HCC at the Erasmus MC in Rotterdam, the Netherlands during 
the period from 1 January 2000 to 31 December 2008, was used. The diagnosis of HCC 
was made from radiological and biochemical findings and, if necessary, confirmed by 
histological examination. Within the group of nodules larger than 2 cm, with the typical 
features of HCC on a dynamic imaging technique, no biopsy was performed. Nodules 
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between 1-2 cm were investigated further with two dynamic studies imaging modalities, 
computed tomography (CT) scan or magnetic resonance imaging (MRI) with contrast. 
If the appearances were typical of HCC (i.e., hypervascular with washout in the portal/ 
venous phase) in two techniques the lesion was treated as HCC. If the findings were not 
characteristic or the vascular profile was not coincidental among techniques, the lesion 
was biopsied, according to the AASLD guidelines [17].
All HBsAg(+) patients were included in this study. Follow-up of HCC recurrence by 
an alpha-fetoprotein (AFP) test and ultrasound, CT, or MRI was done every three to six 
months for up to two years after potential curative treatment. After two years, follow-up 
was continued annually for up to five years after treatment. Recurrence of tumour in 
the treated area or elsewhere was defined as re-appearance of vascular enhancement 
[17]. In the presence of underlying liver cirrhosis, lifetime follow-up was performed. If 
HCC recurred, the size, number, and localisation of the recurrent disease were registered. 
Verification of living patients was done using information obtained from the general 
physician or the civil registration. 
Biochemical and serological markers
Data were collected on patient age, gender, nucleotide or nucleoside analogue therapy 
(lamivudine, adefovir, telbuvidine, tenofovir or entecavir or a combination of these 
drugs),  AFP, size and number of lesions, and the presence of lymph node enlargement or 
metastases. The collected liver parameters included aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), total bilirubin and albumin. In addition, the Model For 
End-Stage Liver Disease (MELD) score was calculated. Cirrhosis was diagnosed using 
established clinical, biochemical, and histological criteria. Patients with cirrhosis were 
classified according to the Child-Pugh classification.
At time of HCC diagnosis, the serum HBV DNA level was assessed using in-house 
Taqman PCR (detection limit 400 copies/ml) based on the Eurohep standard, HBeAg 
(AxSYM, Abbott, Abbot Park, IL, USA) and hepatitis B surface antigen (HBsAg) (AxSYM, 
Abbott) status were measured [18]. A high HBV load was considered to be HBV DNA ≥105 
copies/ml, HBV DNA <105 copies/ml was considered a low viral load [19]. All patients 
were negative for anti-hepatitis C virus antibody and did not report alcohol abuse at 
time of diagnosis and commencement of this study.
statistical analysis
Variables were compared using the Mann-Whitney U test, t-test or with the χ2 test 
whenever appropriate. Statistical significance was considered if the p value was <0.05. 
Univariate analysis was used to assess the importance of prognostic factors on overall 
survival. Survival curves were drawn using the Kaplan-Meier method. The difference 
between Kaplan-Meier curves was tested using the log-rank test. The baseline charac-
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teristics age, gender, log bilirubin, log albumin, log AST, log ALT, log HBV DNA, log AFP, 
MELD score, Barcelona Clinic Liver Cancer (BCLC) score, HBeAg and anti-viral therapy 
were considered.
Multivariate Cox regression analysis was performed with all characteristics with a p 
value <0.20 in univariate analysis and known factors associated with survival to deter-
mine the independent contribution of each variable. Analysis was performed using SPSS 
software.
resUlts
Clinical, biochemical and virological data
A total of 597 patients were diagnosed with HCC. Out of these 597 patients, 98 patients 
(16%) fulfilled the inclusion criteria. The patient characteristics at presentation with HCC 
are shown in table 1. Median follow-up was 22 months (1-114). One year after presenta-
table 1: Patient characteristics at first presentation with HCC
Characteristic (n =98)
Age (years)* 55(23-80)
Gender (male) 79(81%)
Total bilirubin (umol/L)*
Albumin (g/L)*
AST (U/L)*
ALT (U/L)*
AFP (ng/ml)*
18(4-481)
38(22-49)
69(21-1278)
54(19-670)
70(1-652660)
MELD score*
Non-cirrhotic
Child-Pugh-classification
A
B
C
6(6-25)
22(22%)
49(64%)
20(26%)
7(9%)
HBV DNA ≥105 copies/mL
HBeAg‡   
Anti-viral (nucleoside or nucleotide analogue) therapy
37(38%) 
24(25%)
50(51%)
Number of tumours*
Tumour size (mm)*
Metastases
1(1-7)
34(8-227)
29(30%)
BCLC
Stage A
Stage B
Stage C
Stage D
30(31%)
37(38%)
7(7%)
24(24%)
*median(range), ‡ positive value
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tion, 60% of the patients were still alive, and the five-year survival rate of this cohort 
was 21%. In 50 patients (51%), treatment with curative intent was initiated; this included 
surgical resection (wedge resection, segment resection, or hemihepatectomy), liver 
transplantation or radio frequency ablation. In eight patients (8%) transarterial (chemo)
embolisation (TACE) or another therapy such as radiotherapy or systemic chemotherapy 
with palliative intent was started. The remaining group of 40 patients (41%) received no 
therapy.
Fifty patients (51%) received oral anti-viral therapy. Nine patients had an increase of 
HBV DNA during the study period but none of these patients switched from the low HBV 
DNA group to the high HBV DNA group. 
In 21 out of 50 patients (42%) a recurrence of HCC was documented after potentially 
curative treatment. The median time to recurrence was 12 (1-50) months. Recurrence 
of HCC presented as local recurrence in four patients (19%), a new lesion in 11 patients 
(52%) and metastases in six patients (29%).
Factors associated with HBV viral load
Among the 98 patients, 37 (38%) had a high viral load. As expected, the group of patients 
with a high viral load contained more HBeAg(+) patients, had a lower serum albumin 
level and had a higher serum AST, ALT, and total bilirubin level compared with the group 
of patients with a low viral load (table 2). Treatment with curative intent was not signifi-
cantly different between patients with high and low viral load (p=0.188). Treatment of 
HCC was independent of the level of HBV DNA (p=0.202). Patients with a higher viral 
load more often had a recurrence of HCC after treatment with curative intent (p=0.025).
Univariate and multivariate analyses were performed to determine HBV-related pre-
dictors for overall survival (table 3). Multivariate Cox regression analysis was performed 
with all characteristics with a p value <0.20 in univariate analysis and known factors as-
sociated with survival to determine the independent contribution of each variable. The 
strong correlation between AST and HBV DNA made it impossible to join them in one 
model. Separately, multivariate analysis confirmed both a high AST level and a high viral 
load (HBV DNA) to be significantly associated with a shorter survival (HR=2.30; p=0.018, 
HR=1.22; p=0.015, respectively). A higher AFP, a higher MELD score and a higher BCLC 
classification were also associated with a shorter survival (HR=1.30; p=0.008, HR=1.08; 
p=0.021, HR=1.95; p<0.001, respectively).
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table 2: Differences between patients with high and low HBV load
Characteristic HBV DNa 
<10.5
(n =61)
HBV DNa  ≥10.5 
(n =37)
p-value
Age (year)* 56(23-77) 54(27-80) 0.650
Gender (male) 49(80%) 30(81%) 0.928
Total bilirubin(umol/L) *
Albumin(g/L) *
AST(U/L) *
ALT(U/L) *
AFP(ng/ml)*
15(4-481)
39(25-49)
62(21-328)
50(19-356)
70(1-652660)
24(6-372)
35(22-48)
95(33-1278)
67(32-670)
70(2-121000)
0.058
0.032
0.002
0.039
0.640
Non-cirrhotic
MELD score*
15(25%)
6(6-23)
7(19%)
7(6-25)
0.516
0.253
HBeAg‡  
Anti-viral (nucleotide or nucleoside analogue) therapy
11(18%)
32(53%)
13(35%)
18(49%)
0.047
0.716
Number of tumours*
Tumour size (mm)*
Metastases
1(1-7)
34(8-200)
15(25%)
1(1-4)
34(11-227)
14(38%)
1.000
0.714
0.166
BCLC
Stage A
Stage B
Stage C
Stage D
21(34%)
23(38%)
5(8%)
12(20%)
9(24%)
14(38%)
2(5%)
12(32%)
0.466
*median(range), ‡ positive value
table 3: Univariate analysis of factors associated with survival 
Variable hazard ratio (95% confidence 
limits)
p-value
Age (10 years) 1.00 (0.78-1.27) 0.97
Gender (female:male) 0.80 (0.41-1.57) 0.50
log total bilirubin (10 umol/L)*
log albumin(10g/L)*
log AST(U/L)*
log ALT(U/L)*
log AFP(ng/ml)*
1.02 (0.99-1.05)
0.68 (0.44-1.03)
2.30 (1.15-4.60)
0.75 (0.31-1.80)
1.32 (1.09-1.60)
0.31
0.07
0.018
0.51
0.006
MELD score
HBV DNA
HBeAg‡
Anti-viral (nucleotide or nucleoside analogue) 
therapy
1.07 (1.01-1.14)
1.22 (1.04-1.43)
1.47 (0.84-2.55)
0.69 (0.42-1.14)
0.033
0.015
0.19
0.15
BCLC 1.95 (1.54-2.48) <0.001
*continuous value ‡ positive value
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association of serum HBV DNa levels at time of HCC diagnosis and overall 
survival
The median survival time of HCC patients with a high viral load was 15 months (1-62), 
and 25 months (1-114) in HCC patients with a low viral load (figure 1). The one-, three- and 
five-year survival rates of HCC patients with a high viral load were 58%, 32% and 11%, 
respectively. For HCC patients with a low viral load, the one-, three and five-year survival 
rates were 70%, 39% and 35%, respectively (figure 1). Patients with higher serum HBV 
DNA levels at the time of tumour presentation had a shorter overall survival compared 
with patients with lower serum HBV DNA levels (p=0.05). Including HCC treatment into 
the total multivariate analysis, a high viral load continued to be significantly associated 
with a shorter survival (HR=1.18 (95% CL; 1.01 to 1.38); p=0.042). 
DIsCUssIoN
In our study we showed in multivariate analysis that a high AST level and high viral load 
were two independent factors associated with poor survival. A unique and important 
finding of this study is that it demonstrates the impact of high viral load on overall 
survival of HCC patients despite the treatment they received. Consistently, we observed 
that biochemical profiles indicative of active inflammation in our data were worse in 
patients who had high viraemia than in patients who had low viraemia, further sup-
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Figure 1: Overall survival of HCC patients with high and low HBV DNA
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porting the theory of the potential carcinogenic process through active inflammation 
associated with high viraemia.
Localised HCC tumours can be subjected to potentially curative treatments such as 
surgical resection, liver transplantation or radiofrequency ablation [17]. In our study 50 
patients (51%) were able to receive treatment with curative intent. Only 8% of the study 
population received treatment with palliative intent; this low percentage is due to a 
limited availability of TACE treatment during the study period. Patients without treat-
ment were often unable to receive treatment due to more advanced liver disease. 
In many patients, HCC occurs against a background of advanced fibrosis or cirrhosis 
[20-22]. Cirrhosis decreases the regenerative capacity of the liver and therefore not every 
HCC patient is a suitable candidate for local surgical resection. Although many surgical 
and nonsurgical options have been developed for the treatment of HCC, the prognosis 
for these patients remains poor. Even in those who receive radical therapy, prevention of 
post-treatment recurrence remains a medical challenge [23].
Several factors have been reported to be associated with poor survival after surgical 
resection or local ablation therapies, including tumour characteristics, such as multiplic-
ity, size, AFP levels, portal invasion, surgical tumour findings, parameters related to liver 
function such as albumin levels, and Child-Pugh classification [11,15].
Taking into account the fact that HCC arises in cirrhotic livers, evaluation of the 
detailed oncogenic process in patients with cirrhosis is an important subject for cancer 
prediction [17].
Liver cirrhosis due to hepatitis C virus usually shows a rather steady and constant 
clinical course, which enables us to estimate the future carcinogenesis rate only from 
clinical information at the time of the diagnosis of cirrhosis.
However, in contrast to hepatitis C and other risk factors, it is known that HBV-related 
HCC is less associated with the presence of cirrhosis, and this trend becomes more obvi-
ous in younger patients often infected at birth whose duration of infection is not long 
enough to develop full-blown cirrhosis [23]. This observation has prompted the sug-
gestion that HBV itself has direct carcinogenic potential [23]. The detailed mechanism 
of HBV-related liver carcinogenesis is still unclear [18,24]. It is possible that active viral 
replication and HBx-protein expression contribute to the carcinogenic process [11]. Pro-
spective studies have indicated a very strong correlation between the height of the viral 
load and the risk of developing HCC. Lamivudine therapy in patients with HBV-related 
compensated cirrhosis reduced the incidence of HCC in patients when viral suppression 
was sustained, but no previous report has studied the relationship of these viral factors 
and survival of HCC patients [11,15,25,26]. 
When we investigate the relationship between hepatocellular carcinogenesis and 
its affecting and contributing factors, explanatory parameters should include not only 
tumour-related factors but also data on the extent of the liver disease, as e.g. included 
142 Chapter 10
in the Child classification, BCLC and MELD classification. We also suggest including 
quantitative virological data in this prognostic modelling.
In the current study, patients with a higher viral load also had more elevated liver 
enzymes. Oral nucleoside or nucleotide analogue therapy has developed over the last 
years. The profile of drugs such as entecavir or tenofovir combines high efficacy with 
a low potential for resistance. Therefore, a logical next step is to treat all HBV-related 
HCC patients with nucleoside or nucleotide analogue therapy. A meta-analysis also 
suggested a potential efficacy of adjuvant interferon after curative therapy for HCC [27]. 
Two recent prospective studies focusing primarily on the correlation between hepatitis 
B viral load and recurrence of small HCC after curative resection revealed that HBV DNA 
level at resection was an important risk factor for recurrence of small HCC after surgery 
[9,28].
A potential limitation of the present study is that the data were based on a retrospective 
cohort study. A large-scale prospective trial should be conducted in the future to elu-
cidate the effect of sustained viraemia on survival of HCC patients and the prospective 
roles of antiviral treatment.
In theory, treating high viral load patients with antiviral drugs both pre- and post-
operatively is reasonable. Current treatment in patients with advanced HCC is sorafenib, 
where median survival can increase by nearly three months [29]. In this study high HBV 
viral load and hepatic inflammatory activity were both significantly associated with a 
poor prognosis; median survival was ten months longer in HCC patients with a low viral 
load [30].
Given the strong association between HBV viral load and overall survival, it is an-
ticipated that the implementation of strategies for the use of antiviral therapy in this 
setting will result in a durable suppression of HBV replication and ultimately will lead 
to an increase of survival in HCC patients. We suggest that, for HCC patients with high 
serum HBV DNA levels, inhibition of viral replication may decrease inflammation and 
improve survival.
In conclusion, a lower albumin level or a higher serum AST or ALT activity are liver-related 
factors that are closely associated with a higher hepatitis B viral load. In our dataset 
as well as in the data of Qu et al. high HBV DNA shortened overall survival [28]. In the 
current analysis serum AST and viral load independently affected overall survival. This 
association supports the role for antiviral treatment for patients with a high HBV DNA 
together with treatment of HCC to increase overall survival. Further clinical trials with 
this endpoint are required to confirm the beneficial effect of hepatitis B viral suppression 
after HCC treatment to improve survival.
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GeNeral DIsCUssIoN
Part II - treNDs IN HePatoBIlIarY CaNCer
Hepatocellular carcinoma (HCC) is a disease with a highly uneven geographical distribu-
tion due the variation in the main causal factors [1,2]. In industrialised countries HCC is 
an uncommon type of cancer [1-4]. In the Netherlands the incidence of HCC was stable 
until 2000, but since then the incidence has increased. This observation is reported by 
various groups from low-endemic areas [1,2,4].
Chapter 2 describes the increasing incidence of HCC for males, but not for females 
in the Netherlands between 1989 and 2009. The observed increase in HCC in males 
might be related to the higher prevalence of non-alcohol fatty liver disease, which can 
be considered a precursor lesion of non-alcoholic steatohepatitis, as is also suggested 
by others [5]. Remarkably, the overall 1-year survival rate of patients with HCC receiving 
surgery, chemotherapy and/or irradiation, has improved. It has been speculated that 
this outcome may be related to changes in tumour treatment [6]. However, the survival 
of patients receiving no therapy at all has increased as well suggesting that earlier detec-
tion may play a role, perhaps in addition to a better treatment outcome. This lead-time 
bias may be the result of more effective screening programs. In addition, the improved 
outcome may also be attributed to an earlier and better treatment of complications of 
the underlying liver cirrhosis. In the Netherlands over 60% of the patients with HCC has 
underlying cirrhosis [7]. 
It has been suggested that the change in incidence of HCC could also be due to 
improved diagnosis nowadays as compared a decade ago: formerly misdiagnosed liver 
lesions may nowadays be diagnosed more adequately using computed tomography 
(CT) and high-resolution magnetic resonance imaging (MRI) of the liver. To date, the dif-
ferences between HCC and other liver tumours can be demonstrated more clearly and 
the reliability of diagnosing various types of liver tumours has increased significantly. 
If changes in incidence are influenced by the quality of imaging technology, tumours 
previously described as unclassified might be expected to be classified adequately to 
date [8]. In case of misdiagnosis one would expect the incidence of at least one of the 
other hepatobiliary tumour to decrease to compensate the rise of HCC. We analyzed epi-
demiological trends of other liver tumours, including intrahepatic cholangiocarcinoma 
(ICC), that must be differentiated from HCC (Chapter 3). As the incidence rate of ICC has 
increased for both men and women, it’s highly unlikely that misdiagnosis of these liver 
tumours may account for the increase of HCC. The reason for the rising incidence of ICC 
is still unknown [9,10]. Several medical conditions have been suggested as cause for ICC, 
including primary sclerosing cholangitis (PSC) and primary biliary cirrhosis [11,12]. As we 
didn’t analyze data regarding changes in the prevalence of risk factors for ICC, we can 
not explain the rising incidence of ICC.
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As for HCC a survival benefit for ICC patients that have been selected for surgical 
treatment has been observed. Increased ICC survival might be a reflection of patient 
selection over time, with an important role for imaging techniques that allow better 
pre-operative assessment of tumour extension and metastatic disease. Alternatively, 
increased survival could indicate lead-time bias related to early detection, as patients 
with associated factors mentioned above are controlled more often, including patients 
with PSC who have a lifetime risk of ICC ranging from 8-20% [9].
Part III - sCreeNING For HePatoCellUlar CarCINoMa
The epidemiological trend on HCC in the Netherlands might be a reflection of better 
screening programs for patients at risk, thus leading more frequently to early detection 
of the disease. For many years alfa-fetoprotein (AFP) was the standard serum marker for 
the detection of HCC, despite its relatively low sensitivity (60%) [13]. As screening can 
lead to a better prognosis with increased long-term survival, we reviewed the status of 
recently reported new biomarkers for HCC screening. In a systemic review (Chapter 4) we 
correlated biomarkers GP73 (Golgi protein 73), IL-6 (interleukin-6) and SCCA (squamous 
cell carcinoma antigen) for HCC screening as compared to the outcome of screening 
using AFP. In our review process many papers had to be excluded because of limitations 
in study design. Our findings eventually were based on 7 manuscripts and suggested 
an advantage of GP73 over AFP as a serum marker for HCC screening. Although GP73 
appears to better than AFP for diagnosing HCC, more research is required on GP73, 
especially because the assay used in the published  clinical studies was less suitable for 
clinical use as the protein is detected by Western blot analysis.
Screening programs focus on patients with chronic hepatitis and cirrhosis as these 
diseases are related to premalignant lesions leading to HCC [13]. HCC occasionally devel-
ops in the absence of chronic liver disease or cirrhosis [7]. It is questioned whether both 
presentations of HCC have a common pathway of carcinogenesis. Some have suggested 
that HCC in non-hepatitis and non-cirrhotic livers may be the result of a malignant 
transformation of hepatocellular adenoma (HCA) [14]. If this hypothesis is correct one 
might assume the co-existence of both HCA and HCC within the same tumour at a cer-
tain moment. The exact point at which the switch to malignant transformation occurs 
remains unknown. Progression from a precursor lesion to cancer might be a multistep 
process, accompanied by a transition zone from benign hepatocytes towards dysplastic 
and malignant hepatocytes. However, as described in Chapter 5, in none of the 52 HCCs 
in non-cirrhotic livers we studied an HCA component could be demonstrated, nor 
a transition zone displaying HCA changing into HCC. Even after using additional im-
munohistochemical staining (i.e. β-catenin, glutamine syntetase, CRP, L-FABP, and SAA) 
no HCA components were found. Ruling out the potential diagnosis of HCA based on 
the absence of validated markers for HCA is daring, as adenoma can present without 
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markers being positive. However, the immunohistological staining did not provide any 
arguments to support the transition from HCA to HCC [15]. In addition, reviewing the 
radiological images supported our concept as it was confirmed that all lesions were 
diagnosed as HCC and in no case a lesion was depicted as having characteristics of a 
liver adenoma. 
Part IV - oPtIMIZatIoN oF staGING
If patients are diagnosed with HCC it is important to have a prognostic profile to guide 
treatment decision-making. Nowadays, staging models include performance status, 
tumour extent and liver function. For those patients included for liver resection, or 
transplantation, the prognosis can be specified by using histological characteristics of 
the tumour in the resected specimens. Histological presence of microvascular invasion 
and a moderate or poor differentiation grade are accepted as independent predictors 
of poor survival [16-20]. After adjusting for age, gender, level of AFP and tumour size, 
our results display that the histologically differentiated grade and the presence of 
microvascular invasion are significantly associated with recurrence of HCC (Chapter 6). 
However, from a clinical point of view it would be preferable if HCC staging could be 
performed (pre-operatively) by using a non-invasive test. We attempted to correlate 
features of HCC on MRI with morphological findings of microvascular invasion and the 
differentiation grade in resection specimens. We found that the presence of wash-out 
indicates presence of microvascular invasion and/or a moderate or poorly-differentiated 
tumour. This observation might have clinically relevant implications for the imaging 
work-up of patients with HCC. Future studies should focus on the feasibility of predict-
ing microvascular invasion and the various differentiation grades by further improving 
imaging techniques, e.g. diffusion-weighted imaging and hepatobiliary contrast agents 
to distinguish between the various differentiation grades and the presence of microvas-
cular invasion of HCC. In addition these imaging features may be included in a predictive 
model defined by radiological criteria. 
It has been suggested that a more detailed preoperative evaluation might identify 
patients with subclinical extra-hepatic disease. For years, bone scintigraphy was rou-
tinely used in selecting patients with HCC for liver transplantation or extensive resec-
tions. This approach has been subject of debate and for liver transplantation it has 
been demonstrated that scintigraphy is ineffective. The criteria to select patients for 
transplantation (Milan criteria) are restrictive and minimize the risk on metastases. Thus 
a more cost-effective approach is advocated. As described in Chapter 7 many patients 
underwent a bone scintigraphy to exclude metastases in the workup for resection of 
HCC. The clinical indication for bone scintigraphy was based on subjective decisions. 
Our study displayed that at a cost of €53,221 bone scintigraphies (n=134) were performed 
in asymptomatic patients with HCC without detecting subclinical metastases even in 
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one patient. We conclude that baseline bone scintigraphy in patients with HCC is not 
indicated unless specific bone-related complaints are present in patients able to receive 
treatment with curative intent. 
Part V – oUtCoMe 
Studies analysing treatment decision-making are focused on HCC patients with cirrho-
sis. A small number of studies has explored clinicopathological characteristics in HCC 
patients without cirrhosis [13,21,22], although these patients often do have risk factors 
for cirrhosis and HCC [21]. This selection bias may influence overall survival as it is known 
that, for example, chronic hepatitis B virus (HBV) influences survival in HCC patients [23]. 
In Chapter 8 we studied patients with HCC but without any known risk factor for liver 
cancer or cirrhosis. In a multivariate analysis the presence of an increased AFP serum 
level pre-operatively was found to be the most important factor associated with a worse 
outcome and recurrence of HCC in a non-hepatitis and non-cirrhotic liver. Although AFP 
as a serological marker for HCC screening and surveillance in patients with cirrhosis is 
still debated [24], AFP seems a useful marker in patients with HCC without risk factors to 
indicate prognosis. 
Apart from the interest in factors associated with outcome and recurrence of HCC in a 
non-cirrhotic liver, the biological behaviour of HCC in non-diseased liver is also explored 
[25]. In Chapter 9 we investigated the expression of immunohistochemical markers in 
HCC in a non-cirrhotic liver. Our immunohistochemical data demonstrate a similarity in 
immunohistochemical expression of several markers comparing HCC in a non-cirrhotic 
liver with HCC in a cirrhotic liver. Although no definite conclusions can be drawn from 
this study, one may speculate that in line with the lack of difference in the immuno-
histological characteristics between HCC in a non-cirrhotic and in a cirrhotic liver, the 
oncobiological behaviour of HCC in a non-cirrhotic and in a cirrhotic liver doesn’t differ 
as well. It should be noted that a negative AFP immunohistochemical staining does not 
exclude HCC and that this marker should be interpreted with care in case of tumour 
analysis in non-cirrhotic patients. 
It has been demonstrated that β-catenin, Glypican-3 (GPC-3) and antigen Ki67 (MIB-1) 
are significantly more often positive in non-cirrhotic HCC patients with a moderate or 
poorly differentiated tumour. In addition MIB-1 expression is also increased in HCCs with 
the presence of vascular invasion. If one needs to distinguish well-differentiated HCC 
from a HCA on a needle core biopsy, β-catenin, GPC-3 and MIB-1 might be helpful. Also, 
cytokeratine 19 (CK19) was found to be positive more often in patients who displayed 
recurrence of disease during their follow-up. The relevance of these findings needs to 
be validated in a larger cohort in order to establish their use for clinical management. 
The Netherlands is a low-endemic area for HCC with 64% of this malignancy occur-
ring in patients with a cirrhotic liver [7]. Because HCC often arises in a cirrhotic liver, 
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evaluation of the detailed oncogenic process in patients with cirrhosis is an important 
topic for cancer prediction [13]. It is known that HBV-related HCC is less often associ-
ated with the presence of cirrhosis, and this trend becomes more obvious in younger 
patients (often infected at birth) whose duration of infection is not long enough to 
develop full-blown cirrhosis [26]. This observation prompted the suggestion that HBV 
itself has direct carcinogenic potential [26]. Prospective studies have indicated a very 
strong correlation between the level of the viral replication as measured by HBV-DNA 
and the risk of developing HCC [27]. In Chapter 10 we studied the relation between the 
level of hepatocellular carcinogenesis (HBV DNA) and outcome in patients presenting 
with HCC. HCC patients with a high HBV DNA had a worse outcome. Several factors 
reported to be associated with a poor survival are included in the staging classification 
used for prognosis. Until now, however, no quantitative virological data are present in 
the prognostic models. Therefore, based on our results and reports from high-endemic 
areas, we suggest including quantitative virological data in these prognostic models, 
especially because efficient oral treatment of patients with high viral load is available. In 
our study, both high HBV viral load and hepatic inflammatory activity are significantly 
associated with a poor prognosis; median survival was 10 months longer in HCC patients 
with a low viral load. Given the strong association between HBV viral load and overall 
survival, it is anticipated that the implementation of strategies for the use of antiviral 
therapy in this setting will result in a durable suppression of HBV replication and lead 
to an increase of survival in HCC patients. It should be advocated for HCC patients with 
high serum HBV DNA levels to start antiviral treatment as it will decrease inflammation 
and may improve survival. 
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CoNClUsIoNs 
Chapter 2: The age-standardized incidence of hepatocellular carcinoma (HCC) among 
all-male age groups, and among women aged under 60 years, has increased in the Neth-
erlands between 1989 and 2009. Earlier disease detection affected the overall relative 
survival for HCC patients, while overall treatment-specific survival improved as well. 
Chapter 3: The age-standardized incidence of intrahepatic cholangiocarcinoma among 
both sexes has increased in the Netherlands since 1999. Overall survival improved, sug-
gesting a possible influence of improved imaging techniques, a better patient selection 
for surgery, and/or improved surgical techniques. 
Chapter 4: A review of the literature displayed GP73 to be a valuable serum marker that 
is superior to AFP and can be useful in the diagnosis and screening for HCC. GP73 may 
improve detection and treatment of one of the most common malignancies worldwide. 
More studies are needed to further elucidate the influence of the aetiology of disease 
on signal strength of GP73. 
Chapter 5: Using extensive immunohistochemical staining of non-cirrhotic livers we 
found no hepatocellular adenoma (HCA) components or a transition zones indicating 
the transition from HCA into HCC. It is highly unlikely that HCC in a non-cirrhotic liver is 
a HCA degenerated into a malignancy, and one should be aware of possible overtreat-
ment in patients with HCA.
Chapter 6: Moderate to poorly-differentiated HCC and microvascular invasion are sig-
nificantly associated with the presence of a capsule and wash-out, as demonstrated on 
dynamic contrast-enhanced MRI. 
Chapter 7: There is no indication for routine use of a bone scintigraphy at baseline to 
detect metastases in asymptomatic patients included for surgical treatment for resect-
able HCC. 
Chapter 8: If surgical resection is performed in a patient with HCC in a non-cirrhotic 
liver, good results can be achieved. The higher the preoperative AFP serum level, the 
worse the outcome.
Chapter 9: The immunohistochemical profile of HCC in a non-cirrhotic liver is compa-
rable to the immunohistochemical profile of HCC in a cirrhotic liver. A negative immu-
nohistochemical AFP marker does not exclude the presence of HCC in cirrhotic as well 
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as non-cirrhotic lesions. Immunohistochemical markers β-catenin, GPC-3 and MIB-1 may 
be helpful in establishing HCC differentiation grade. However, these markers cannot be 
used as a predictor for prognosis and survival.
Chapter 10: In HBV patients enhanced viral load and enhanced AST independently af-
fect overall survival in patients with HCC. This correlation supports the role for antiviral 
treatment in HCC patients with a high HBV DNA, together with treatment of HCC to 
increase overall survival.
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FUtUre PersPeCtIVes
The new insights in hepatocellular carcinoma, as discussed in this thesis, indicate that 
future research should focus on three main topics. 
First of all, early tumour detection. Benefit can be gained from a proper surveillance 
program, as HCC is a tumour with a well-defined population at risk. Patients at risk 
should be registered and closely monitored by a social healthcare program. Primary and 
secondary surveillance remains important. The second topic should be the development 
of imaging techniques. This will continue to be important as non-invasive diagnostic 
test are preferred. Future research should focus on the feasibility of predicting prognosis 
by imaging, by developing new diffusion-weighted imaging techniques, or producing 
new targeted hepatobiliary contrast agents. However, we have to bear in mind the 
cost of staging investigations, as healthcare costs and (in particular) cancer costs are 
rising. Unnecessary staging investigations should be avoided; therefore, patients with 
a HCC should be discussed in a multidisciplinary team. Besides developing imaging 
techniques, research in biomarkers should be continued. With a non-invasive test serum, 
saliva or urine can be analyzed to see whether they contain biomarkers superior to GP73. 
Finally, future studies should examine whether HCC in a non-cirrhotic liver has a different 
entity compared to HCC in a cirrhotic liver and compared to hepatocellular adenoma. In 
order to answer these questions, research on the oncogenic process of HCC in a non-
cirrhotic liver is needed. Molecular genetic studies will  be of importance to support 
or to reject the hypothesis of an adenoma-carcinoma sequence in HCC, and to confirm 
the hypothesis that the carcinogenesis of HCC in a cirrhotic and a non-cirrhotic liver is 
comparable using common pathways.  
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DIsCUssIe
Deel II – treNDs IN HePatoBIlIaIre KaNKer 
Het voorkomen van het hepatocellulair carcinoom (HCC) kent wereldwijd een sterk 
variatie [1,2]. Dit verschil is een uiting van de verscheidenheid aan oorzaken [1,2]. In 
geïndustrialiseerde landen is HCC een weinig voorkomende vorm van kanker [1-4]. In 
Nederland was de incidentie met 1,7 en 0,5 per 100.000 personen per jaar voor respectie-
velijk mannen en vrouwen tot het jaar 2000 stabiel [4]. Daarna is er een toename te zien 
die overeenkomt met de toename in andere laag endemische landen [1,2,4].
In hoofdstuk 2 wordt de stijgende incidentie voor mannelijke HCC patiënten in 
Nederland in de periode 1989 tot 2009 beschreven. De stijgende incidentie bij mannen 
kan gerelateerd zijn aan een hogere prevalentie van niet-alcoholische leververvetting 
(NAFLD). Onderzoekers suggereren dat NAFLD gezien kan worden als een voorstadium 
van niet-alcoholische steatohepatitis, een indirecte risicofactor voor HCC [5]. 
De 1-jaars overleving van HCC patiënten is verbeterd; dit geldt niet alleen voor pati-
enten die behandeld zijn met chirurgie, chemotherapie en/of radiotherapie, maar ook 
voor onbehandelde patiënten. Een verklaring zou kunnen zijn dat naast een verbeterd 
behandelingsresultaat, vroegdetectie een rol speelt [6]. Deze ‘lead-time bias’ kan het ge-
volg zijn van de introductie van een echografisch screeningsprogramma voor patiënten 
die een verhoogd risico lopen op HCC door een onderliggende leverziekte. Bovendien 
kan de verbeterde overleving een gevolg zijn van een snellere en betere behandeling 
van de complicaties van levercirrose [7]. 
Met behulp van computertomografie (CT) en hoogresolutie magnetische resonantie 
beeldvorming (MRI) kan op een adequatere manier de diagnose HCC gesteld worden. 
De verschillen tussen HCC en andere levertumoren zijn duidelijker te definiëren zon-
der dat een biopsie nodig is voor de uitvoering van weefselonderzoek. Men kan de 
vraag stellen of de geconstateerde veranderingen in incidentie beïnvloed zijn door de 
verbetering in de kwaliteit van de beeldvormende technologie; immers, tumoren die 
eerder beschreven werden als “niet-geclassificeerd” zouden met de huidige, verbeterde 
technieken een diagnose kunnen krijgen [8]. Bij een onjuiste of onvolledige diagnose 
in het verleden is te verwachten dat percentueel tenminste een van de andere hepa-
tobiliaire tumoren afneemt om de toename van HCC te verklaren. Wij analyseerden de 
epidemiologische trends van de andere levertumoren, waaronder het intrahepatische 
cholangiocarcinoom (ICC), om te bestuderen of dit effect bij deze tumor zichtbaar was 
(hoofdstuk 3). Het is zeer onwaarschijnlijk dat een verbeterde classificatie verantwoor-
delijk is voor de toename van HCC omdat ook de incidentie van ICC is toegenomen voor 
zowel mannen als vrouwen. De reden voor de stijgende incidentie van ICC is ondui-
delijk [9,10]. Verschillende aandoeningen zijn in verband gebracht met ICC waaronder 
primaire scleroserende cholangitis (PSC) en primaire biliare cirrose [11,12]. Omdat we de 
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prevalentie van de risicofactoren voor ICC niet konden analyseren met het beschikbare 
databestand, kunnen we de stijgende incidentie van ICC niet verklaren. 
Een overlevingsvoordeel dat bij HCC patiënten gezien werd, is ook waargenomen bij 
ICC patiënten die chirurgische behandeld werden. Een verbetering van de overleving 
van ICC patiënten kan een gevolg zijn van een verbeterde patiëntenselectie. Hierin 
spelen de beeldvormende technieken een belangrijke rol, omdat de preoperatieve 
beoordeling van tumoruitbreiding en metastasering sterk verbeterd is. Een andere mo-
gelijkheid is ook hier dat de toename van de overleving een gevolg is van ‘lead-time 
bias’, omdat patiënten met risicofactoren vaker gecontroleerd worden. Patiënten met 
PSC hebben gedurende hun leven bijvoorbeeld een life-time risico op ICC, dat geschat 
wordt, tussen de 8-20% [9]. 
Deel III- sCreeNeN Voor Het HePatoCellUlaIr CarCINooM
De epidemiologische trend van HCC in Nederland kan een afspiegeling zijn van een 
screeningsprogramma bij risicopatiënten. Vele jaren was het alfa-fetoproteïne (AFP) de 
standaard serummarker voor het opsporen van HCC, ondanks de relatief lage sensitiviteit 
(60%) [13]. Omdat screening kan leiden tot een betere prognose, hebben we de status 
van de recent gerapporteerde nieuwe biomarkers voor HCC screening geanalyseerd. In 
een systematische review (hoofdstuk 4) hebben we de biomarkers GP73 (Golgi-eiwit 
73), IL-6 (interleukine-6) en SCCA (plaveiselcelcarcinoom antigeen) vergeleken met AFP 
als detectiemarker. Onze bevinding, gebaseerd op 7 goed opgezette publicaties, stelt 
een voordeel van GP73 boven AFP als serummarker voor HCC screening. Hoewel GP73 
superieur aan AFP lijkt, is meer onderzoek nodig. Ook zal de klinische bruikbaarheid 
van de test moeten worden aangepast naar een ELISA formaat omdat de test die in de 
gebruikte publicaties gebruikt wordt, een ‘Western blot’ analyse, zeer bewerkelijk is voor 
de routine diagnostiek.
Screeningsprogramma’s richten zich op patiënten met chronische hepatitis en 
levercirrose omdat deze patiënten een risicogroep vormen voor het ontwikkelen van 
HCC [13]. HCC kan zich echter ook ontwikkelen in afwezigheid van chronische lever-
ziekten of levercirrose [7]. Het is de vraag of beide vormen van HCC een vergelijkbare 
carcinogenese kennen. Door sommige auteurs wordt gesuggereerd dat HCC in een niet-
hepatitis en niet-cirrose lever ontstaat uit een maligne getransformeerd hepatocellulair 
adenoom (HCA) [14]. Als deze veronderstelde hypothese juist is, kan het naast elkaar 
bestaan van HCA en HCC binnen dezelfde tumor verwacht worden. Een premaligne 
laesie zal een overgangszone tonen van goedaardige hepatocyten naar dysplatische 
(en kwaadaardige) hepatocyten. Wij onderzochten deze hypothese van benigne naar 
maligne transformatie en beschrijven in hoofdstuk 5 dat wij geen aanwijzingen vinden 
die het concept bevestigen. Er zijn geen HCC- delen in niet-cirrotische levers waarin 
een HCA-component kan worden aangetoond. Ook na gebruik van aanvullende im-
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munohistochemische kleuringen (o.a. β-catenine, glutamine syntetase, CRP, L-FABP en 
SAA) worden geen HCA componenten teruggevonden in HCC-haarden. Het uitsluiten 
van de mogelijke diagnose HCA op basis van het ontbreken van gevalideerde immuno-
histochemische markers voor HCA is gedurfd, adenomen kunnen zich namelijk presen-
teren zonder aanwezigheid van een positieve immunohistochemische marker. Echter, 
de immunohistochemische kleuringen geven geen enkel argument om de overgang 
van HCA naar HCC te steunen [15]. Ter ondersteuning van ons concept hebben we de 
radiologische beelden herbeoordeeld. Bij de herbeoordeling zijn alle tumoren geduid 
als HCC, geen van de laesies werd geduid als HCA. 
Deel IV – Het oPtIMalIsereN VaN De staDIerING 
Voor patiënten met een HCC is het maken van een prognostisch profiel belangrijk om-
dat dit kan dienen als leidraad bij de besluitvorming over de behandeling. Modellen die 
gebruikt worden richten zich op de vitaliteit van de patiënt, de grootte van de tumor 
en de functionaliteit van de lever. Voor patiënten die geopereerd of getransplanteerd 
zijn, geven de histologische kenmerken postoperatief een goed beeld van de prognose. 
Aanwezigheid van vasculaire invasie en een matige of slechte differentiatiegraad vor-
men geaccepteerde voorspellers van een slechte overleving [16-20]. Na correctie voor 
leeftijd, geslacht, hoogte van het serum AFP en grootte van de tumor zijn in onze resul-
taten histologische differentiatiegraad en aanwezigheid van vasculaire invasie signifi-
cant geassocieerd met het optreden van recidief HCC (hoofdstuk 6). Echter, uit klinisch 
oogpunt verdient het de voorkeur dat de prognose pre-operatief bepaald kan worden, 
bijvoorkeur met een niet-invasieve methoden. Wij probeerden om histologische eigen-
schappen van HCC, zoals vasculaire invasie en differentiatiegraad, te correleren aan 
radiologische kenmerken bij MRI onderzoek en stellen vast dat een typische opname 
en uitscheiding patroon van contrast (‘washout’) vaker aanwezig was bij tumoren met 
vasculaire invasie en/of een matige of slechte differentiatiegraad. Deze observatie kan 
gevolgen hebben voor de waarde van beeldvorming tijdens de preoperatieve analyse 
van patiënten met een HCC en vervolgonderzoek zal dit moeten bevestigen. Dit kan 
gedaan worden door diffusie-gewogen beeldvorming te gebruiken of door gebruik te 
maken van andere hepatobilliare contrastmiddelen. Gedetailleerde pre-operatieve eva-
luatie draagt bij aan het identificeren van patiënten met subklinische extra-hepatische 
ziekten. Jarenlang was botscintigrafie een routine onderzoek bij HCC patiënten die in 
aanmerking kwamen voor een uitgebreide leverresectie of -transplantatie. Deze aanpak 
is echter onderwerp van debat nu aangetoond is dat het geen zin heeft om routinema-
tig een botscintigrafie te maken bij patiënten die getransplanteerd worden voor HCC. 
De criteria om patiënten te selecteren voor transplantatie (Milaan criteria) zijn restrictief 
en minimaliseren het risico op uitzaaiingen. De patiënten beschreven in hoofdstuk 7 
ondergingen een botscintigrafie om te beoordelen of er sprake was van gemetasta-
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seerde ziekten bij patiënten die in aanmerking kwamen voor een leverresectie. De 
klinische indicatie voor de botscintigrafie was gebaseerd op subjectieve bevindingen. 
Onze studie geeft weer dat een bedrag van €53.221,- wordt besteed aan botscintigrafiën 
bij asymptomatische patiënten (n=134) zonder dat er één metastase ontdekt wordt. Wij 
concluderen dat preoperatieve botscintigrafie bij patiënten die in aanmerking komen 
voor een in opzet curatieve behandeling van het HCC niet geïndiceerd is tenzij er speci-
fieke botgerelateerde klachten zijn. 
Deel V – De UItKoMst 
Veel studies richten zich op patiënten met HCC in aanwezigheid van levercirrose. In een 
enkele studie onderzocht men klinisch-pathologische kenmerken van HCC patiënten 
zonder levercirrose [13,21,22]. Deze patiënten hebben echter vaak risicofactoren voor het 
ontwikkelen van levercirrose en een HCC [21]. Deze selectie bias kan van invloed zijn op 
de uitkomst, vooral op de overleving aangezien bekend is dat bijvoorbeeld chronische 
hepatitis B (HBV) de overleving van HCC patiënten beïnvloed [23].
In hoofdstuk 8 analyseerden we patiënten met HCC in afwezigheid van risicofacto-
ren voor levercirrose of HCC. In de multivariabele analyse bleek de aanwezigheid van 
een preoperatief verhoogd serum AFP als belangrijkste factor geassocieerd te zijn met 
een slechtere uitkomst en een grotere kans op HCC recidieven in een niet-hepatitis 
en niet-cirrotische lever. Hoewel AFP als een serologische marker voor HCC screening 
en surveillance bij patiënten met levercirrose nog steeds ter discussie staat [24], lijkt 
het een nuttige prognostische marker bij patiënten met een HCC zonder risicofacto-
ren. Naast de belangstelling voor factoren die samenhangen met recidief HCC in een 
niet-cirrotische lever, werd het biologische gedrag van HCC in een niet-hepatitis en 
niet-cirrotische lever onderzocht [25]. In hoofdstuk 9 analyseerden we de kenmerken 
van immunohistochemische markers bij HCC in een niet-cirrotische lever. Als we HCC 
in een niet-cirrotische en HCC in een cirrotische lever vergelijken tonen onze resultaten 
veel overeenkomsten tussen de tumor markers in de verschillende groepen. Dit ge-
geven, gecombineerd met het oncobiologisch gedrag van HCC in een niet-cirrotische 
en cirrotische lever, lijkt de conclusie te rechtvaardigen dat de onderliggende cirrose 
niet van invloed is op de oncologische genese van het HCC. Opgemerkt moet worden 
dat een negatieve AFP immunohistochemische kleuring een HCC niet uitsluit en dat 
deze marker dan ook met zorg geïnterpreteerd dient te worden bij het analyseren van 
tumoren in niet-cirrose patiënten. Aangetoond is dat β-catenine, Glypican-3 (GPC-3) en 
antigen Ki67 (MIB-1) significant vaker positief zijn bij patiënten met een matig of slecht 
gedifferentieerd HCC in een niet-cirrotische lever. Bovendien is de MIB-1 expressie 
verhoogd bij HCC met vasculaire invasie. Het gebruik van β-catenine, GPC-3 en MIB-1 
kan misschien nuttig zijn als het onderscheid tussen een goed gedifferentieerd HCC en 
HCA gemaakt moet worden op bijvoorbeeld weefsel afkomstig van een naaldbiopsie. 
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Cytokeratine 19 (CK19) is vaker positief bij patiënten met een recidief. De relevantie van 
deze bevindingen moet worden gevalideerd in een groter cohort om de voorspellende 
waarde klinisch te toetsen. 
Nederland is een laagendemisch gebied voor HCC en HCC presenteert zich in 64% bij 
patiënten met levercirrose [7]. Omdat HCC zich vaak in een cirrotische lever ontwikkelt, is 
studie naar de carcinogenese bij levercirrose belangrijk [13]. Het is bekend dat een HBV-
gerelateerd HCC minder vaak geassocieerd is met de aanwezigheid van levercirrose. Dit 
is meer voor de handliggend bij jonge patiënten (vaak besmet bij de geboorte), waarbij 
de duur van de infectie niet lang genoeg is om een volledige levercirrose te ontwikkelen 
[26]. Dit geeft aan dat HBV zelf carcinogenese kan induceren zonder de tussenstap van 
cirrose [26]. Recente studies hebben aangetoond dat er een sterke correlatie is tussen 
het niveau van de virale replicatie gemeten als kwantitatief HBV-DNA en de kans op 
het ontwikkelen van HCC [27]. In hoofdstuk 10 hebben we de relatie tussen de hoogte 
van het HBV-DNA en de uitkomst bij patiënten met een geopereerd HCC geanalyseerd. 
HCC patiënten met een hoog HBV-DNA hadden een slechtere uitkomst. Verschillende 
factoren zijn in verband gebracht met een slechtere overleving en daarom opgenomen 
in classificatie systemen waarmee de prognose van HCC patiënten voorspeld wordt. 
Echter, tot nu toe zijn kwantitatieve virologische gegevens niet geïmplementeerd in 
deze prognostische modellen. Op basis van onze resultaten en verslagen uit hoogen-
demische gebieden, stellen we voor om de kwantitatieve virologische gegevens in de 
prognostische modellen te implementeren. Vooral ook omdat een efficiënte behande-
ling van patiënten met een hoog HBV-DNA beschikbaar is. In onze studie zijn zowel een 
hoog HBV-DNA als leverinflammatie significant geassocieerd met een slechtere prog-
nose; de mediane overleving was 10 maanden langer in HCC patiënten met een laag 
HBV-DNA. Gezien de sterke associatie tussen het HBV-DNA en de totale overleving, is de 
verwachting dat het gebruik van antivirale therapie zal resulteren in een onderdrukking 
van HBV replicatie, wat zal leiden tot een toename van de overleving van HCC patiënten. 
Wij pleiten ervoor om bij HCC patiënten met een hoog serum HBV-DNA te starten met 
antivirale therapie om zo de ontsteking te verminderen en de overleving te verbeteren. 
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CoNClUsIes
Hoofdstuk 2: Tussen 1989 en 2009 is in Nederland de voor leeftijd gecorrigeerde inci-
dentie van het hepatocellulair carcinoom voor mannen in alle leeftijdsgroepen en voor 
vrouwen tot 60 jaar gestegen. Het vroeg vaststellen van de diagnose heeft geresulteerd 
in een stijging van de relatieve algehele overleving voor patiënten met een hepatocel-
lulair carcinoom. 
Hoofdstuk 3: De voor leeftijd gecorrigeerde incidentie van het intrahepatische cholan-
giocarcinoom bij zowel mannen als vrouwen is toegenomen in Nederland sinds 1999. 
De overleving verbeterde, hetgeen duidt op een mogelijke invloed van verbeterde 
beeldvormende technieken, een betere patiëntselectie voor operatie en een verbete-
ring van de chirurgische technieken. 
Hoofdstuk 4: Een meta-analyse van de literatuur geeft aan dat Golgi-eiwit 73 een waar-
devolle serummarker is, superieur aan alfa-fetoproteïne en nuttig bij de diagnostiek en 
het screenen voor hepatocellulair carcinoom. Golgi-eiwit 73 kan het diagnosticeren en 
behandelen verbeteren en aanvullende studies zijn nodig om de plaatsbepaling van 
deze tumormarker te bevestigen.
Hoofdstuk 5: Wij vinden het hoogst onwaarschijnlijk dat hepatocellulair carcinoom in 
een niet-cirrotische lever ontstaat uit een hepatocellulair adenoom. Gebruik makend 
van immunohistochemische kleuringen vonden we geen hepatocellulair adenoom 
componenten of een overgangszone van hepatocellulair adenoom naar hepatocellulair 
carcinoom. Deze bevinding kan erop wijzen dat het risico op maligne degeneratie van 
een leveradenoom zeer klein is en dat overbehandeling uit angst voor maligniteit voor-
komen moet worden. 
Hoofdstuk 6: Een matig tot slecht gedifferentieerd hepatocellulair carcinoom en/ of 
een hepatocellulair carcinoom met vasculaire invasie is geassocieerd met de aanwezig-
heid van een kapsel en ‘washout’ zoals zichtbaar is op een dynamische MRI met contrast. 
Hoofdstuk 7: Er is geen indicatie voor het routinematig verrichten van een preopera-
tieve botscintigrafie ter opsporing van metastasen bij asymptomatische patiënten die 
in aanmerking komen voor een in opzet curatieve behandeling van het hepatocellulair 
carcinoom. 
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Hoofdstuk 8: Goede resultaten kunnen bereikt worden bij een chirurgische resectie van 
een hepatocellulair carcinoom bij patiënten met een niet-cirrotische lever. Echter, hoe 
hoger het preoperatieve serum alfa-fetoproteïne, hoe slechter de uitkomst. 
Hoofdstuk 9: Het immunohistochemische profiel van een hepatocellulair carcinoom in 
een niet-cirrotische lever is vergelijkbaar met het immunohistochemische profiel van 
een HCC in een cirrotische lever. Een negatieve alfa-fetoproteïne marker sluit de aanwe-
zigheid van een hepatocellulair carcinoom niet uit. De markers β-catenine, Glypican-3 
en antigen Ki67 kunnen nuttig zijn bij het vaststellen van de differentiatiegraad. Deze 
markers zijn echter geen prognostische voorspellers, noch van invloed op de overleving. 
Hoofdstuk 10: De hoogte van het HBV-DNA en het aspartaat aminotransferase 
beïnvloeden onafhankelijk van elkaar de overleving van hepatocellulair carcinoom 
patiënten. Deze correlatie ondersteunt de rol van antivirale therapie bij hepatocellulair 
carcinoom patiënten met een hoog HBV-DNA, dat deze tezamen met de behandeling 
van het hepatocellulair carcinoom de totale overleving zal verbeteren. 
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toeKoMst VIsIe
De nieuwe inzichten in het hepatocellulair carcinoom, zoals besproken is in dit proef-
schrift, maken dat toekomstig onderzoek zich moet richten op drie belangrijke onder-
werpen. 
Allereerst vroegdetectie. Voordeel kan behaald worden uit een goed georganiseerd 
screeningsprogramma, aangezien hepatocellulair carcinoom voornamelijk voorkomt in 
een goed definieerde risicopopulatie. Patiënten die een verhoogd risico lopen moeten 
geregistreerd worden en primaire en secundaire preventie moet worden aangeboden. 
Het tweede onderwerp is de verdere perfectionering van beeldvormende technieken. 
Dit is belangrijk omdat er vraag is naar niet-invasieve diagnostische testen, voornamelijk 
voor de kleinere afwijkingen. Toekomstig onderzoek moet zich richten op de haalbaar-
heid van het voorspellen van de aard van voornamelijk de kleine afwijkingen met 
behulp van beeldvormend onderzoek. Het ontwikkelen van nieuwe diffusie-gewogen 
beeldvormende technieken, of het produceren van nieuwe hepatobiliair specifieke 
contrastmiddelen kan bijdragen aan de bepaling van de mate van agressiviteit van de 
tumor. We moeten echter rekening houden met de kosten van deze onderzoeken. Naast 
het ontwikkelen van beeldvormende technieken moet onderzoek naar biomarkers 
voortgezet worden. Met niet-invasieve testen kan serum, speeksel of urine geanalyseerd 
worden om te zien of ze biomarkers bevatten die superieur zijn aan GP73. 
Het derde onderwerp van onderzoek moet gericht zijn op de analyse van hepatocellulair 
carcinoom in cirrotische en niet-cirrotische levers en het proces van carcinogenese. Om 
deze vragen te beantwoorden, is moleculair genetische onderzoek naar het oncoge-
netisch profiel van hepatocellulair carcinoom in verschillende situaties nodig met als 
controlemateriaal leverweefsel met chronische hepatitis en leverweefsel met cirrose. 
Beter inzicht in het mechanisme van tumorontwikkeling en groei in diverse parenchy-
male condities kan de behandelingsmogelijkheden verder verbeteren. 
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DaNKWoorD
Het is af, met opluchting begin ik aan het dankwoord van mijn proefschrift! Vele hebben 
een bijgedrage geleverd aan de totstandkoming van dit proefschrift. Zonder hun hulp 
zou het niet gelukt zijn en daarom is mijn dank aan hen groot. Een aantal personen wil 
ik in het bijzonder bedanken.
Allereerst mijn promotor, prof.dr. J.N.M. IJzermans, beste Jan, als student gaf je me de 
mogelijkheid om me te bewijzen. Dank voor je vertrouwen, enthousiasme, maar bovenal 
ook kritisch noot die ik vaak pas op een later moment ging waarderen. Ik ben blij met 
jouw blijk van steun en waardering op de momenten die er toe doen. Ik kijk uit naar het 
moment waarop ik chirurgisch technische vaardigheden van je mag leren. 
Mijn copromotor, dr. R.A. de Man, beste Rob, pas later realiseerde ik me dat ik tijdens 
onze eerste ontmoeting al kennis maakte met je alles overziende blik. Je hebt de kwa-
liteit om haarfijn de kern van een onderwerp bloot te kunnen leggen. Ik waardeer je 
om je scherpe visie, het meedenken en je opbeurende woorden. Ik ben blij dat je mijn 
copromotor bent. 
Mijn copromotor, dr. C. Verhoef, beste Kees, onze eerste ontmoeting verliep verre van 
soepel, sindsdien neem ik dan ook het ‘busje’. Vanaf dat moment heb jij er voor gezorgd 
dat ik niet verdwaalde tijdens mijn onderzoek. Ik heb bewondering voor je gedreven-
heid met een onuitputbaar enthousiasme. Bovenal waardeer ik je gave om op het juiste 
moment de juiste woorden te gebruiken. Ik ben blij dat je mij als copromotor hebt bij-
gestaan bij het doorgronden van jouw onderwerp. Ik hoop dat er tijdens mijn loopbaan 
een moment komt waarop ik ook chirurgisch technische vaardigheden van je kan leren. 
Graag wil ik de leescommissie, prof.dr. H.W. Tilanus, prof.dr. H. J. Metselaar en prof.dr. 
C. Verslype, bedanken voor het beoordelen van dit proefschrift en zitting nemen in de 
oppositie. Teven dank ik prof.dr. J.W.W. Coebergh, prof.dr. F.J.W. ten Kate, prof.dr. T.M. 
van Gulik en dr. Moelker voor de bereidheid om als opponent zitting te nemen in de 
promotiecommissie. 
De medeauteurs van de gebruikte artikelen zijn van grote waarde geweest. Hoofdstuk 2, 
3 en 4 zouden niet gelukt zijn zonder de hulp van de Intergrale Kanker Centra. Speciale 
dank gaat uit naar professor Coebergh, Henrike Karim-Kos, Esther de Vries en Otto Visser. 
De pathologen professor ten Kate en Joanne Verheij hebben een grote bijdrage 
geleverd aan de hoofdstukken 6, 7, 9 en 10. Wojciech Polak dank voor je tijd, inhoudelijk 
commentaar en vertrouwen. Ferry Eskens dank voor je tijd en schrikbarend rode ma-
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nuscripten die ik retour kreeg met daarin het kritische maar o zo terechte commentaar. 
Bettina Hansen, dank voor je statistische ondersteuning voor als ik weer eens helemaal 
vastliep en vooral ook de mooie momenten tijdens de buitenlandse congressen. 
Als laatste coauteurs wil ik noemen Roy Dwarkasing en François Willemssen, dank 
voor jullie toewijding en François dank voor je geduld en grote inzet.
Heel veel dank aan de secretaresses van de afdeling heelkunde. Carola; heel veel dank 
voor je hulp en het creëren van tijd in de agenda terwijl die er eigenlijk niet was. Conny 
heel veel dank voor je tijd, gezelligheid en kritische noot. Jij kan als geen ander haarfijn 
de vinger op de juiste plek leggen, dank voor het ondersteunen en controleren van mijn 
ontwikkelingen.
Onderzoekers en assistenten van de heelkunde, ik ga jullie niet allemaal apart benoe-
men omdat jullie me allemaal om diverse reden dierbaar zijn. Ik heb genoten en hoop in 
de toekomst nog veelvuldig te genieten van de gezellige koffie, lunch, borrels, diners en 
discussies. Evenals alle sportieve activiteiten op de racefiets of de schaatsbaan. 
Uiteraard een speciaal woord voor de bewoners van Z-836. Wat kunnen wij elkaar 
meeslepen in alle mogelijke stemmingen, werkelijk niets was te gek. Ik ben jullie dank-
baar voor de diepe dalen en de briljante hoogtepunten.
Lieve vrienden en vriendinnen, lieve jaarclub, lief huis en lief 89ste,  wat ben ik blij dat ik 
jullie om me heen heb. Jullie onvoorwaardelijke steun, interesse, opbeurende praatjes, 
maar vooral er gewoon zijn als het nodig is. Jullie vertrouwen dat het wel goed zou 
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